WO1993015078A1 - Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics - Google Patents

Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics Download PDF

Info

Publication number
WO1993015078A1
WO1993015078A1 PCT/GB1993/000217 GB9300217W WO9315078A1 WO 1993015078 A1 WO1993015078 A1 WO 1993015078A1 GB 9300217 W GB9300217 W GB 9300217W WO 9315078 A1 WO9315078 A1 WO 9315078A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolidin
hydroxyethyl
ylthio
methylcarbapenem
carboxy
Prior art date
Application number
PCT/GB1993/000217
Other languages
French (fr)
Inventor
Michael John Betts
Gareth Morse Davies
Michael Lingard Swain
Original Assignee
Zeneca Limited
Zeneca-Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69322007T priority Critical patent/DE69322007T2/en
Priority to DE2002199041 priority patent/DE10299041I2/en
Priority to PL93317448A priority patent/PL174936B1/en
Priority to AU34574/93A priority patent/AU668133B2/en
Priority to US08/129,056 priority patent/US5478820A/en
Priority to KR1019930702942A priority patent/KR100200986B1/en
Priority to JP5513073A priority patent/JP2730600B2/en
Priority to CA002106370A priority patent/CA2106370C/en
Priority to PL93317447A priority patent/PL174601B1/en
Priority to EP93914514A priority patent/EP0579826B1/en
Priority to DK93914514T priority patent/DK0579826T3/en
Priority to CZ19932067A priority patent/CZ286878B6/en
Priority to SK1063-93A priority patent/SK280890B6/en
Priority to PL93300768A priority patent/PL174649B1/en
Application filed by Zeneca Limited, Zeneca-Pharma S.A. filed Critical Zeneca Limited
Publication of WO1993015078A1 publication Critical patent/WO1993015078A1/en
Priority to NO933530A priority patent/NO304315B1/en
Priority to US08/833,056 priority patent/US5856321A/en
Priority to HK98115416A priority patent/HK1013998A1/en
Priority to NO2002010C priority patent/NO2002010I2/en
Priority to LU90970C priority patent/LU90970I2/en
Priority to NL300104C priority patent/NL300104I2/en
Priority to US10/293,561 priority patent/US7041836B2/en
Priority to US11/126,331 priority patent/US7342005B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568—Four-membered rings

Definitions

  • the present invention relates to carbapenems and in particular to such compounds containing a carboxy substituted phenyl group- This invention further relates to processes for their preparation, to intermediates in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.
  • the compounds of this invention are antibiotics and can be used in the treatment of any disease that is conventionally treated vith antibiotics for example in the treatment of bacterial infection in mammals including humans.
  • imipenem N-formimidoyl thienamycin
  • This compound has a broad spectrum of antibacterial activity.
  • the present invention provides compounds with a broad spectrum of antibacterial activity including against both Gram positive and negative, aerobic and anaerobic bacteria. They exhibit good stability to beta-lactamases. In addition representative compounds of this invention exhibit a very favourable duration of action.
  • R is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl
  • R is hydrogen or C. .alkyl
  • R 3 is hydrogen or C- .alkyl
  • R 4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C, .alkyl, nitro, hydroxy, carboxy, C-_,alkoxy,
  • Alkyl when used herein includes straight chain and branched chain substituents for example methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl.
  • R is 1-hydroxyethyl
  • R is hydrogen or C. .alkyl for example methyl, ethyl,
  • R is hydrogen or methyl
  • R is methyl
  • R is hydrogen or C, .alkyl for example methyl, ethyl,
  • R is hydrogen
  • E SHEET 4 5 R and R are the same or different and are selected from hydrogen; halo for example fluoro, bromo or chloro; cyano; C. .alkyl for example methyl, ethyl, n-propyl, isopropyl or n-butyl; nitro; hydroxy; carboxy; C. .alkoxy for example methoxy or ethoxy; C. .alkoxycarbonyl for example methoxycarbonyl, ethoxycarbonyl and n-propoxycarbonyl; aminosulphonyl; C, .alkylaminosulphonyl for example methylaminosulphonyl and ethylaminosulphonyl; di-C.
  • .alkylamino ⁇ sulphonyl for example di-methylaminosulphonyl, methylethylaminosulphonyl and di-ethylaminosulphonyl; carbamoyl; C. .alkylcarbamoyl for example metbylcarbamoyl or ethylcarbamoyl; di-C. .alkylcarbamoyl for example dimethylcarbamoyl or diethylcarbamoyl; trifluoromethyl; sulphonic acid; amino; C. .alkylamino for example methylamino or ethylamino; di-C.
  • .alkylamino for example dimethylamino or diethylamino
  • C. .alkanoylamino for example acetamido or propionamido
  • C, ,alkanoyl(N-C, .alkyl)amino for example N-methylacetamido
  • C. .alkanesulphonamido for example methanesulphonamido
  • C. .alkylS(O) - for example methylthio, methylsulphinyl or methylsulphonyl.
  • a suitable class of compounds is that
  • R and R are the same or different and are selected from hydrogen, fluoro, chloro, hydroxy, carboxy, cyano, nitro, methyl, ethyl, methoxy, ethoxy, methoxycarbonyl, carbamoyl, metbylcarbamoyl, dimethylcarbamoyl, trifluoromethyl, sulphonic acid, methylsulphinyl, methylsulphonyl, methanesulphonamido or acetamido.
  • R and R may both be other than hydrogen but, in general, it
  • R 4 5 is particularly preferred that at least one of R and R is hydrogen.
  • Particularly preferred compounds are those in which R is hydrogen, carboxy, fluoro, chloro, methyl, methoxy, cyano, sulphonic acid or methoxycarbonyl and R is hydrogen.
  • the present invention covers all epimeric, diastereoisomeric and tautomeric forms of the compounds of the formula (I) wherein the absolute stereochemistry at the 5-position is as illustrated in
  • Preferred compounds are those in which the beta-lactam ring protons are in trans configuration with respect to one another.
  • R is 1-hydroxyethyl or l-fluoroethyl it is preferred that the 8-substituent has the R-configuration.
  • a preferred class of compounds is that of the formula (III):
  • R is C. ,alkyl for example methyl it is preferred that the compound is in the form of the IR configuration.
  • Preferred compounds are those in which the pyrrolidine ring has the following absolute stereochemistry at the 2 '- and 4'- positions:
  • a preferred class of compounds of the present invention is that of the formula (IV):
  • R is hydrogen and R and R are the same or different and are selected from hydrogen, fluoro, chloro, hydroxy, carboxy, cyano, nitro, methyl, ethyl, methoxy, ethoxy, methoxycarbonyl, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, methanesulphonyl, trifluoromethyl, sulphonic acid, methylsulphinyl, methanesulphonamido or acetamido.
  • R and R are both hydrogen and R is hydrogen, carboxy, fluoro, chloro, methyl, methoxy, cyano, sulphonic acid or methoxycarbonyl.
  • Suitable pharmaceutically acceptable salts include acid addition salts such as hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid.
  • suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine,
  • Preferred pharmaceutically acceptable salts are sodium and potassium salts. However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically acceptable or not.
  • In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, eg. intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include C.
  • ,alkoxymethyl esters for example methoxymethyl, C, ,aIkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C- R cycloalkoxycarbonyloxy- C, ,alkyl esters for example 1-cyclohexyloxycarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2- onylmethyl; and C- ,alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • Suitable in vivo hydrolysable ester forming groups for hydroxy include acetyl, propionyl, pivaloyl, C,_,alkoxycarbonyl for example ethoxycarbonyl and phenylacetyl.
  • Preferred compounds of the present invention are:
  • a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.
  • compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration.
  • the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, emulsions, dispersible powders, suppositories and sterile injectable aqueous or oily solutions or suspensions.
  • the compounds of the present invention may be formulated as dry powder filled vials, which may contain the compound of the present invention alone or as a dry blended mixture.
  • an acidic compound of the present invention may be dry blended with an alkali metal carbonate or bicarbonate. Freeze dried formulations of compounds of the present invention, alone or as a mixture with standard excipients, are possible.
  • Standard excipients include structure formers, cryoprotectants and pH modifiers, such as, mannitol, sorbitol, lactose, glucose, sodium chloride, dextran, sucrose, maltose, gelatin, bovine serum albumin (BSA), glycine, mannose, ribose, polyvinylpyrrolidine (PVP), cellulose derivatives, glutamine, inositol, potassium glutamate, erythritol, serine and other amino acids and buffer agents e.g. disodium hydrogen phosphate and potassium citrate.
  • pH modifiers such as, mannitol, sorbitol, lactose, glucose, sodium chloride, dextran, sucrose, maltose, gelatin, bovine serum albumin (BSA), glycine, mannose, ribose, polyvinylpyrrolidine (PVP), cellulose derivatives, glutamine, inositol, potassium glutamate, erythrito
  • the pharmaceutical composition of this invention may also contain, or be co-administered with, one or more known drugs selected from other clinically useful antibacterial agents (for example other beta-lactams or aminoglycosides) , inhibitors of beta-lactamase (for example clavulanic acid), renal tubular blocking agents (e.g. probenecid) and inhibitors of metabolising enzymes (for example inhibitors of dehydropeptidases, for example Z-2-acylamino-3-substituted propenoates such as cilastatin) and N-acylated amino acids (for example see EP-A-178911) which reduce adverse effects on the kidney.
  • drugs selected from other clinically useful antibacterial agents (for example other beta-lactams or aminoglycosides) , inhibitors of beta-lactamase (for example clavulanic acid), renal tubular blocking agents (e.g. probenecid) and inhibitors of metabolising enzymes (for example inhibitors of dehydropeptidases, for
  • a suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between lOOmg and lg of the compound of this invention.
  • a preferred pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example a sterile injectable containing between 1 and 50% w/w of the compound of this invention.
  • compositions which are constituted as a IX solution in water, freeze dried and may be made up by adding 0.9% aqueous sodium chloride solution to give the required concentration, preferably lmg-lOmg/ml, are as follows:
  • compositions are as above, but where the compound of example 1 is replaced by any one of examples 2 to 37.
  • compositions of the invention will normally be administered to man in order to combat infections caused by bacteria, in the same general manner as that employed for imipenem due allowance being made in terms of dose levels for the potency and duration of action of the compound of the present invention relative to the clinical use of imipenem.
  • each patient will receive a daily intravenous, subcutaneous or intramuscular dose of 0.05 to 5g, and preferably 0.1 to 2.5g, of the compound of this invention, the composition being administered 1 to 4 times per day, preferably 1 or 2 times a day.
  • the intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time.
  • each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose.
  • a suitable daily oral dose is 0.05 to 5g of the compound of this invention, the composition being administered 1 to 4 times per day.
  • the present invention provides a process for preparing the compounds of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises deprotecting a compound of the formula (V):
  • R , R and R are as hereinbefore defined (R and R being optionally protected if appropriate); -C00R and -C00R are carboxy or
  • R is a group R or an amino protecting group
  • R is hydrogen or an amino protecting group
  • R is a group R , protected
  • Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
  • Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • the compounds of the formula (V) are novel and form another aspect of the invention.
  • protecting groups are given below for the sake of convenience, in which "lower” signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.
  • a carboxyl protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).
  • carboxy protecting groups include straight or branched chain (l-12C)alkyl groups (eg isopropyl, t-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (eg acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (eg p-methoxybenzyl, o-nitrobenzyl, p_-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (eg trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups
  • Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis.
  • hydroxyl protecting groups include lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxycarbonyl groups (eg t-butoxycarbonyl); lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzoyloxycarbonyl, p_-methoxybenzyloxycarbonyl, £-nitrobenzyloxycarbonyl, £-nitrobenzyloxycarbonyl) ; tri lower alkylsilyl (eg trimethylsilyl, t-butyldimethylsilyl) and aryl lower alkyl (eg benzyl) groups.
  • lower alkenyl groups eg allyl
  • lower alkanoyl groups eg acetyl
  • lower alkoxycarbonyl groups eg t-butoxycarbonyl
  • lower alkenyloxycarbonyl groups eg
  • amino protecting groups include formyl, aralkyl groups (eg benzyl and substituted benzyl, eg £-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl) ; di-£-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (eg t-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, £-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, £-nitrobenzyloxycarbonyl; trialkylsilyl (eg trimethylsilyl and t-butyldimethylsilyl); alkylidene (eg methylidene); benzylidene and substituted benzylidene groups.
  • aralkyl groups eg benzyl
  • Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or
  • Preferred protecting groups for carboxy and hydroxy groups in compounds of the formula (I) are the groups allyl and £-nitrobenzyl.
  • a preferred method for removal of the allyl group is by palladium catalysis using tetrakis(triphenylphosphine)palladium and Meldrum's acid, in a dipolar aprotic solvent tetrahydrofuran mixture, such as dimethylsulphoxide/tetrahydrofuran or 1,3-dimethyl-2-oxo-tetrahydro- pyrimidine/tetrahydrofuran, or an alcohol/tetrahydrofuran mixture such as isopropanol/tetrahydrofuran or ethanol/tetrahydrofuran, preferably at ambient temperature.
  • methylaniline may be used in place of Meldrum's acid, in dichloromethane.
  • a preferred method for removal of the £-nitrobenzyl group is hydrogenation using a palladium catalyst.
  • R , R -R are as hereinbefore defined and L is a leaving group, or b) cyclising a compound of the formula (VIII):
  • R , R -R as hereinbefore defined and R -R are independently selected from C. ,alkoxy, aryloxy, di-C. ⁇ alkylamino and
  • R 11 13 or one of R -R is C. ,alkyl, allyl, benzyl or phenyl, and the other two values are independently selected from C,_,alkyl, trifluoromethyl or phenyl, wherein any phenyl group is optionally substituted with
  • the reactive ester of a hydroxy group such as a sulphonate (for ' example C, ,alkanesulphonyloxy, trifluoromethanesulphonylbxy, benzenesulphonyloxy, toluenesulphonyloxy) , a phosphoric ester (for example a diarylphosphoric ester such as diphenylphosphoric ester) or L is a halide (for example chloride).
  • L is diphenylphosphoric ester (-OP(O)(OPh)-,) .
  • reaction between the compounds of the formulae (VI) and (VII) is typically performed in the presence of a base such as an
  • SUBSTITUTE SHEET organic amine for example di-isopropylethylamine or an inorganic base for example an alkali metal carbonate such as potassium carbonate.
  • the reaction is conveniently performed at a temperature between -25°C and ambient, suitably at about -20°C.
  • the reaction is generally performed in an organic solvent such as acetonitrile or dimethylformamide.
  • the reaction is generally performed in a manner similar to that described in the literature for similar reactions.
  • the compounds of the formula (VII) are novel and form another aspect of the present invention.
  • the compounds of the formula (VII) may be prepared by the deprotection of a compound of the formula (IX):
  • R -R , R and R as hereinbefore defined and R is a protecting group, for example C, .-alkanoyl, C,_,alkoxycarbonyl or benzoyl.
  • Preferred values for R are acetyl and t-butoxycarbonyl.
  • the compounds of the formula (IX) can be converted to the compounds of the formula (VII) by standard methods of deprotection, for example acetyl groups can be removed by basic hydrolysis in aqueous alkanol or alkenol for example allyl alcohol.
  • the compounds of the formula (IX) are novel and form another aspect of the present invention.
  • the compounds of the formula (IX) may be prepared by the reaction of an activated derivative of a compound of the formula (X) , which may be formed in situ, with a compound of the formula (XI) :
  • R -R , R , R and R are as hereinbefore defined.
  • Activated derivatives of the compound of the formula (X) include acid halides, anhydrides and 'activated' esters such as lH-benzo[l,2,3] triazol-1-yl, pentafluorophenyl and 2,4,5-trichlorophenyl esters or the benzimidazol-2-yl ester of the thiocarboxylic acid corresponding to
  • R -R are independently selected from Cl-6 alkoxy such as methoxy, ethoxy, isopropoxy, n-propoxy or n-butoxy; aryloxy such as optionally phenoxy; di-C. ,alkylamino such as dimethylamino or diethylamino;
  • each of R -R have the same value and are C. ,alkoxy for example methoxy, ethoxy, isopropoxy or n-butoxy or are phenoxy.
  • the compounds of the formula (VIII) are cyclized under conventional conditions known in the art to form compounds of the formula (V) .
  • Typical conditions are heating in a substantially inert
  • BSTITUTE SHEET organic solvent such as toluene, xylene or ethyl acetate at temperatures in the region 60-150°C.
  • the reaction is performed in an atmosphere of nitrogen and is carried out in the presence of a radical scavenger for example hydroquinone.
  • the compounds of the formula (VIII) may be formed and cyclized in situ.
  • the compounds of the formula (VIII) may conveniently be prepared by reacting compounds of the formulae (XII) and (XIII):
  • the compound of the formula (XIII) is a phosphite or is the functional equivalent of such a compound.
  • reaction between the compounds of the formulae (XII) and (XIII) is conveniently performed in an organic solvent such as toluene, xylene, ethyl acetate, chloroform, dichloromethane, acetonitrile or dimethylformamide. Typically the reaction is carried out at an elevated temperature for example 60-150°C.
  • the compounds of the formula (XII) may be prepared by a number of methods known in the art.
  • the compounds of the formula (XII) may be prepared by the acylation of a compound of the formula (XIV):
  • the compounds of the formula (XIV) may be prepared by reacting compounds of the formulae (XVI) and (VII):
  • SUBSTITUTE SHEET present invention are useful antibacterial agents having a broad spectrum of activity in vitro against standard laboratory microorganisms, both Gram-negative and Gram-positive, which are used to screen for activity against pathogenic bacteria.
  • the antibacterial spectrum and potency of a particular compound may be determined in a standard test system.
  • the carbapenems of the present invention show good stability to beta-lactamases and have a particularly good elimination half life in mammals. In general compounds show significant improvement over imipenem.
  • the antibacterial properties of the compounds of the invention may also be demonstrated in vivo in conventional tests.
  • Carbapenem compounds have generally been found to be relatively non-toxic to warm-blooded animals, and this generalisation holds true for the compounds of the present invention.
  • Compounds representative of the present invention were administered to mice at doses in excess of those required to afford protection against bacterial infections, and no overt toxic symptoms or side effects attributable to the administered compounds were noted.
  • the antibacterial activity is described in terms of the minimum inhibitory concentration (MIC) determined by the MIC
  • NMR spectra were taken at 200MHz or 400MHz;
  • THF means tetrahydrofuran;
  • DMF means dimethylformamide;
  • Meldrum's acid is 2,2-dimethyl-l,3-dioxane-4,6-dione.
  • Evaporation of solvents was carried out under reduced pressure;
  • EtOAc means ethyl acetate
  • EEDQ means N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline
  • DMSO means dimethyl sulfoxide
  • DCCI means dicyclohexylcarbodiimide
  • the solution was stirred, under argon with protection from light, for 2 hours.
  • the solution was diluted with diethyl ether (40 ml) , and the resultant precipitate centrifuged, and the supernatant was removed.
  • the product was washed by resuspension in ether followed by centrifugation, and finally dried under high vacuum.
  • the crude product was dissolved in water (10 ml) and the pH adjusted to 6.8 with NaHCO-.. After filtration, the solution was subjected to chromatography on Diaion CHP20P resin, and the fractions combined as appropriate to give the title product (66%).
  • Nmr (DMSO-d, + acetic acid-d,): ⁇ 1.18 (d, 6H); 1.82 (m, part obscured, IH); 2.79 (m, IH); 3.03 (dd, IH) ; 3.22 (dd, IH); 3.38 (quintet, IH) ; 3.57 (dd, IH); 3.82 (quintet, IH) ; 3.99 (quintet, IH); 4.19 (dd + m, 2H); 7.13 (t, IH); 7.44 (t, IH); 7.65 (t, IH).
  • the starting materials were prepared as follows:
  • the cyclohexylamine salt of 4-acetylthio-l-allyloxycarbonyl- 2-carboxy-pyrrolidine (5.6 g, 15 mM) was suspended in ethyl acetate, and shaken successively with 2M HC1 (20 ml and 10 ml), water and brine, and the ethyl acetate layer dried over MgSO,. Evaporation gave the free acid.
  • Vilsmeier reagent was prepared by treatment of dimethylformamide (0.51 ml, 6.6 mM) in dichloromethane (20 ml) under argon with oxalyl chloride (0.52 ml, 6 mM) in dichloromethane (5 ml) for 30 minutes.
  • Nmr (CDCL-,): ⁇ 2.32 (s, 3H); 2.58 (br, 2H); 3.39 (dd, IH); 4.03 (quintet, IH); 4.13 (dd, IH); 4.55 (t, part obscured, IH) ; 4.58 (dt, 2H) 4.68 (dt, 2H); 4.81 (dt, 2H); 5.23-5.49 (m, 6H) ; 5.84-6.15 ( , 3H) ; 7.36 (t, IH); 7.57 (t, IH); 7.66 (t, IH); 9.10 (br, IH).
  • (2S,4S)-4-Acetylthio-l-allyloxycarbonyl-2-(3-allyloxy-5- allyloxycarbonylphenylcarbamoyl)pyrrolidine (1.89 g, 3.9 mM) was dissolved in allyl alcohol (25 ml) and the solution flushed with argon. 1M Sodium hydroxide (4 ml, 4 mM) was added, the mixture stirred at ambient temperature for 2 hours, and then evaporated to dryness.
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.17 (d, 6H) ; 1.85 (m, obscured, IH) ; 2.73 (m, obscured, IH); 2.95 (dd, IH) ; 3.21 (dd, IH); 3.40 (m, IH); 3.54 (dd, IH); 3.78 (quintet, IH); 3.99 (t, IH); 4.11 (t, IH) ; 4.18 (dd, IH); 7.41 (d, IH); 7.75 (dd, IH); 8.06 (d, IH) .
  • the starting materials were prepared as follows:
  • Nmr (CDC1 3 ): ⁇ 2.33 (s, 3H); 2.57 (br, 2H); 3.39 (dd, IH); 4.03 (quintet, IH); 4.13 (dd, IH); 4.55 (t, IH); 4.66 (dt, 2H) 4.83 (dt, 2H); 5.24-5.47 (m, 4H); 5.85-6.02 (m, 2H); 7.36 (d, IH); 7.70 (dd, IH); 7.92 (d, IH); 9.32 (br, IH).
  • Nmr (CDCL,): ⁇ 1.24 (d, 3H); 1.36 (d, 3H); 2.65 (br, 2H); 3.25 (dd overlapping m, 2H); 3.48 (m, IH); 3.80 (quintet, IH); 3.98 (dd, IH) ; 4.20-4.31 (dd overlapping quintet, 2H); 4.52 (t, IH); 4.51-4.76 (m, 4H); 4.83 (dt, 2H); 5.20-5.47 (m, 6H); 5.85-6.11 (m, 3H); 7.39 (d, IH); 7.77 (dd, IH); 7.99 (d, IH); 9.05 (br, IH).
  • Nmr (DHSO-dg + acetic acid-d 4 ): ⁇ 1.16 (d, 3H); 1.19 (d, 3H); 1.82 (m, obscured, IH) ; 2.70 (dd overlapping m, 2H) ; 3.22 (dd, IH) ; 3.35-3.60 (overlapping m, 3H) ; 3.95-4.08 (overlapping m, 2H); 4.16 (dd, IH) ; 7.57 (d, IH); 7.69 (dd, IH); 8.36 (d, IH).
  • the starting materials were prepared as follows:
  • Nmr (CDC1 3 ): ⁇ 2.32 (s, 3H) ; 2.56 (br, IH); 2.66 (br, IH); 3.43 (dd, IH) ; 4.04 (quintet, IH); 4.16 (dd, IH); 4.61 (t, IH); 4.66 (dt, 2H) 4.82 (dt, 2H); 5.21-5.45 (m, 4H); 5.84-6.11 (m, 2H); 7.45 (d, IH); 7.77 (dd, IH) ; 9.00 (d, IH); 9.08 (br, IH) .
  • Nmr (CDCL,): ⁇ 1.23 (d, 3H) ; 1.36 (d, 3H); 2.65 (br, 2H); 3.24 (dd overlapping , 2H) ; 3.88 (quintet, IH) ; 4.08 (m, IH); 4.19-4.30 (dd overlapping quintet, 2H); 4.60 (t, IH); 4.67 (m, 4H); 4.82 (dt, 2H); 5.18-5.45 (m, 6H); 5.82-6.01 (m, 3H); 7.44 (d, IH); 7.76 (dd, IH); 9.04 (d, IH); 8.98 (br, IH).
  • Nmr (DMSO-dg + acetic acid-d 4 ) : ⁇ 1.18 (d, 6H); 1.94 (m, obscured, IH); 2.85 (m, IH); 3.10 (dd, IH); 3.23 (dd, IH); 3.40 (quintet, IH) ; 3.66 (dd, IH) ; 3.89 (quintet, IH); 3.99 (t, IH); 4.21 (dd, IH); 4.27 (t, IH) ; 7.46 (t, IH); 7.71 (d, IH) ; 7.86 (d, IH); 8.27 (s, IH).
  • the starting materials were prepared as follows:
  • Nmr (CDC1,): ⁇ 2.32 (s, 3H); 2.60 (br, 2H) ; 3.40 (dd, IH) ; 4.03 (quintet, IH) ; 4.13 (dd, IH); 4.57 (t, IH) ; 4.66 (dm, 2H); 4.82 (dt, 2H) ; 5.23-5.46 (m, 4H) ; 5.86-6.12 (m, 2H) ; 7.41 (t, IH); 7.82 (d, IH); 7.91 (d, IH) ; 8.07 (t, IH) ; 9.18 (br, IH).
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 1.20 (d, 6H); 1.99 (quintet, IH) ; 2.75 (m, part obscured, IH) ; 2.87 (dd, IH) ; 3.22 (s, 3H); 3.25 (dd, part obscured, IH); 3.44 (quintet, IH) ; 3.62 (dd, IH) ; 3.75 (quintet, IH) ; 4.03 (quintet, IH) ; 4.16-4.23 (m, 2H); 7.90 (dd, IH); 8.17 (d, IH); 9.00 (d, IH).
  • the starting materials were prepared as follows:
  • Nmr (DMS0-d fi + acetic acid-d 4 ): ⁇ 1.30 (d, 6H) ; 2.00 (m, part obscured, IH); 2.91 (m, part obscured, IH); 3.13 (dd, IH) ; 3.36 (dd, IH) ; 3.55 (dq, IH) ; 3.73 (dd, IH) ; 3.95 (m, IH); 4.12 (m, IH) ; 4.29 (dd, IH); 4.34 (dd, IH) ; 7.40 (dd, IH) ; 7.98 (m, IH); 8.32 (dd, IH).
  • the starting materials were prepared as follows:
  • the thiol was condensed with carbapenem phosphate as in Example 1, and product purified by chromatography on silica, eluting with ethyl acetate/dichloromethane (75:25) to give allyl (1R,5S,6S,8R,2S',4S')- 2-(l-allyloxycarbonyl-2-(3-carboxy-4-fluorophenylcarbamoyl)-pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate.
  • the starting materials were prepared as follows:
  • Nmr (DMSO-d, + acetic acid-d,): ⁇ 1.90 (m, part obscured, IH); 2.78 (m, IH); 3.22 (dd, IH); 3.26 (m, IH); 3.52 (ra, IH); 3.83-4.03 (m, 2H) ; 4.09 (dd, IH); 4.22 (m, IH); 4.53 (m, IH) ; 4.53-4.65 (m, 4H); 4.80 (dt, 2H); 5.05-5.43 ( , 6H) ; 5.73-5.98 (m, 2H); 5.98-6.09 (m, IH); 7.38 (dd, IH) ; 7.78 (br s, IH); 8.49 (m, IH) ; 8.62 ( , IH).
  • the starting materials were prepared as follows:
  • Nmr (CDCL-.): ⁇ 2.32 (s, 3H); 2.60 (br, 2H); 3.40 (dd, IH); 3.95-4.19 (m, 2H); 4.57 (t, IH) ; 4.67 (dt, 2H); 4.86 (dt, 2H); 5.20-5.50 (m, 4H); 5.81-6.13 (m, 2H); 6.95 (ddd, IH); 8.4 (ddd, IH); 9.2 (br, IH).
  • Nmr (DMS0-d fi + acetic acid-d 4 ): ⁇ 1.18 (d, 6H); 1.84 (m, part obscured, IH); 2.78 (m, IH); 3.02 (dd, IH) ; 3.23 (dd, IH); 3.40 (quintet, IH) ; 3.58 (dd, IH); 3.83 (quintet, IH); 4.00 (quintet, IH) ; 4.20 (dd overlapping m, 2H); 7.92 (dd, IH) ; 8.17 (d, IH) ; 8.33 (d, IH).
  • the starting material was prepared as follows:
  • Example 2 The above amine was condensed with proline acid as Example 1, purifying by medium pressure chromatography on silica using a gradient from dichloromethane to 20% diethyl ether in dichloromethane, to give (2S,4S)-l-allyloxycarbonyl-2-(3,4-diallyloxycarbonylphenylcarbamoyl) pyrrolidin-4-ylthioacetate.
  • Nmr (CDCL,): ⁇ 2.32 (s, 3H); 2.59 (br, 2H) ; 3.37 (dd, IH); 4.03 (quintet, IH) ; 4.12 (dd, IH) ; 4.56 (t, IH) ; 4.67 (d, 2H); 4.77 (t, 4H) ; 5.25-5.42 (m, 6H) ; 5.84-6.11 (m, 3H); 7.79 (m, 3H); 9.52 (br, IH).
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.17 (d, 6H); 1.95 (m, obscured, IH); 2.87 (m, obscured, IH) ; 3.17 (dd, IH) ; 3.25 (dd, IH) ; 3.42 (dt, IH); 3.75 (dd, IH); 3.99-4.05 (m, 2H); 4.22 (dd, IH) ; 4.33 (t, IH); 6.76 (d, IH); 7.56 (dd, IH); 7.97 (d, IH).
  • the starting materials were prepared as follows:
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 1.15 (d, 6H) ; 1.77 (m, part obscured, IH); 2.69 (m, part obscured, IH) ; 2.85 (m, part obscured, IH) ; 3.19 (dd, IH); 3.33-3.51 (m, 2H) ; 3.71 (quintet, IH) ; 3.94 (quintet, IH); 4.03 (t, IH); 4.15 (dd, IH) ; 8.18 (t, IH); 8.45 (d, 2H).
  • the starting materials were prepared as follows:
  • Nmr (CDCL,): ⁇ 2.33 (s, 3H); 2.60 (br, 2H); 3.40 (dd, IH) ; 4.03 (quintet, IH) ; 4.14 (dd, IH); 4.58 (t, IH); 4.65-4.70 (m, 2H) ; 4.83-4.87 ( , 4H); 5.24-5.47 (m, 6H); 5.84-6.16 (m, 3H) ; 8.39 (d, 2H) ; 8.45 (t, IH) ; 9.36 (br, IH).
  • the starting material was prepared as follows;
  • 3-Nitrobenzoic acid 50 g, 0.3 M was allylated by a similar method to that described in Example 1.
  • Solid -.C0, (82.7 g, 0.6 M) was added to the acid in dry DMF (700 ml) with stirring. There was a slight exotherm and the mixture became thick. Allyl bromide (38.8 ml, 0.45 M) was added over 30 minutes and the mixture was left stirring overnight. After filtration through diatomaceous earth, the solution was evaporated to dryness under reduced pressure and the residue partitioned between ether and aqueous NaHCO,. The ether layer was washed with dilute HCl, brine and water, dried and evaporated giving a yellow oil (62g).
  • the above thioacetate (52.7 g, 0.1 M) was converted to the thiol by dissolving it in degassed allyl alcohol (11) and adding aqueous NaOH (2M, 50 ml) at 0°C. After 3 hours aqueous HCl (2 M, 52.5 ml) was added, the solvent evaporated and the residue partitioned between EtOAc and brine. The EtOAc phase was dried over MgS0 4 , filtered and evaporated. The thiol was used without further purification.
  • the starting material was prepared as follows:
  • 5-Nitroisophthalic acid (5g) was converted to the mono allyl ester using one equivalent of allyl bromide (2 ml) using a similar method to that described in example 1.
  • the required acid (2.7 g) was extracted from the organic phase with aqueous NaHCO,.
  • the organic layer contained the di-allyl ester (2.7 g).
  • the mono acid, 3-allyloxycarbonyl-5-nitrobenzoic acid was obtained as a white solid.
  • BSTITUTE SHEET DCCI (1.3 g) was added to a solution of the above acid (1.5 g) and N-hydroxysuccinimide (0.76 g) in methylene chloride (50 ml) and the mixture stirred at ambient temperature for 2 hours. A white solid was filtered and the solution evaporated to dryness. The active ester was purified on silica gel eluting with methylene chloride then it was dissolved in methylene chloride and treated with ammonia gas at 5°C. The white solid which precipitated was 3-allyloxycarbonyl-5- nitrobenzamide (1.1 g).
  • the thiol was generated from the above thioacetate by the method described in example 12.
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 1.3-1.38 (2xd, 6H); 2.0-2.11 (m, IH) ; 2.85-2.96 (m, IH) ; 3.09 (dd, IH); 3.37 (dd, IH); 3.53 (quintet, IH) ; 3.79 (dd, IH) ; 3.94 (t, IH); 4.16 (t, IH); 4.33 (dd, IH); 4.43 (t, IH) ; 7.87 (dd, IH); 7.97 (d, IH); 9.12 (d, IH).
  • the starting material was prepared as follows: Nitroterephthalic acid (6.33 g) in methylene chloride (75 ml) and THF (15 ml) was converted to the mono acid chloride using oxalyl chloride (2.63 ml), DMF (2.55 ml) and N-methylmorpholine (7.95 ml) at -10 C. After 1 hour the solvents were removed and, without further purification, the product was dissolved in allyl alcohol (20 ml) and THF (10 ml) and stirred overnight at ambient temperature. The solvents were removed and the residue partitioned between EtOAc and aqueous NaHCO-..
  • the thiol was generated from the above thioacetate by a similar method to that described in example 12.
  • the starting material was prepared as follows:
  • allyl ester (0.44 g) was reduced with SnCl., by a similar method to the reduction described in example 1, giving allyl 2-dimethylaminocarbonyl-3-aminobenzoate (0.41 g) as a clear red oil.
  • Nmr (CDCl,, mixture of rotamers): ⁇ 2.32 (s, 3H); 2.38 (br m, part obscured, IH); 2.38 (br m, part obscured, IH); 2.74,2.76 (2 x s overlapping br m, 4H) ; 3.11,3.14 (2 x s, 3H); 3.36-3.45 (m, IH) ; 3.98-4.14 (m, 2H) ; 4.50 (dd, IH); 4.56-4.79 (m, 4H); 5.16-5.44 ( , 4H); 5.93-6.06 (m, 2H) ; 7.45 (t, IH); 7.81-7.86 (m, IH); 8.33-8.41 (2 x d, IH); 8.60 (br, IH) .
  • the thiol was generated from the above thioacetate by a similar method to that described in example 12.
  • Nmr (CDCL,, mixture of rotamers): ⁇ 1.24 (d, 3H) ; 1.35 (2 x d, 3H); 1.98 (br, IH); 2.34 (br, IH); 2.73 (s, 3H) ; 3.11,3.13 (2 x s, 3H) ; 3.22-3.46 (m, 3H) ; 3.66-3.85 (m, IH) ; 4.00-4.26 (m, 3H) ; 4.50 (t, IH); 4.62-4.80 (m, 6H); 5.08-5.46 (m, 6H); 5.83-6.06 (m, 3H); 7.46 (td, IH); 7.86 (d, IH); 8.29 (m, IH); 8.55 (br, IH).
  • Nmr (DMS0-d g + acetic acid-d 4 ) : ⁇ 1.15 (d, 3H) ; 1.17 (d, 3H); 1.74 (m, IH); 2.06 (s, 3H); 2.66 (m, IH); 2.84 (m, IH) ; 3.20 (dd, IH); 3.40 (m, 2H); 3.70 (m, IH); 3.97 (m, 2H) ; 4.16 (dd, IH) ; 7.92 (s, IH); 7.94 (s, IH) ; 8.19 (s, IH).
  • the starting material was prepared as follows:
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.15 (d, 3H) ; 1.17 (d, 3H), 2.05 (s, 3H); 2.17 (m, IH); 2.81 (m, IH); 3.26 (dd, IH); 3.36 (td, IH); 4.56-4.74 (m, 2H); 5.02-5.73 (m, 4H) ; 5.91 (m, IH) ; 7.47 (d, IH); 7.68 (d, IH) ; 7.85-7.99 (m, 3H) ; 8.20-8.29 (m, 2H).
  • the title compound was prepared from 4-allyl (1R,5S,6S,8R, 2'S,4'S)-2-(l-(4-nitrobenzyloxycarbonyl)-2-(4-acetamido-3-carboxy- phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarba- penem-3-carboxylate (diisopropylethylamine salt) using a similar method to that of example 16.
  • Nmr (DMS0-d 6 + acetic acid-d 4 ): ⁇ 1.14 (d, 3H) ; 1.16 (d, 3H); 1.75 (m, IH) ; 2.07 (s, 3H) ; 2.73 (m, IH); 2.96 (dd, IH) ; 3.21 (dd, IH); 3.39 (m, IH); 3.54 (dd, IH); 3.78 (m, IH); 3.96 (m, IH); 4.08 (t, IH); 4.18 (dd, IH); 7.69 (dd, IH); 8.18 (d, IH); 8.42 (d, IH) .
  • the starting material was prepared as follows:
  • (2S,4S)-l-(4-Nitrobenzyloxycarbonyl) -2-( -acetamido-3- carboxyphenylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from 2-acetamido-5-aminobenzoic acid using a similar method to that of example 16.
  • (2S,4S)-1-(4-Nitrobenzyloxycarbonyl) -2-(4-acetamido-3- carboxyphenylcarbamoyl)pyrrolidin-4-ylthiol was prepared from (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(4-acetamido-3-carboxy- phenylcarbamoyl)pyrrolidin-4-ylthioacetate using a similar method to that of example 16.
  • the title compound was prepared from allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5- methylsulphonamidophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem 3-carboxylate using a similar method to that of example 16.
  • Nmr (DMSOd, + acetic acid-d 4 ): ⁇ 1.16 (d, 3H); 1.17 (d, 3H); 1.74 (m, IH) ; 2.64 (m, IH); 2.81 (dd, IH); 3.01 (s, 3H); 3.20 (m, IH); 3.40 (m, 2H); 3.68 (m, IH) ; 3.96 (m, 2H) ; 4.17 (dd, IH); 7.54 (s, IH); 7.82 (s, IH) ; 8.00 (s, IH) .
  • the starting material was prepared as follows:
  • (2S,4S)-l-(4-(Nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methyl- sulphonamidophenylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from 3-amino-5-methylsulphonamidobenzoic acid using a similar method to that of example 16.
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 2.00 (m, IH) ; 2.30 (s, 3H); 2.84 (m, IH); 2.95 (s, 3H) ; 3.20-3.51 (m, IH); 3.83-4.20 (m, 2H); 4.30-4.58 (m, IH); 5.20 (m, 2H) ; 7.48-8.22 (m, 7H) .
  • (2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methyl- sulphonamidophenylcarbamoyl)pyrrolidin-4-ylthiol was prepared from (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methylsulphonamido- phenylcarbamoyl)pyrrolidin-4-ylthioacetate using a similar method to that of example 16.
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 2.10 (m, IH) ; 2.78 (m, IH); 2.99 (s, 3H); 3.43 (m, IH) ; 3.68 (m, IH) ; 4.05 (m, IH) ; 4.42 (m, IH); 5.13-5.32 (m, 3H); 7.50-8.82 (m, 7H).
  • Nmr (DMS0-d fi + acetic acid-d 4 ): ⁇ 1.20 (d, 3H); 1.22 (d, 3H); 1.96 (m, IH); 2.83 (m, IH); 3.00 (s, 3H); 2.26-3.57 (m, 3H) ; 3.87-4.28 (m, 4H); 4.42-4.76 (m, 3H); 5.08-5.42 (m, 4H) ; 5.92 (m, IH) ; 7.22-8.22 (m, 7H) .
  • the reaction mixture was stirred for 1 hour and the pH of the solution was adjusted to 8 by adding a saturated aqueous solution of sodium hydrogen carbonate. After filtration over diatomaceous earth, the filtrate was concentrated and purified by subjecting to preparative chromatography (Nucleosil C-18), using water as the eluant. Concentration and lyophilisation of the required fractions gave the title compound (44 mg, 12%).
  • Nmr (DMS0-d g + acetic acid-d 4 ): ⁇ 1.15 (d, 3H); 1.16 (d, 3H) ; 1.78 (m, IH) ; 2.73 (m, IH); 2.92 (m, IH); 3.21 (dd, IH); 3.40 (m, IH); 3.48 (m, IH) ; 3.75 (m, IH) ; 3.97 (m, IH); 4.03 (m, IH); 4.18 (m, IH); 7.93 (s, IH); 8.11 (s, IH) ; 8.29 (s, IH) .
  • (2S,4S)-l-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5-sulpho- phenylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from 3-amino-5- sulphobenzoic acid using a similar method to that of example 16.
  • Nmr (DMS0-d 6 + acetic acid-d 4 ): ⁇ 1.97 (m, IH); 2.30 (s, 3H); 2.80 (m, IH); 3.37 (m, IH); 3.86-4.15 (m, 2H); 4.46 (m, IH); 5.05-5.28 (m, 2H); 7.46-9.25 (m, 7H).
  • (2S,4S)-l-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5- sulphophenylcarbamoyl)pyrrolidin-4-ylthiol was prepared from (2S,4S)-1- (4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-sulphophenylcarbamoyl)- pyrrolidin-4-ylthioacetate using a similar method to that of example 16.
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.25 (d, 3H) ; 1.27 (d, 3H) ; 2.07 (m, IH); 2.70 (m, IH) ; 3.4 (m, IH) ; 3.67 (m, IH) ; 3.99 (m, IH) ; 4.49 (m, IH); 5.07-5.30 (m, 2H) ; 7.47-8.40 (m, 7H).
  • the starting allyl (5R,6S,8R,2'S,4'S)-2-(l-allyloxy- carbonyl-2-(3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-yl-thio)-6- (l-hydroxyethyl)carbapenem-3-carboxylate was prepared in 67% yield using a similar procedure to that described in example 1, by reacting (2S,4S) l-allyloxycarbonyl-2-(3-allyloxycarbonylphenyl- carbamoyl)pyrrolidine-4-thiol, described in example 4, with allyl (5R,6S,8R)-6-(l-hydroxyethyl)-2-diphenylphosphoryloxycarbapenem-3- carboxylate (EP-A-126780 and EP-A-208889).
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 1.17 (d, 6H); 1.95 (m, part obscured, IH); 2.83 (m, IH); 3.09 (dd, IH) ; 3.25 (dd, IH) ; 3.41 (quintet, IH); 3.64 (dd, IH); 3.88 (quintet, IH); 4.02 (quintet, IH); 4.22 (dd, IH); 4.31 (t, IH); 8.00 (s, IH); 8.28 (t, IH); 8.46 (t, IH) .
  • the starting materials were prepared as follows:
  • 3-Amino-5-nitrobenzoic acid (3.64 g, 20 mM) was dissolved in concentrated hydrochloric acid (20 ml), diluted with water (75 ml), cooled to 0°, and added over 30 minutes to a solution of NaN0 2 (1.38 g, 20 mM) in water (10 ml). The pH was adjusted to 6.2 with saturated Na 2 C0 3 solution. A mixture of CuS0 4 -5H 2 0 (10 g, 42 mM) in water (40 ml) and KCN (10 g, 154 mM) in water (20 ml) was heated to 65°, the solution of diazonium salt added over 15 minutes, and the mixture refluxed for 40 minutes.
  • Nmr (CDCL,): ⁇ 1.90 (d, IH) ; 2.52 (br, IH); 2.65 (br, IH) ; 3.34-3.52 (m, 2H) ; 4.07 (dd, IH); 4.54 (t, IH); 4.69 (d, 2H); 4.84 (d, 2H); 5.27-5.47 (m, 4H) ; 5.87-6.11 (m, 2H) ; 8.01 (s, IH); 8.21 (t, IH); 8.28 (s, IH) ; 9.56 (br, IH).
  • Nmr (DMSO-dg + acetic acid-d : ⁇ 1.17 (d, 3H); 1.18 (d, 3H); 1.83 (m, part obscured, IH); 2.76 (quintet, IH); 2.98 (dd, IH); 3.22 (dd, IH); 3.39 (quintet, IH) ; 3.56 (dd, IH) ; 3.81 (s overlapping m, 4H); 4.00 (quintet, IH); 4.15,4.18 (t overlapping dd, 2H); 7.22 (t, IH); 7.58 (t, IH); 7.84 (t, IH) .
  • the starting materials were prepared as follows:
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloro ethane/ethyl acetate (60:40 to 45:55) to give allyl (IR,5S,6S,8R,2'S, 'S)-2-(l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate.
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.18 (d, 6H); 1.87 (m, part obscured, IH); 2.64-2.91, 2.82, 2.84 (m overlpping 2 x s, 5H); 3.21 (dd, IH); 3.40 (quintet, IH) ; 3.52 (dd, IH) ; 3.71 (quintet, IH) ; 4.01 (quintet, IH); 4.01 (m, IH) , 4.18 (dd, IH); 7.83 (t, IH); 7.94 (td, IH); 8.45 (d, IH).
  • the starting materials were prepared as follows:
  • Nmr (DMSO-dg at 100°): ⁇ 1.98 (m, IH); 2.32 (s, 3H); 2.73 (s, 3H); 2.86 (m, part obscured, IH); 3.36 (m, IH); 3.91-4.10 (overlapping m, 2H); 4.48 (dd, IH); 4.53 (m, 2H) ; 4.86 (d, 2H); 5.11-5.49 (m, 4H) ; 5.80-5.97 (m, IH); 6.01-6.15 (m, IH); 8.09 (s, 2H); 8.35 (s, IH).
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from ethyl acetate to ethyl acetate/isopropanol (98:2) to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5- allyloxycarbonyl-2-methanesulphinylphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylate.
  • Nmr (DMSO-dg, mixture of rotamers): ⁇ 1.18 (d, 6H); 1.99 (br, IH); 2.80 (s overlapping m, 5H) ; 3.25 (solvent overlapping m, 2H); 3.54 (m, IH); 3.90-4.18 (m, 3H) ; 4.15 (dd, IH); 4.55 (m, 4H); 4.85 (d, 2H) ; 5.06 (d, IH); 5.14-5.46 (m, 6H); 5.79-6.13 (m, 3H); 7.80-8.05(m, 2H) ; 8.12 (m, IH); 10.10 (m, IH).
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.16 (d, 3H); 1.18 (d, 3H); 1.75 (quintet, IH) ; 2.63 (m, IH) ; 2.79 (dd, IH); 3.20 (s overlapping m, 4H) ; 3.38 (m, 2H) ; 3.64 (quintet, IH) ; 3.95 (m, 2H); 4.14 (dd, IH) ; 8.09 (t, IH); 8.44 (m, 2H) .
  • the starting materials were prepared as follows:
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloromethane/ethyl acetate (55:45 to 20:80) to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-met-hanesulphonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate.
  • Nmr (DMSO-d, + acetic acid-d 4 ): ⁇ 1.16 (d, 6H); 1.92 (m, part obscured, IH); 2.77 (m, part obscured, IH); 3.00 (dd, IH); 3.21 (dd, IH) ; 3.37 (quintet, IH); 3.59 (quintet, IH) ; 3.80 (quintet, IH) ; 3.97 (quintet, IH); 4.20 (m, 2H) ; 7.91 (br s, IH); 8.27 (br s, IH); 8.44 (br s, IH).
  • the starting materials were prepared as follows:
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.21 (d, 6H) ; 2.05 (br, IH); 2.85 (br, IH) ; 3.29 (dd, IH); 3.44 (dd, IH); 3.51 (quintet, IH) ; 3.93 (br, IH); 4.05-4.18 (m, 2H); 4.27 (dd, IH); 4.43-4.71 (overlapping m, 5H); 4.85 (d, 2H); 5.16-5.46 (m, 6H); 5.70-6.16 (m, 3H) ; 7.94 (br s, IH); 8.37 (br s, IH); 8.53 (br s, IH).
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.20 (d, 6H); 1.93 (m, part obscured, IH) ; 2.86 (quintet, IH) ; 3.02 (dd, IH); 3.26 (dd, IH) ; 3.44 (quintet, IH) ; 3.68 (dd, IH); 3.84 (quintet, IH) ; 3.95 (s, 3H); 4.03 (quintet, IH) ; 4.22 (dd, IH) ; 4.34 (t, IH); 7.13 (d, IH) ; 7.78 (dd, IH); 8.25 (d, IH) .
  • the starting materials were prepared as follows:
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2- methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate.
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.17 (d, 6H) ; 1.83 (m, part obscured, IH) ; 2.75 (quintet, IH) ; 2.97 (dd, IH) ; 3.23 (dd, IH) ; 3.40 (quintet, IH); 3.56 (dd, IH); 3.82 (s + m, 4H) ; 3.99 (quintet, IH); 4.12 (t, IH); 4.19 (dd, IH); 7.09 (d, IH) ; 7.75 (dd, IH); 7.95 (d, IH).
  • Example 4 The above amine was condensed with proline acid as Example 4, except that the material was purified by chromatography on silica, using a gradient from dichloromethane to dichloromethane/diethyl ether (4:1), giving (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl-4- methoxyphenylcarbamoyl)pyrrolidin-4-ylthioacetate.
  • TE SHEET methylcarbapenem-3-carboxylate Nmr (CDCl,): ⁇ 1.25 (d, 3H); 1.36 (d, 3H); 2.65 (br, 2H) ; 3.25 (dd, IH) ; 3.28 (quintet, IH); 3.47 (br, IH); 3.79 (quintet, IH) ; 3.89 (s, 3H); 4.01 (dd, IH); 4.18-4.29 (overlapping m, 2H); 4.51 (t, IH) ; 4.66 (m, 4H); 4.79 (dt, 2H); 5.19-5.46 (m, 6H); 5.84-6.11 (m, 3H); 6.95 (d, IH) ; 7.79-7.87 (m, 2H); 8.70 (br, IH).
  • Nmr (DMSO-dg + acetic acid-d 4 ) : ⁇ 1.18 (d, 6H); 1.85 (m, part obscured, IH); 2.66-2.86 (overlapping m, 2H) ; 3.21 (dd, IH); 3.41 (quintet, IH); 3.52-3.72 (overlapping m, 2H); 3.82 (s, 3H); 3.99 (quintet, IH); 4.08 (dd, IH); 4.17 (dd, IH); 7.17 (t, IH); 7.45 (dd, IH); 8.41 (dd, IH).
  • the starting materials were prepared as follows:
  • 2-Hydroxy-3-nitrobenzoic acid was methylated essentially as the allylation step of Example 1, except that the allyl bromide was replaced by methyl iodide, and purification by chromatography was unnecessary, to give methyl 2-methoxy-3-nitrobenzoate.
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-2- methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l- methylcarbapenem-3-carboxylate.
  • Nmr (DMSO-dg + acetic acid-d 4 ) : ⁇ 1.19 (d, 6H); 1.88 (m, part obscured, IH); 2.31 (s, 3H); 2.77 (dt, IH); 2.93 (dd, IH) ; 3.22 (dd, IH) ; 3.42 (quintet, IH); 3.57 (dd, IH); 3.77 (quintet, IH); 4.01 (quintet, IH); 4.16 (t, IH); 4.19 (dd, IH); 7.35 (d, IH); 7.69 (dd, IH); 8.39 (d, IH).
  • the starting materials were prepared as follows:
  • the starting materials were prepared as follows:
  • Nmr (DMSO-d,, mix of rotamers): ⁇ 1.91 (br m, IH); 2.33 (s, 3H); 2.76 (br m, IH) ; 3.28 (s overlapping m, 4H); 4.00 (br m, 2H); 4.38 (t, IH); 4.51 (br, 2H) ; 4.78 (dt, 2H) ; 5.01-5.46 (m overlapping br, 4H); 5.68-6.16 (m overlapping br, 2H); 7.27 (d, IH) ; 7.72 (dd, IH); 8.11 (br, 0.5H); 8.05 (br, 0.5H); 10.17 (br, IH).
  • Ms (+ FAB) 447 (MH) + ; 469 (M + Na) +
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyl- oxycarbonyl-4-methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate.
  • Nmr (DMSO-d, + acetic acid- d 4 ): ⁇ 1.19 (d, 6H) ; 1.92 (br, part obscured, IH); 2.48 (s, 3H); 2.79 (br, IH); 3.25 (dd, IH); 3.32 (t, IH); 3.54 (quintet, IH); 3.91 (br m, IH); 4.01 (quintet, IH) ; 4.12 (dd, IH); 4.25 (dd, IH) ; 4.45 (m, IH); 4.50-4.68 (m, 4H); 4.78 (dt, 2H); 5.18-5.45 (m, 6H) ; 5.70-6.13 (m over ⁇ lapping br, 3H); 7.25 (d, IH); 7.76 (dd, IH) ; 8.12 (br m, IH).
  • Nmr (DMSO- dg + acetic acid-d 4 ): ⁇ 1.13 (d, 3H); 1.15 (d, 3H); 1.76 (dt, IH) ; 2.32 (s, 3H); 2.68 (dt, IH) ; 2.87 (dd, IH); 3.18 (dd, IH); 3.36 (quintet, IH); 3.45 (dd, IH) ; 3.71 (quintet, IH) ; 3.95 (quintet, IH) ; 4.02 (t, IH); 4.14 (dd, IH); 7.49 (s, IH) ; 7.65 (s, IH); 8.05 (s, IH).
  • the starting materials were prepared as follows:
  • 3,5-Dimethylnitrobenzene (30 g, 0.198 M) was heated with stirring to 80° in a mixture of pyridine (400 ml) and water (250 ml).
  • Mn0 4 (62.7 g, 0.396 M) was added in portions over 0.75 hours, and heating continued at 85-90° for 1.75 hours.
  • the hot solution was filtered through celite, washing with hot water (150 ml).
  • the pink filtrates were decolourised with a few drops of sodium metabisulfite, and evaporated to dryness.
  • the residue was dissolved in water (250 ml), and extracted with diethyl ether (2 x 90 ml).
  • the aqueous layer was acidified (concentrated hydrochloric acid), and extracted with ethyl acetate (3 x 120 ml) . Combined organic extracts were washed with NaH-,P0 4 solution, brine, and dried over MgS0 4 . Crude product was eluted through a pad of silica, using a mixture of ethyl acetate/dichloromethane/acetic acid (25:25:1), to give 3-methyl-5- nitrobenzoic acid (14.5 g, 40%), mp 171-172°. Nmr (DMSO-dg): ⁇ 2.51 (s, 3H); 8.17 (s, IH) ; 8.30 (t, IH) ; 8.42 (t, IH) ; 13.58 (br, IH) .
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloromethane/ethyl acetate (3:2 to 2:3), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5- methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylate.
  • Nmr (CDC1 3 ): ⁇ 1.23 (d, 3H) ; 1.35 (d, 3H) ; 2.38 (s, 3H); 2.63 (br, 2H); 3.23 (dd, IH); 3.27 (quintet, IH) ; 3.46 (br, IH); 3.78 (quintet, IH) ; 4.00 (dd, IH); 4.24 (overlapping m, 2H) ; 4.51 (t, IH); 4.59-4.63 (m, 4H); 4.79 (d, 2H) ; 5.17-5.42 (m, 6H) ; 5.82- 6.09 (m, 3H); 7.61 (s, IH); 7.73 (s, IH); 7.99 (s, IH); 8.87 (br, IH).
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.18 (d, 6H); 1.92 (br, part obscured, IH); 2.81 (m, IH) ; 3.03 (dd, IH); 3.23 (dd, IH); 3.41 (quintet, IH); 3.61 (m, IH); 3.90 (s overlapping m, 4H); 4.00 (quintet, IH); 4.21 (overlapping m, 2H) ; 8.25 (t, IH) ; 8.50 (m, 2H).
  • the starting materials were prepared as follows:
  • the thiol was condensed without further purification with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyl- oxycarbonyl-5-methoxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate.
  • SU carboxylic acid, disodium salt was prepared using the technique of Example 2.
  • the starting materials were prepared as follows:
  • 2,4-Difluorobenzoic acid (5 g, 0.031 M) was dissolved in concentrated sulfuric acid (30 ml), and cooled to 0°. The mixture was stirred, and fuming nitric acid (d 1.567 g/ml, 1.91 ml, 0.047 M) added dropwise, keeping the temperature below 5°. After stirring for 3 hours, the mix was poured onto ice, and organics extracted into dichloromethane (2 x 75 ml). The combined organic layers were washed with water, dried (MgS0 4 ), and evaporated to give 2,4-difluoro-5-nitro- benzoic acid (3.9 g, 61%). Nmr (DMSO-dg): ⁇ 7.18 (t, IH); 8.88 (t, IH); 9.93 (br, IH).
  • Nmr (CDC1 3 ): ⁇ 2.33 (s, 3H); 2.63 (br, 2H); 3.39 (dd, IH); 4.04 (quintet, IH); 4.14 (dd, IH) ; 4.59 (t, IH) ; 4.66 (dt, 2H) ; 4.83 (dt, 2H); 5.22-5.49 (m, 4H); 5.84-6.13 (m, 2H) ; 6.94 (t, IH) ; 8.82 (t, IH); 9.22 (br, IH) .
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyl- oxycarbonyl-2,4-difluorophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1- hydroxyethyl)-l-methylcarbapenem-3-carboxylate.
  • the starting materials were prepared as follows:
  • a solution of sodium methoxide was prepared by dissolving sodium metal (1.42 g, 0.062 M) in methanol (40 ml) with cooling. Allyl 2,4-difluoro-5-nitrobenzoate (5 g, 0.021 M) was added and the mixture was stirred for 2 hours. A solution of NaOH (2 g, 0.05 M) in water (10 ml) was added, and the mixture stirred at ambient temperature for 16 hours. Solvent was evaporated, the residue dissolved in water (50 ml), and extracted with diethyl ether (40 ml).
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate, to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2,4- dimethoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate.
  • Nmr (CDCL-,): ⁇ 1.22 (d, 3H) ; 1.36 (d, 3H); 2.48 (br, IH) ; 2.65 (br, IH) ; 3.23 (dd, IH); 3.28 (quintet, IH) ; 3.43 (dd, IH); 3.80 (quintet, IH); 3.91 (s, 3H) ; 3.92 (s, 3H) ; 4.09 (dd, IH); 4.24 (quintet, IH); 4.27 (dd, IH) ; 4.51 (t, IH); 4.66 (m, 4H); 4.77 (dt, 2H) ; 5.20-5.45 (m, 6H) ; 5.83-6.11 (m overlapping br, 3H); 6.49 (s, IH) ; 8.45 (br, IH) ; 8.82 (s, IH) .
  • the starting materials were prepared as follows:
  • Nmr (CDCl,, mix of rotamers): ⁇ 2.25 (quintet, IH); 2.28 (s, 3H); 2.82 (br, IH); 3.52 (dd, IH); 4.13 (t, IH); 4.20 (br m, IH) ; 4.52 (dd, IH) ; 4.61 (br, 2H); 4.85 (d, 2H) ; 5.01-5.48 (m overlapping br, 4H); 5.66-6.12 (m overlapping br, 2H); 6.55 (br, IH); 6.89 (br, IH); 7.64 (br m, IH); 7.79 (br m, IH); 9.30 (br m, IH); 11.68 (br, 0.5H); 12.06 (br, 0.5H).
  • Nmr (DMSO-dg + acetic acid-d 4 ): ⁇ 1.20 (d, 6H) ; 1.99 (dt, IH) ; 2.91 (dt, IH) ; 3.26 (dd overlapping m, 3H) ; 3.42 (quintet, IH); 3.74 (dd, IH); 3.96 (quintet, IH); 4.04 (quintet, IH); 4.22 (dd, IH) ; 4.41 (t, IH) ; 7.43 (dm, IH) ; 7.81 (dd, IH); 8.00 (t, IH).
  • the starting materials were prepared as follows:
  • Nmr (CDC1 3 ): ⁇ 2.33 (s, 3H); 2.59 (br, 2H); 3.48 (dd, IH); 4.03 (quintet, IH); 4.13 (dd, IH); 4.56 (t, IH); 4.68 (dt, 2H); 4.82 (dt, 2H); 5.25-5.46 (m, 4H); 5.86-6.11 (m, 2H); 6.47 (dm, IH); 7.72 (t, IH); 7.87 (dt m, IH); 9.38 (br, IH).
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5- fluorophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl- carbapenem-3-carboxylate.
  • the starting materials were prepared as follows:
  • the above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2 / S,4 S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-N'- methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylate.
  • Nmr (CDCl,, mixture of rotamers): ⁇ 1.20 (2 x d, 3H); 1.34 (2 x d, 3H); 1.87 (br, IH); 2.30 (br, IH); 3.29, 3.31 (2 x s, overlapping m, 6H); 4.05-4.30 (m, 4H); 4.50-4.81 (m, 5H); 4.96 (d, 2H); 5.20-5.48 (m, 6H); 5.85-6.13 (m, 3H) ; 7.39-7.68 ( , 2H); 7.91-8.11 (m, 2H).

Abstract

The present invention relates to carbapenems and provides a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C¿1-4?alkyl; R?3¿ is hydrogen or C¿1-4?alkyl; R?4 and R5¿ are the same or different and are selected from hydrogen, halo, cyano, C¿1-4?alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n- wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR?3¿-. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.

Description

CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS
The present invention relates to carbapenems and in particular to such compounds containing a carboxy substituted phenyl group- This invention further relates to processes for their preparation, to intermediates in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.
The compounds of this invention are antibiotics and can be used in the treatment of any disease that is conventionally treated vith antibiotics for example in the treatment of bacterial infection in mammals including humans.
Carbapenems were first isolated from fermentation media in 1974 and were found to have broad spectrum antibacterial activity. Since this discovery substantial investigations have been made into new carbapenem derivatives and many hundreds of patents and scientific papers have been published.
The first, and so far the only, carbapenem to be commercially marketed is imipenem (N-formimidoyl thienamycin). This compound has a broad spectrum of antibacterial activity.
The present invention provides compounds with a broad spectrum of antibacterial activity including against both Gram positive and negative, aerobic and anaerobic bacteria. They exhibit good stability to beta-lactamases. In addition representative compounds of this invention exhibit a very favourable duration of action.
The carbapenem derivatives referred to herein are named in accordance with the generally accepted semi-systematic nomenclature:
Figure imgf000003_0001
UTE SHEET Accordingly the present invention provides a compound of the formula (I):
Figure imgf000004_0001
or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein:
R is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;
2 R is hydrogen or C. .alkyl; R 3 is hydrogen or C- .alkyl; R 4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C, .alkyl, nitro, hydroxy, carboxy, C-_,alkoxy,
C, ,alkoxycarbonyl, aminosulphonyl, C, ,alkylaminosulphonyl, di-C, ,- alkylaminosulphonyl, carbamoyl, C. .alkylcarbamoyl, di-C, , alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C. .alkylamino, di-C- .alkylamino, C. ,alkanoylamino, C. ,alkanoyl(N—C, .alkyl)amino,
C, .alkanesulphonamido and C, .alkylS(O) - wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a
3 position ortho to the link to -NR -.
Alkyl when used herein includes straight chain and branched chain substituents for example methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl.
Preferably R is 1-hydroxyethyl.
2 R is hydrogen or C. .alkyl for example methyl, ethyl,
2 n-propyl, isopropyl or n-butyl. Preferably R is hydrogen or methyl
2 and in particular R is methyl.
3 R is hydrogen or C, .alkyl for example methyl, ethyl,
3 n-propyl, isopropyl or n-butyl. Preferably R is hydrogen.
E SHEET 4 5 R and R are the same or different and are selected from hydrogen; halo for example fluoro, bromo or chloro; cyano; C. .alkyl for example methyl, ethyl, n-propyl, isopropyl or n-butyl; nitro; hydroxy; carboxy; C. .alkoxy for example methoxy or ethoxy; C. .alkoxycarbonyl for example methoxycarbonyl, ethoxycarbonyl and n-propoxycarbonyl; aminosulphonyl; C, .alkylaminosulphonyl for example methylaminosulphonyl and ethylaminosulphonyl; di-C. .alkylamino¬ sulphonyl for example di-methylaminosulphonyl, methylethylaminosulphonyl and di-ethylaminosulphonyl; carbamoyl; C. .alkylcarbamoyl for example metbylcarbamoyl or ethylcarbamoyl; di-C. .alkylcarbamoyl for example dimethylcarbamoyl or diethylcarbamoyl; trifluoromethyl; sulphonic acid; amino; C. .alkylamino for example methylamino or ethylamino; di-C. .alkylamino for example dimethylamino or diethylamino; C. .alkanoylamino for example acetamido or propionamido; C, ,alkanoyl(N-C, .alkyl)amino for example N-methylacetamido; C. .alkanesulphonamido for example methanesulphonamido; and C. .alkylS(O) - for example methylthio, methylsulphinyl or methylsulphonyl.
In a particular aspect a suitable class of compounds is that
4 5 in which R and R are the same or different and are selected from hydrogen, fluoro, chloro, hydroxy, carboxy, cyano, nitro, methyl, ethyl, methoxy, ethoxy, methoxycarbonyl, carbamoyl, metbylcarbamoyl, dimethylcarbamoyl, trifluoromethyl, sulphonic acid, methylsulphinyl, methylsulphonyl, methanesulphonamido or acetamido.
4 5 R and R may both be other than hydrogen but, in general, it
4 5 is particularly preferred that at least one of R and R is hydrogen.
Particularly preferred compounds are those in which R is hydrogen, carboxy, fluoro, chloro, methyl, methoxy, cyano, sulphonic acid or methoxycarbonyl and R is hydrogen.
The present invention covers all epimeric, diastereoisomeric and tautomeric forms of the compounds of the formula (I) wherein the absolute stereochemistry at the 5-position is as illustrated in
SUB formula (I). When a bond is represented by a wedge, this indicates that in three dimensions the bond would be coming out of the paper and when a bond is hatched, this indicates that in three dimensions the bond would be going back into the paper. The compounds of the formula (I) have a number of other stereocentres, namely: within the group R
(when R is 1-hydroxyethyl or l-fluoroethyl); at the 6-position; at the
2 1-position (when R is C, ,alkyl); and at the 2' and 4' positions in the pyrrolidine ring:
Figure imgf000006_0001
Preferred compounds are those in which the beta-lactam ring protons are in trans configuration with respect to one another. When R is 1-hydroxyethyl or l-fluoroethyl it is preferred that the 8-substituent has the R-configuration. Thus a preferred class of compounds is that of the formula (III):
Figure imgf000006_0002
and pharmaceutically acceptable salts and In vivo hydrolysable esters
2 3 4 5 thereof, wherein R , R , R and R are as hereinbefore defined.
2 When R is C. ,alkyl for example methyl it is preferred that the compound is in the form of the IR configuration.
Preferred compounds are those in which the pyrrolidine ring has the following absolute stereochemistry at the 2 '- and 4'- positions:
HEET
Figure imgf000007_0001
A preferred class of compounds of the present invention is that of the formula (IV):
Figure imgf000007_0002
and pharmaceutically acceptable salts and iji vivo hydrolysable esters
3 4 5 tthheerreeooff wwhhee:rein R , R , and R are as defined hereinbefore in formula (I)
Particularly preferred compounds within the formula (IV) are
3 4 5 those wherein R is hydrogen and R and R are the same or different and are selected from hydrogen, fluoro, chloro, hydroxy, carboxy, cyano, nitro, methyl, ethyl, methoxy, ethoxy, methoxycarbonyl, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, methanesulphonyl, trifluoromethyl, sulphonic acid, methylsulphinyl, methanesulphonamido or acetamido.
Especially preferred compounds within the formula (IV) are
3 5 4 those wherein R and R are both hydrogen and R is hydrogen, carboxy, fluoro, chloro, methyl, methoxy, cyano, sulphonic acid or methoxycarbonyl.
Suitable pharmaceutically acceptable salts include acid addition salts such as hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine,
SUBSTITUTE SHEET dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine. For the avoidance of doubt there may be one, two or three salt-forming cations dependent on the number of carboxylic acid functions and the valency of said cations.
Preferred pharmaceutically acceptable salts are sodium and potassium salts. However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically acceptable or not.
In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, eg. intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include C. ,alkoxymethyl esters for example methoxymethyl, C, ,aIkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C- Rcycloalkoxycarbonyloxy- C, ,alkyl esters for example 1-cyclohexyloxycarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2- onylmethyl; and C- ,alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention. Suitable in vivo hydrolysable ester forming groups for hydroxy include acetyl, propionyl, pivaloyl, C,_,alkoxycarbonyl for example ethoxycarbonyl and phenylacetyl.
Particular compounds of the present invention are:
(IR,5S,6S,8R,2'S,4 rS)-2-(2-(3-carboxy-5-hydroxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic
SUBSTITUTE SHEET acid,
( lR,5S, 6S, 8R, 2 'S, 4 'S) -2- (2- (3-carboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-methanesulphonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-2,4-difluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3,4-dicarboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-hydroxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3,5-dicarboxyphenylcarbamoyl)pyrrolidin-
4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(2-carbamoyl-3-carboxyphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-carbamoylphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-carbamoylphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-acetamidophenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-acetamidophenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic
SUBSTITUTE SHEET acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methylsulphonamidophenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-sulphophenylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-carbamoylphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-2-dimethylaminocarbonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(5R,6S,8R,2'S,4 rS)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)carbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S, 8R,2'S, 4'S)-2-(2-(3-carboxy-5-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , ' S) -2- (2- (3-carboxy-6-methylphenylcarbamoyl) - pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , 4 ' S ) -2- (2- (3-carboxy-2-methoxyphenylcarbamoyl) - pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , 4 ' S ) -2- (2- (3-carboxy-4-methoxyphenylcarbamoyl) - pyrrolidin-4-ylthio) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S, 8R, 2 'S , 4 'S)-2-(2-(3-carboxy-5-methoxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-methoxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
TE SHEET ( lR,5S, 6S,8R, 2 'S, 4 'S)-2- (2-(3-carboxy-4, 6-dimethoxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methoxycarbonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-metbylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-cyanophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-trifluoromethylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4,6-difluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-methylsulphinylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6- ( l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methylsulphonylcarbamoyl)- pyrrolidin-4-ylthio)-6-( l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
( lR,5S, 6S, 8R, 2 'S, 4 'S)-2- (2- (3-carboxy-5-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6- ( l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , 4 ' S ) -2- ( 2- (3-carboxy-6-cyanophenylcarbamoyl) - pyrrolidin-4-ylthio)-6- ( l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy N'-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof.
Preferred compounds of the present invention are:
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methylphenylcarbamoyl)-
SUBST1TUTE SHEET pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) - l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S,8R,2 'S,4'S)-2-(2-(3-carboxy-5-methoxyphenylcarbamoyl)- pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) - l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S,8R,2'S,4'S)-2-(2-(3-carbo-cy-6-methoxyphenylcarbamoyl)- pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) - l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2 S,4'S)-2-(2-(3-carboxy-5-methoxycarbonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-cyanophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid.
(lR,5S, 6S, 8R,2'S,4'S)-2-(2-(3-carboxy-4-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) - l-methylcarbapenem-3-carbox lic acid,
(lR,5S, 6S,8R,2'S, 4'S)-2-(2-(3-carboxy-6-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3,4-dicarboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid.
(IR,5S,6S,8R,2'S,4'S) -2-(2-(3,5-dicarboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid.
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-sulphophenylcarbamoyl)- pyrrolidin-4-ylthio) -6- (1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid, and pharmaceutically acceptable salts thereof.
In order to use a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.
The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, emulsions, dispersible powders, suppositories and sterile injectable aqueous or oily solutions or suspensions.
The compounds of the present invention may be formulated as dry powder filled vials, which may contain the compound of the present invention alone or as a dry blended mixture. For example an acidic compound of the present invention may be dry blended with an alkali metal carbonate or bicarbonate. Freeze dried formulations of compounds of the present invention, alone or as a mixture with standard excipients, are possible. Standard excipients include structure formers, cryoprotectants and pH modifiers, such as, mannitol, sorbitol, lactose, glucose, sodium chloride, dextran, sucrose, maltose, gelatin, bovine serum albumin (BSA), glycine, mannose, ribose, polyvinylpyrrolidine (PVP), cellulose derivatives, glutamine, inositol, potassium glutamate, erythritol, serine and other amino acids and buffer agents e.g. disodium hydrogen phosphate and potassium citrate.
SUBSTITUTE SHEET In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered with, one or more known drugs selected from other clinically useful antibacterial agents (for example other beta-lactams or aminoglycosides) , inhibitors of beta-lactamase (for example clavulanic acid), renal tubular blocking agents (e.g. probenecid) and inhibitors of metabolising enzymes (for example inhibitors of dehydropeptidases, for example Z-2-acylamino-3-substituted propenoates such as cilastatin) and N-acylated amino acids (for example see EP-A-178911) which reduce adverse effects on the kidney.
A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between lOOmg and lg of the compound of this invention.
A preferred pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example a sterile injectable containing between 1 and 50% w/w of the compound of this invention.
Specific examples of compositions, which are constituted as a IX solution in water, freeze dried and may be made up by adding 0.9% aqueous sodium chloride solution to give the required concentration, preferably lmg-lOmg/ml, are as follows:
Composition 1
Compound of Example 1 50mg
Composition 2
Compound of Example 1 50mg Glycine 31mg
Further specific examples of compositions are as above, but where the compound of example 1 is replaced by any one of examples 2 to 37.
The pharmaceutical compositions of the invention will normally be administered to man in order to combat infections caused by bacteria, in the same general manner as that employed for imipenem due allowance being made in terms of dose levels for the potency and duration of action of the compound of the present invention relative to the clinical use of imipenem. Thus each patient will receive a daily intravenous, subcutaneous or intramuscular dose of 0.05 to 5g, and preferably 0.1 to 2.5g, of the compound of this invention, the composition being administered 1 to 4 times per day, preferably 1 or 2 times a day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose. Thus a suitable daily oral dose is 0.05 to 5g of the compound of this invention, the composition being administered 1 to 4 times per day.
In a further aspect the present invention provides a process for preparing the compounds of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises deprotecting a compound of the formula (V):
Figure imgf000015_0001
2 4 5 4 5 wherein R , R and R are as hereinbefore defined (R and R being optionally protected if appropriate); -C00R and -C00R are carboxy or
8 3 9 protected carboxy; R is a group R or an amino protecting group; R is hydrogen or an amino protecting group; and R is a group R , protected
EET 1-hydroxyethyl or protected hydroxymethyl; and wherein at least one protecting group is present; and thereinafter if necessary;
(i) forming a pharmaceutically acceptable salt,
(ii) esterifying to form an in vivo hydrolysable ester.
Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
The compounds of the formula (V) are novel and form another aspect of the invention.
Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.
A carboxyl protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).
Examples of carboxy protecting groups include straight or branched chain (l-12C)alkyl groups (eg isopropyl, t-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (eg acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (eg p-methoxybenzyl, o-nitrobenzyl, p_-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (eg trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (eg trimethylsilylethyl) ; and (2-6C)alkenyl groups (eg allyl and vinylethyl).
Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis.
Examples of hydroxyl protecting groups include lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxycarbonyl groups (eg t-butoxycarbonyl); lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzoyloxycarbonyl, p_-methoxybenzyloxycarbonyl, £-nitrobenzyloxycarbonyl, £-nitrobenzyloxycarbonyl) ; tri lower alkylsilyl (eg trimethylsilyl, t-butyldimethylsilyl) and aryl lower alkyl (eg benzyl) groups.
Examples of amino protecting groups include formyl, aralkyl groups (eg benzyl and substituted benzyl, eg £-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl) ; di-£-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (eg t-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, £-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, £-nitrobenzyloxycarbonyl; trialkylsilyl (eg trimethylsilyl and t-butyldimethylsilyl); alkylidene (eg methylidene); benzylidene and substituted benzylidene groups.
Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or
SUBSTITUTE SHEET enzymically-catalysed hydrolysis, for groups such as £-nitrobenzyloxycarbonyl, hydrogenation and for groups such as (j-nitrobenzyloxycarbonyl, photolytically.
Preferred protecting groups for carboxy and hydroxy groups in compounds of the formula (I) are the groups allyl and £-nitrobenzyl. A preferred method for removal of the allyl group is by palladium catalysis using tetrakis(triphenylphosphine)palladium and Meldrum's acid, in a dipolar aprotic solvent tetrahydrofuran mixture, such as dimethylsulphoxide/tetrahydrofuran or 1,3-dimethyl-2-oxo-tetrahydro- pyrimidine/tetrahydrofuran, or an alcohol/tetrahydrofuran mixture such as isopropanol/tetrahydrofuran or ethanol/tetrahydrofuran, preferably at ambient temperature. Alternatively, methylaniline may be used in place of Meldrum's acid, in dichloromethane. These conditions allow isolation of the product by precipitation of the sodium salt on the addition of a sodium salt such as sodium 2-ethylhexanoate.
A preferred method for removal of the £-nitrobenzyl group is hydrogenation using a palladium catalyst.
In another aspect of the present invention the compounds of the formulae (I) and (V) may be prepared by
a) reacting compounds of the formulae (VI) and (VII):
Figure imgf000018_0001
wherein R , R -R are as hereinbefore defined and L is a leaving group, or b) cyclising a compound of the formula (VIII):
Figure imgf000019_0001
wherein R , R -R as hereinbefore defined and R -R are independently selected from C. ,alkoxy, aryloxy, di-C. ^alkylamino and
11 13 diarylamino or any two of R -R represent £-phenylenedioxy;
11 13 or one of R -R is C. ,alkyl, allyl, benzyl or phenyl, and the other two values are independently selected from C,_,alkyl, trifluoromethyl or phenyl, wherein any phenyl group is optionally substituted with
C. -.alkyl or C. _alkoxy: and wherein any functional group is optionally protected and thereinafter if necessary:
(i) removing any protecting groups;
(ii) forming a pharmaceutically acceptable salt;
(iii) esterifying to form an in vivo hydrolysable ester.
Suitably in the compound of the formula (VI) is the reactive ester of a hydroxy group such as a sulphonate (for 'example C, ,alkanesulphonyloxy, trifluoromethanesulphonylbxy, benzenesulphonyloxy, toluenesulphonyloxy) , a phosphoric ester (for example a diarylphosphoric ester such as diphenylphosphoric ester) or L is a halide (for example chloride). In an alternative is a sulphoxide for example -S0CH=CH-NHC0CH3 which may be readily displaced. Preferably L is diphenylphosphoric ester (-OP(O)(OPh)-,) .
Compounds of the formula (VI) and their preparation are well known in the carbapenem literature, for example see EP-A-126587, EP-A-160391, EP-A-243686 and EP-A-343499.
The reaction between the compounds of the formulae (VI) and (VII) is typically performed in the presence of a base such as an
SUBSTITUTE SHEET organic amine for example di-isopropylethylamine or an inorganic base for example an alkali metal carbonate such as potassium carbonate. The reaction is conveniently performed at a temperature between -25°C and ambient, suitably at about -20°C. The reaction is generally performed in an organic solvent such as acetonitrile or dimethylformamide. The reaction is generally performed in a manner similar to that described in the literature for similar reactions.
The compounds of the formula (VII) are novel and form another aspect of the present invention.
The compounds of the formula (VII) may be prepared by the deprotection of a compound of the formula (IX):
Figure imgf000020_0001
4 6 8 9 14 wherein R -R , R and R as hereinbefore defined and R is a protecting group, for example C, .-alkanoyl, C,_,alkoxycarbonyl or benzoyl. Preferred values for R are acetyl and t-butoxycarbonyl.
The compounds of the formula (IX) can be converted to the compounds of the formula (VII) by standard methods of deprotection, for example acetyl groups can be removed by basic hydrolysis in aqueous alkanol or alkenol for example allyl alcohol.
The compounds of the formula (IX) are novel and form another aspect of the present invention.
The compounds of the formula (IX) may be prepared by the reaction of an activated derivative of a compound of the formula (X) , which may be formed in situ, with a compound of the formula (XI) :
ET
Figure imgf000021_0001
4 6 8 9 14 wherein R -R , R , R and R are as hereinbefore defined. Activated derivatives of the compound of the formula (X) include acid halides, anhydrides and 'activated' esters such as lH-benzo[l,2,3] triazol-1-yl, pentafluorophenyl and 2,4,5-trichlorophenyl esters or the benzimidazol-2-yl ester of the thiocarboxylic acid corresponding to
(X). The reaction of the compounds of the formulae (X) and (XI) is performed under standard methods, for example in the presence of
Vilsmeier reagent (thus forming the reactive derivative of (X) in situ) at temperatures in the region -30°C to 25°C, preferably in the region
-20°C to 5°C.
The compounds of the formulae (X) and (XI) are prepared by standard methods known to the skilled chemist such as the methods of the Examples hereinafter, the methods described in EP-A-126587 or by methods analogous or similar thereto.
11 13 Suitably, in the compounds of the formula (VIII), R -R are independently selected from Cl-6 alkoxy such as methoxy, ethoxy, isopropoxy, n-propoxy or n-butoxy; aryloxy such as optionally phenoxy; di-C. ,alkylamino such as dimethylamino or diethylamino;
11 13 diarylamino such as diphenylamino or any two of R -R represent
11 13 £-phenylenedioxy. Preferably each of R -R have the same value and are C. ,alkoxy for example methoxy, ethoxy, isopropoxy or n-butoxy or are phenoxy.
The compounds of the formula (VIII) are cyclized under conventional conditions known in the art to form compounds of the formula (V) . Typical conditions are heating in a substantially inert
BSTITUTE SHEET organic solvent such as toluene, xylene or ethyl acetate at temperatures in the region 60-150°C. Typically the reaction is performed in an atmosphere of nitrogen and is carried out in the presence of a radical scavenger for example hydroquinone.
The compounds of the formula (VIII) may be formed and cyclized in situ. The compounds of the formula (VIII) may conveniently be prepared by reacting compounds of the formulae (XII) and (XIII):
Figure imgf000022_0001
11 12 13 PR^ ^R1"3 (XIII)
2 4 13 wherein R , and R -R are as hereinbefore defined.
Suitably the compound of the formula (XIII) is a phosphite or is the functional equivalent of such a compound.
The reaction between the compounds of the formulae (XII) and (XIII) is conveniently performed in an organic solvent such as toluene, xylene, ethyl acetate, chloroform, dichloromethane, acetonitrile or dimethylformamide. Typically the reaction is carried out at an elevated temperature for example 60-150°C.
The compounds of the formula (XII) may be prepared by a number of methods known in the art. For example the compounds of the formula (XII) may be prepared by the acylation of a compound of the formula (XIV):
B TITUTE SHEET
Figure imgf000023_0001
wherein R , R -R , and R -R aarree aa-s hereinbefore defined with a compound of the formula (XV)
C1-CO-C00R7 (XV)
wherein R is as hereinbefore defined.
The compounds of the formula (XIV) may be prepared by reacting compounds of the formulae (XVI) and (VII):
Figure imgf000023_0002
wherein R 2 and R10 are as hereinbefore defined. The compounds of the formula (XVI) are known in the art and may be reacted with the compounds of the formula (VII) under conventional acylation methods known in the art.
Compounds of the formulae (VII), (XII) and (XIV) are novel and, as such, form another aspect of this invention.
The following biological test methods, data and Examples serve to illustrate the present invention.
Antibacterial Activity
The pharmaceutically acceptable carbapenem compounds of the
SUBSTITUTE SHEET present invention are useful antibacterial agents having a broad spectrum of activity in vitro against standard laboratory microorganisms, both Gram-negative and Gram-positive, which are used to screen for activity against pathogenic bacteria. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system. In particular the carbapenems of the present invention show good stability to beta-lactamases and have a particularly good elimination half life in mammals. In general compounds show significant improvement over imipenem.
The antibacterial properties of the compounds of the invention may also be demonstrated in vivo in conventional tests.
Carbapenem compounds have generally been found to be relatively non-toxic to warm-blooded animals, and this generalisation holds true for the compounds of the present invention. Compounds representative of the present invention were administered to mice at doses in excess of those required to afford protection against bacterial infections, and no overt toxic symptoms or side effects attributable to the administered compounds were noted.
The following results were obtained for representative compounds on a standard in vitro test system using Diagnostic
Sensitivity Test. The antibacterial activity is described in terms of the minimum inhibitory concentration (MIC) determined by the
4 agar-dilution technique with an inoculum size of 10 CFU/spot.
ET
Figure imgf000025_0001
In the examples:
(a) NMR spectra were taken at 200MHz or 400MHz; (b) Allyloxy means the propen-1-yloxy group -0CH2CH=CH-,; (c) THF means tetrahydrofuran; (d) DMF means dimethylformamide; (e) Meldrum's acid is 2,2-dimethyl-l,3-dioxane-4,6-dione. (f) Evaporation of solvents was carried out under reduced pressure;
(g) EtOAc means ethyl acetate; (h) EEDQ means N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline; (i) DMSO means dimethyl sulfoxide; (j) DCCI means dicyclohexylcarbodiimide; and (k) The peak positions in NMR spectra taken in DMSO-d, and acetic acid-d, vary depending on the ratio of DMSO to acetic acid.
SUBSTITUTE SHEET Example 1
(lR,5S,6S,8R,2 S,4 S)-2-(2-(3-Carboxy-5-hydroxyphenylcarbamoyl)- pyrrolidin-4-yl-thio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt
To a solution of allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxy- carbonyl-2-(3-allyloxy-5-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate (500 mg, 0.72 mM) and 2,2-dimethyl-l,3-dioxane-4,6-dione (Meldrum's acid, 829 mg, 5.75 mM) in a mixture of DMF (8 ml) and THF (4 ml), under an argon atmosphere, was added tetrakis(triphenylphosphine)palladium (83 mg, 0.072 mM) . The solution was stirred, under argon with protection from light, for 2 hours. The solution was diluted with diethyl ether (40 ml) , and the resultant precipitate centrifuged, and the supernatant was removed. The product was washed by resuspension in ether followed by centrifugation, and finally dried under high vacuum. The crude product was dissolved in water (10 ml) and the pH adjusted to 6.8 with NaHCO-.. After filtration, the solution was subjected to chromatography on Diaion CHP20P resin, and the fractions combined as appropriate to give the title product (66%). Nmr (DMSO-d, + acetic acid-d,): δ 1.18 (d, 6H); 1.82 (m, part obscured, IH); 2.79 (m, IH); 3.03 (dd, IH) ; 3.22 (dd, IH); 3.38 (quintet, IH) ; 3.57 (dd, IH); 3.82 (quintet, IH) ; 3.99 (quintet, IH); 4.19 (dd + m, 2H); 7.13 (t, IH); 7.44 (t, IH); 7.65 (t, IH).
The starting materials were prepared as follows:
Allyl 3-allyloxy-5-aminobenzoate
3-Hydroxy-5-nitrobenzoic acid (3.9 g, 21.3 mM) was dissolved in DMF (55 ml), and anhydrous K2 C03 (11.78 g, 76.5 mM) added with stirring. Allyl bromide (5.4 ml, 62.4 mM) was run in, and the mixture stirred for 18 hours at ambient temperature. The solvent was removed by evaporation, the residue treated with water, the pH was adjusted to
SUBSTITUTE SHEET 5.5, and product was extracted into ethyl acetate. The combined extracts were washed with aqueous NaH2P0,, water, brine, and dried over MgSO,. The residue after evaporation was subjected to chromatography on silica, eluting with a mixture of petrol/EtOAc (10:1), to give allyl 3-allyloxy-5-nitrobenzoate (5.94 g, 90%). Nmr (CDCL-,): δ 4.66 (dt, 2H); 4.87 (dt, 2H); 5.31-5.52 (m, 4H) ; 5.94-6.14 (m, 2H) ; 7.92 (m, 2H) ; 8.46 (t, IH).
Ms (CI): 264 (MH)+
The above ester (2 g, 7.6 mM) was dissolved in ethyl acetate (15 ml), and added to a suspension of SnCl„.2H20 (13.7 g, 61 mM) , heated under reflux, in ethyl acetate (35 ml) under argon. The mixture was heated to reflux for 4 hours, cooled, and poured into a mix of 880 ammonia (20 ml) and water (20 ml). The organic layer was separated and three further extractions made with ethyl acetate. The combined extracts were washed with dilute ammonia solution, water and brine, dried over MgSO, , and evaporated to give a yellow oil of allyl 3-allyloxy-5-aminobenzoate (1.53 g, 86%). Nmr (CDC1-.): δ 3.60 (br, 2H); 4.53 (dt, 2H); 4.78 (dt, 2H); 5.25-5.44 (m, 4H); 5.96-6.12 (m, 2H); 6.43 (dt, IH); 7.00 (m, 2H) .
Ms (CI): 233 (MH)+
Preparation of Side Chain Pyrrolidin-4-ylthioacetate
The cyclohexylamine salt of 4-acetylthio-l-allyloxycarbonyl- 2-carboxy-pyrrolidine (5.6 g, 15 mM) was suspended in ethyl acetate, and shaken successively with 2M HC1 (20 ml and 10 ml), water and brine, and the ethyl acetate layer dried over MgSO,. Evaporation gave the free acid. Vilsmeier reagent was prepared by treatment of dimethylformamide (0.51 ml, 6.6 mM) in dichloromethane (20 ml) under argon with oxalyl chloride (0.52 ml, 6 mM) in dichloromethane (5 ml) for 30 minutes. 4-Acetylthio-l-allyloxycarbonyl-2-carboxypyrrolidine (1.64 g, 6 mM) in dichloromethane (7 ml) was added to this in one portion, followed by N-methylmorpholine (0.79 ml, 7.2 mM) , in dichloro-
SUBSTITUTE SHEET methane (3 ml) and stirring continued for 30 minutes at -10°. After cooling to -20°, allyl 3-allyloxy-5-aminobenzoate (1.39 g, 5.9 mM) plus N-methylmorpholine (0.79 ml, 7.2 mM) dissolved in dichloromethane (15 ml) were added dropwise. The temperature was allowed to rise to 0°, and the reaction stored for 18 hours. After dilution with dichloromethane (100 ml), the mixture was washed with 2M HCl, H-.0, and saturated NaHCO.-,, dried over HgSO,, and evaporated. Crude material was purified by medium pressure chromatography on silica using a gradient of petrol in dichloromethane (3:1 to 2:1) to give (2S,4S)-l-allyloxy- carbonyl-2-(3-allyloxy-5-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4- ylthioacetate as a gum (2.37 g, 81%). Nmr (CDCL-,): δ 2.32 (s, 3H); 2.58 (br, 2H); 3.39 (dd, IH); 4.03 (quintet, IH); 4.13 (dd, IH); 4.55 (t, part obscured, IH) ; 4.58 (dt, 2H) 4.68 (dt, 2H); 4.81 (dt, 2H); 5.23-5.49 (m, 6H) ; 5.84-6.15 ( , 3H) ; 7.36 (t, IH); 7.57 (t, IH); 7.66 (t, IH); 9.10 (br, IH).
Ms (+ve FAB): 489 (HH)+, 511 (M + Na)+
Conversion to Pyrrolidin-4-ylthiols
(2S,4S)-4-Acetylthio-l-allyloxycarbonyl-2-(3-allyloxy-5- allyloxycarbonylphenylcarbamoyl)pyrrolidine (1.89 g, 3.9 mM) was dissolved in allyl alcohol (25 ml) and the solution flushed with argon. 1M Sodium hydroxide (4 ml, 4 mM) was added, the mixture stirred at ambient temperature for 2 hours, and then evaporated to dryness. The residue taken up in ethyl acetate (100 ml), washed with 2M HCl, water, NaHCO-., brine, dried (MgSO,) and evaporated, to give (2S,4S)-1- allyloxycarbonyl-2-(3-allyloxy-5-allyloxycarbonylphenylcarbamoyl)- pyrrolidin-4-ylthiol as a gum (1.57 g, 76%). Crude material was used in the next stage.
Preparation of Protected Carbapenems
A solution of allyl (lR,5R,6S,8R)-6-(l-hydroxyethyl)- l-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (1.5 g, 3 mM) was dissolved in dry acetonitrile (18 ml) under argon, cooled to -20°, and diisopropylethylamine (0.63 ml, 3.6 mM) added, followed by dropwise addition of (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxy-5-allyloxy- carbonylphenylcarbamoyl)pyrrolidin-4-yl-thiol (1.57 g, 3.5 mM) in acetonitrile (12 ml). The reaction mixture was then stored at -20° for 3 days. Solvent was evaporated, and the residue purified by medium pressure chromatography on silica with gradient elution (dichloromethane/ethyl acetate 40:60 to 70:30), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxy-5-allyloxy- carbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l- methylcarbapenem-3-carboxylate as a gum (1.25 g, 60%). Nmr (CDC1-.): δ 1.23 (d, 3H); 1.35 (d, 3H); 2.65 (br, 2H) ; 3.26,3.31 (dd overlapping m, 2H); 3.46 (m, IH); 3.79 (quintet, IH); 4.01 (dd, IH) ; 4.19-4.29 (m, 2H); 4.50-4.78 (m, 9H) ; 5.19-5.46 (m, 8H); 5.83-6.12 (m, 4H) ; 7.36 (br s, IH); 7.64 (m, 2H); 9.00 (br, IH).
Ms (+ve FAB): 696 (MH)+, 718 (M + Na)'
Allyl (lR,5R,6S,8R)-6-(l-hydroxyethyl)-l-methyl-2-diphenyl- phosphoryloxy-carbapenem-3-carboxylate was prepared as follows.
To a solution of allyl (lR,5S,6S,8R)-6-(l-hydroxyethyl)- l-methyl-2-oxocarbapenam-3-carboxylate (2.66 mMol) [prepared in situ from allyl 2-diazo-3-oxo-4-methyl-4-(3-(1-hydroxyethyl)-2-oxoazetidin- 4-yl)butanoate and rhodium octanoate: see for example EP-A-208889] and diisopropylethylamine (1.1 equivalents in acetonitrile, at 0°C, under an argon atmosphere, was added dropwise diphenyl chlorophosphate (1.1 equivalents). The solution was stirred at ambient temperature for 30 minutes to form the corresponding 2-diphenylphosphoryloxycarbapenem.
UBSTITUTE SHEET The following further examples were prepared:
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000031_0001
Figure imgf000032_0001
Example 2
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-4-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, disodium salt was prepared in the same general manner as Example 1 except that after the addition of the palladium catalyst the solution was
SUBSTITUTE SHEET gently warmed to dissolve the catalyst and was stirred under argon with protection from light for 1 hour. A solution of sodium 2-ethylhexanoate in THF was added and the combined solutions poured into THF with vigorous stirring. The resultant precipitate was centrifuged and supernatant removed. The product was washed twice by resuspension in THF followed by centrifugation and finally dried under high vacuum to give the title product. Nmr (DMSO-dg + acetic acid-d4): δ 1.17 (d, 6H) ; 1.85 (m, obscured, IH) ; 2.73 (m, obscured, IH); 2.95 (dd, IH) ; 3.21 (dd, IH); 3.40 (m, IH); 3.54 (dd, IH); 3.78 (quintet, IH); 3.99 (t, IH); 4.11 (t, IH) ; 4.18 (dd, IH); 7.41 (d, IH); 7.75 (dd, IH); 8.06 (d, IH) .
Ms (+ve FAB): 532/534 (MH)+, (Na salt)+; 554/556 (Na2 salt)"1"
The starting materials were prepared as follows:
2-Chloro-5-nitrobenzoic acid was allylated essentially as in Example 1, except that the final extraction solvent was toluene, to give allyl 2-chloro-5-nitrobenzoate. Nmr (CDC1-.): δ 4.89 (dt, 2H) ; 5.33-5.51 (m, 2H); 5.96-6.15 (m, IH); 7.66 (d, IH); 8.27 (dd, IH); 8.72 (d, IH) .
Ms (CI): 241/243 M+, 259/261 (M + NH,)'
Stannous chloride dihydrate was refluxed in ethanol, under an argon blanket, to give a solution. The heat was removed, and the above nitro compound in ethanol was run in. Refluxing was then continued for 3 hours, the mixture cooled, and solvents removed. The residue was dissolved in ethyl acetate, and treated with 880 ammonia until basic. The organic phase was decanted from precipitated tin salts, and the slurry re-extracted similarly with more solvent. Combined organic phases were then washed with diluted ammonia, water, and brine, before drying over MgSO,. Evaporation gave allyl 5-amino-2-chlorobenzoate. Nmr (CDC1-.): δ 3.74 (br, 2H); 4.81 (dt, 2H) ; 5.27-5.47 (m, 2H) ; 5.93-6.13 (m, IH); 6.73 (dd, IH); 7.15 (d, IH) ; 7.24 (d, IH) .
Ms (CI): 212/214 M+, 229/231 (M + NH4)+
SUBSTITUTE SHEET The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of dichloromethane/diethyl ether (100:0 to 95:5) to give (2S,4S)-l-allyloxycarbonyl-2-(3- allyloxycarbonyl-4-chlorophenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDC13): δ 2.33 (s, 3H); 2.57 (br, 2H); 3.39 (dd, IH); 4.03 (quintet, IH); 4.13 (dd, IH); 4.55 (t, IH); 4.66 (dt, 2H) 4.83 (dt, 2H); 5.24-5.47 (m, 4H); 5.85-6.02 (m, 2H); 7.36 (d, IH); 7.70 (dd, IH); 7.92 (d, IH); 9.32 (br, IH).
Ms (+ve FAB): 467/469 (MH)+, 489/491 (M + Na)+
The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as in Example 1, purifying by chromatography using gradient elution from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl- 4-chlorophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (CDCL,): δ 1.24 (d, 3H); 1.36 (d, 3H); 2.65 (br, 2H); 3.25 (dd overlapping m, 2H); 3.48 (m, IH); 3.80 (quintet, IH); 3.98 (dd, IH) ; 4.20-4.31 (dd overlapping quintet, 2H); 4.52 (t, IH); 4.51-4.76 (m, 4H); 4.83 (dt, 2H); 5.20-5.47 (m, 6H); 5.85-6.11 (m, 3H); 7.39 (d, IH); 7.77 (dd, IH); 7.99 (d, IH); 9.05 (br, IH).
Ms (+ve FAB): 674/676 (MH)+, 696/698 (M + Na)+
Example 3
(lR,5S,6S,8R,2'S,4'S)-2-(2-(5-Carboxy-2-chlorophenylcarbamoyl)- pyrrolidin-4-yl-thio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic' acid, disodium salt was prepared using the technique of Example 2. Nmr (DHSO-dg + acetic acid-d4): δ 1.16 (d, 3H); 1.19 (d, 3H); 1.82 (m, obscured, IH) ; 2.70 (dd overlapping m, 2H) ; 3.22 (dd, IH) ; 3.35-3.60 (overlapping m, 3H) ; 3.95-4.08 (overlapping m, 2H); 4.16 (dd, IH) ; 7.57 (d, IH); 7.69 (dd, IH); 8.36 (d, IH). Ms (+ve FAB): 532/534 (MH)+, (Na salt)+; 554/556 (Na2 salt)+
The starting materials were prepared as follows:
4-Chloro-3-nitrobenzoic acid was allylated essentially as in Example 1 above to give allyl 4-chloro-3-nitrobenzoate. Nmr (CDC1-,): δ 4.86 (d, 2H); 5.31-5.48 (m, 2H); 5.94-6.13 (m, IH); 7.50 (d, IH); 8.18 (dd, IH); 8.52 (d, IH).
Ms (CI): 241/243 M+, 259/261 (M + NH4)+
Reduction of the above nitro compound by the method of Example 2 gave allyl 3-amino-4-chlorobenzoate. Nmr (CDCL,): δ 4.08 (br, 2H); 4.79 (dt, 2H); 5.25-5.44 (m, 2H); 5.92-6.11 (m, IH); 7.30 (d, IH); 7.38 (dd, IH); 7.47 (d, IH).
Ms (CI): 212/214 M+, 229/231 (M + NH4)+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of dichloromethane/diethyl ether (100:0 to 95:5) to give (2S,4S)-l-allyloxycarbonyl-2-(5- allyloxycarbonyl-2-chlorophenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDC13): δ 2.32 (s, 3H) ; 2.56 (br, IH); 2.66 (br, IH); 3.43 (dd, IH) ; 4.04 (quintet, IH); 4.16 (dd, IH); 4.61 (t, IH); 4.66 (dt, 2H) 4.82 (dt, 2H); 5.21-5.45 (m, 4H); 5.84-6.11 (m, 2H); 7.45 (d, IH); 7.77 (dd, IH) ; 9.00 (d, IH); 9.08 (br, IH) .
Ms (+ve FAB): 467/469 (MH)+, 489/491 (M + Na)+
The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as Example 1, purifying by chromatography using gradient elution from dichloromethane to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2-chloro phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylate. Nmr (CDCL,): δ 1.23 (d, 3H) ; 1.36 (d, 3H); 2.65 (br, 2H); 3.24 (dd overlapping , 2H) ; 3.88 (quintet, IH) ; 4.08 (m, IH); 4.19-4.30 (dd overlapping quintet, 2H); 4.60 (t, IH); 4.67 (m, 4H); 4.82 (dt, 2H); 5.18-5.45 (m, 6H); 5.82-6.01 (m, 3H); 7.44 (d, IH); 7.76 (dd, IH); 9.04 (d, IH); 8.98 (br, IH).
Ms (+ve FAB): 674/676 (MH)+, 696/698 (M + Na)+
Example 4
(lR,5S,6S,8R,2'S,4 S)-2-(2-(3-Carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)- 6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, disodium salt was prepared using the technique of Example 2 except that a mixture of DMSO and THF was used. Nmr (DMSO-dg + acetic acid-d4) : δ 1.18 (d, 6H); 1.94 (m, obscured, IH); 2.85 (m, IH); 3.10 (dd, IH); 3.23 (dd, IH); 3.40 (quintet, IH) ; 3.66 (dd, IH) ; 3.89 (quintet, IH); 3.99 (t, IH); 4.21 (dd, IH); 4.27 (t, IH) ; 7.46 (t, IH); 7.71 (d, IH) ; 7.86 (d, IH); 8.27 (s, IH).
Ms (+ve FAB): 498 (MH)+, (Na salt)"1"; 520 (Na2 salt)"1"
The starting materials were prepared as follows:
3-Nitrobenzoic acid was allylated essentially as in Example 1, except that the final extraction solvent was diethyl ether, to give allyl 3-nitrobenzoate. Nmr (CDCL-,): δ 4.88 (d, 2H) ; 5.33-5.49 (m, 2H); 5.96-6.17 (m, IH); 7.66 (t, IH); 8.41 (td, 2H); 8.88 (t, IH).
Reduction of the above nitro compound by the method of Example 2, except that the solvent was methanol, gave allyl 3-aminobenzoate. Nmr" (CDC13): δ 3.38 (br, 2H); 4.79 (dt, 2H) ; 5.24-5.44 (m, 2H); 5.93-6.09 (m, IH); 6.86 (dm, IH) ; 7.21 (t, IH) ; 7.37 (t, IH); 7.45 (dt, IH) .
Preparation of Side Chain Pyrrolidin-4-ylthioacetate
(2S,4S)-4-Acetylthio-l-allyloxycarbonyl-2-carboxypyrrolidine (2.54 g, 9.3 mM), allyl 3-aminobenzoate (1.5 g, 8.5 mM), and 2-ethoxy-l-ethoxycarbonyl-l,2-dihydroquinoline (2.72 g, 11 mM) were dissolved in toluene (50 ml) and stirred for 18 hours at ambient temperature. The reaction mixture was diluted with ethyl acetate (150 ml) and washed with 2M HCl (3 by 30 ml), water, saturated NaHCO-., and brine. Drying over MgS04 and evaporation gave (2S,4S)-4-acetylthio-l- allyloxycarbonyl-2-(3-allylόxycarbonylphenylcarbamoyl)pyrrolidine as a gum (3.7 g, 100%) in a state sufficiently pure for further work. Nmr (CDC1,): δ 2.32 (s, 3H); 2.60 (br, 2H) ; 3.40 (dd, IH) ; 4.03 (quintet, IH) ; 4.13 (dd, IH); 4.57 (t, IH) ; 4.66 (dm, 2H); 4.82 (dt, 2H) ; 5.23-5.46 (m, 4H) ; 5.86-6.12 (m, 2H) ; 7.41 (t, IH); 7.82 (d, IH); 7.91 (d, IH) ; 8.07 (t, IH) ; 9.18 (br, IH).
The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as Example 1, purifying by chromatography using gradient elution from dichloromethane to ethyl acetate/dichloromethane 1:1, to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2- (3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDC1-.): δ 1.24 (d, 3H); 1.36 (d, 3H); 2.64 (br, 2H); 3.26,3.28 (dd overlapping m, 2H) ; 3.48 (m, IH); 3.81 (quintet, IH) ; 4.01 (dd, IH) ; 4.22-4.32 (m, 2H) ; 4.54 (t, IH); 4.62-4.75 (m, 4H) ; 4.82 (m, 2H); 5.19-5.45 (m, 8H) ; 5.82-6.10 (m, 4H); 7.41 (d, IH); 7.81 (d, IH) ; 7.92 (dm, IH); 8.11 (t, IH) ; 8.98 (br, IH).
Ms (+ve FAB): 640 (MH)+, 662 (M + Na)+
Example 5
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-6-methanesulphonylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid disodium salt was prepared from the appropriate protected carbapenem as described in Example 1. Nmr (DMSO-d, + acetic acid-d4): δ 1.20 (d, 6H); 1.99 (quintet, IH) ; 2.75 (m, part obscured, IH) ; 2.87 (dd, IH) ; 3.22 (s, 3H); 3.25 (dd, part obscured, IH); 3.44 (quintet, IH) ; 3.62 (dd, IH) ; 3.75 (quintet, IH) ; 4.03 (quintet, IH) ; 4.16-4.23 (m, 2H); 7.90 (dd, IH); 8.17 (d, IH); 9.00 (d, IH).
SUBSTITUTE SHEET Ms (+ve FAB) : 554 (MH)+, 576 (Na salt)"1", 598 (Na2 salt)"1"
The starting materials were prepared as follows:
4-Methanesulphonyl-3-nitrobenzoic acid was allylated essentially as in Example 1, except that crude product was purified by chromatography over silica, eluting with a gradient of dichloromethane to dichloromethane/diethyl ether 9:1, to give allyl 4-methanesulphonyl- 3-nitrobenzoate. Nmr (CDCl..): δ 3.45 (s, 3H); 4.90 (dt, 2H); 5.30-5.49 (m, 2H); 5.96-6.12 (m, IH); 8.29 (d, IH); 8.40-8.46 (m, 2H).
Reduction as in Example 1, except that the solvent was methanol, gave allyl 3-amino-4-methanesulphonylbenzoate. Nmr (CDCl,): δ 3.07 (s, 3H); 4.82 (dt, 2H); 5.05 (br, 2H); 5.29-5.44 (m, 2H); 5.95-6.11 (m, IH); 7.46 (m, 2H); 7.81 (d, IH).
Ms (+ve FAB): 256 (MH)+, 273 (M + NH4)+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of dichloromethane/diethyl ether (100:0 to 90:10), to give (2S,4S)-l-allyloxycarbonyl-2-(5- allyloxycarbonyl-2-methanesulphonylphenylcarbamoyl)pyrrolidin-4- ylthioacetate. Nmr (CDCl.-): δ 2.31 (s, 3H) ; 2.41 (m, IH); 2.80 (m, IH); 3.11 (s, 3H); 3.51 (dd, IH) ; 4.00-4.18 (m, 2H); 4.53 (dd, IH); 4.65 (2m, 2H) 4.87 (dt, 2H); 5.23-5.47 (m, 4H) ; 5.83-6.13 (m, 2H) ; 7.93 (dd, IH) ; 8.03 (d, IH); 9.09 (br s, IH) .
Hs (+ve FAB): 511 (MH)+, 533 (M + Na)+
The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as Example 1, purifying by chromatography using gradient elution from dichloromethane through to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl- 2-methanesulphonylphenylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1- hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.21 (d,
SUBSTITUTE SHEET 3H); 1.35 (d, 3H) ; 2.43 (m, IH); 2.75 (br, IH) ; 3.08 (s, 3H) ; 3.23 (dd overlapping m, 2H); 3.55 (dd, IH); 3.85-4.08 (m, 2H); 4.19-4.28 (m, 2H); 4.53-4.68 (m, 5H); 4.86 (dt, 2H); 5.17-5.47 (m, 6H); 5.79-6.12 (m, 3H); 7.92 (dd, IH); 8.00 (d, IH); 9.16 (br s, IH); 10.14 (br, IH).
Ms (+ve FAB): 718 (MH)+, 740 (M + Na)+
Example 6
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-4-fluorophenylcarbamoyl)pyrrolidin- 4-yl-thio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid
To a solution of allyl (lR,5S,6S,8R,2'S,4'S)-2-(l'- allyloxycarbonyl-2'-(3-allyloxycarbonyl-4-fluorophenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate (199 mg, 0.3 mM) and 2,2-dimethyl-l,3-dioxane-4,6-dione (Meldru 's acid, 259 mg, 1.8 mM) in DMF (1.5 ml), under an argon atmosphere, was added tetrakis(triphenylphosphine)palladium (10 mg, 0.009 mM) in THF (0.1 ml). The solution was stirred under argon for 2 hours and tetrakis(triphenyl- phosphine)palladium (5 mg, 0.0045 mM) in THF (0.1 ml) was added. After stirring for 30 minutes, THF (3 ml) and ether (9 ml) were added, the resultant solid filtered off, washed with ether (9 ml), and dried under high vacuum to give the title product (72 mg, 49%). Nmr (DMS0-dfi + acetic acid-d4): δ 1.30 (d, 6H) ; 2.00 (m, part obscured, IH); 2.91 (m, part obscured, IH); 3.13 (dd, IH) ; 3.36 (dd, IH) ; 3.55 (dq, IH) ; 3.73 (dd, IH) ; 3.95 (m, IH); 4.12 (m, IH) ; 4.29 (dd, IH); 4.34 (dd, IH) ; 7.40 (dd, IH) ; 7.98 (m, IH); 8.32 (dd, IH).
Ms (+ve FAB): 494 (MH)+, 516 (M + Na)+
The starting materials were prepared as follows:
Allyl 5-amino-2-fluorobenzoate
2-Fluoro-5-nitrobenzoic acid (4.16 g, 22.5 mM) was dissolved in DMF (45 ml), and anhydrous K2C0, (4.65 g, 33.7 mM) added with stirring.
ET Allyl bromide (2.38 ml, 28.1 mM) was run in, the mixture was stirred for 18 hours at ambient temperature before being poured into water (450 ml) and extracted with diethyl ether (3 x 100 ml). The combined extracts were dried over MgS04, and evaporated to give a yellow oil (5.4 g). The oil was purified by chromatography on silica, eluting with a mixture of ethyl acetate/hexane (12.5:87.5), to give allyl 2-fluoro-5-nitrobenzoate (4.64 g, 92%). Nmr (CDCl-.): δ 4.89 (d, 2H) ; 5.30-5.50 (m, 2H) ; 5.90-6.10 (m, IH); 7.32 (t, IH); 8.38-8.46 (m, IH); 8.86 (dd, IH).
Ms (El): 226 (MH)+; (CI) : 225 M+, 243 (M + NH4)+
The above ester (2.47 g, 10.97 mM) was dissolved in methanol (40 ml), and stannous chloride dihydrate (9.89 g, 43.76 mM) in cone HCl (9 ml) was added to the stirred solution while maintaining the temperature between 5° and 15°. The mixture was then stirred overnight at ambient temperature before being poured into water (200 ml) and neutralized with solid NaHCO, (17.6 g) to pH6. The mixture was extracted with chloroform (3 x 200 ml) , the combined extracts were dried over MgS04, and evaporated to give allyl 5-amino-2-fluorobenzoate (2.09 g, 98%) as a yellow oil. Nmr (CDC13): δ 3.60 (br s, 2H); 4.82 (dt, 2H); 5.25-5.48 (m, 2H); 5.93-6.12 (m, IH); 6.78 (ddd, IH); 6.93 (dd, IH) ; 7.20 (dd, IH) .
Hs (El): 195 M+; (CI) : 196 (MH)+; 213 (H + NH4)+
The above amine was condensed with the proline acid as in Example 1. The product was purified by chromatography on silica using ethyl acetate/hexane (42.5:57.5) to give (2S,4S)-l-allyloxycarbonyl- 2-(3-allyloxycarbonyl-4-fluorophenylcarbamoyl)pyrrolidin-4-ylthioacetate.- Nmr (CDC13): δ 2.32 (s, 3H); 2.50-2.70 (br s, 2H); 3.40 (d, IH); 3.98-4.20 (m, 2H); 4.56 (t, IH); 4.67 (dt, 2H); 4.84 (dt, 2H); 5.20-5.50 (m, 4H); 5.83-6.12 ( , 2H); 7.10 (dd, IH); 7.80-7.89 (m, IH) ; 7.93 (dd, IH) ; 8.90-9.40 (br s, IH).
Ms (+ve FAB): 451 (MH)+, 473 (M + Na)+ Conversion to Pyrrolidin-4-ylthiol
(2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl-4-fluorophenyl carbamoyl)-pyrrolidin-4-ylthioacetate (1.33 g, 2.96 mM) was dissolved in allyl alcohol (30 ml) and the solution flushed with argon. 1M Sodium hydroxide (3.1 ml, 3.1 mM) was added, the mixture stirred at ambient temperature for 30 minutes, treated with acetic acid (0.3 ml), stirred fo a further 5 minutes, and then evaporated to dryness. The residue was taken up in ethyl acetate (60 ml), washed with saturated aq. NaHCO, (60 ml), brine, dried (MgS04) and evaporated, to give (2S,4S)-l-allyloxy- carbonyl-2-(3-allyloxycarbonyl-4-fluorophenylcarbamoyl)pyrrolidin-4- ylthiol as a gum (1.07 g, 89%). The crude material was used as such in the next stage.
The thiol was condensed with carbapenem phosphate as in Example 1, and product purified by chromatography on silica, eluting with ethyl acetate/dichloromethane (75:25) to give allyl (1R,5S,6S,8R,2S',4S')- 2-(l-allyloxycarbonyl-2-(3-carboxy-4-fluorophenylcarbamoyl)-pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDCl,) : δ 1.24 (d, 3H); 1.35 (d, 3H) ; 2.40-2.80 (br, 2H) ; 3.24-3.28 (m, 2H); 3.40-3.58 (br, IH); 3.80 (dq, IH); 3.99 (dd, IH); 4.19-4.33 (m, 2H); 4.53 (t, IH); 4.59-4.77 (m, 4H) ; 4.77-4.88 (m, 2H); 5.17-5.50 (m, 6H) ; 5.80-6.13 (m, 3H) ; 7.10 (dd, IH) ; 7.82-7.95 (m, IH); 8.00 (dd, IH); 8.70-9.20 (br s, IH) .
Ms (+ve FAB): 658 (MH)+
Example 7
(IR,5S,6S,8R,2'S,4'S)-2-(2-(5-Carboxy-2-fluorophenylcarbamoyl)- pyrrolidin-4-yl-thio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid was prepared from the appropriate protected carbapenem as in Example 6. Nmr (DMS0-d6 + acetic acid-d4): δ 1.30 (d, 6H) ; 1.84 (m, IH) ; 2.80-2.93 (m, 2H) ; 3.36 (dd, IH) ; 3.58 (m, IH) ; 3.66 (dd, IH) ; 3.81 (m, IH); 4.09( dq, IH); 4.21 (m, IH); 4.31 (dd, IH); 7.56 (dd, IH); 8.07 (m, IH); 8.90 (d, IH). Ms (+ve FAB) : 494 (HH)+, 516 (H + Na)+
The starting materials were prepared as follows:
Allyl 3-amino-4-fluorobenzoate
4-Fluoro-3-nitrobenzoic acid was allylated as in Example 6 to give allyl 4-fluoro-3-nit.ro benzoate. Nmr (CDCL-.): δ 4.87 (dt, 2H); 5.48-5.32 (m, 2H) ; 5.95-6.14 (m, IH); 7.40 (dd, IH); 8.30-8.38 (m, IH); 8.76 (dd, IH).
Ms (El): 225 M+; (CI): 225 M+, 243 (M + NH4)+
The above was reduced essentially as in Example 2, except that methanol was used as solvent to give allyl 3-amino-4-fluorobenzoate. Nmr (CDC13): δ 3.70 (br, 2H) ; 4.79 (dt, 2H); 5.25-5.44 (m, 2H); 5.96-6.09 (m, IH); 7.02 (dd, IH); 7.41-7.54 (m, 2H).
Ms (El): 195 M+; (CI): 196 (MH)+
The above amine was condensed with the proline acid as in Example 1, purifying the product by chromatography on silica using ethyl acetate/hexane (50:50) as eluent, to give (2S,4S)-l-allyloxycarbonyl- 2-(5-allyloxycarbonyl-2-fluorophenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCLj): δ 2.33 (s, 3H); 2.62 (br, 2H) ; 3.40 (dd, IH) ; 3.98-4.20 (m, 2H); 4.60 (t, IH); 4.67 (dt, 2H); 4.82 (dt, 2H) ; 5.2-5.5 (m, 4H); 5.8-6.15 (m, 2H); 7.16 (dd, IH); 7.83 (ddd, IH); 8.97 (dd, IH); 9.27 (br, IH).
Ms (El): 451 (MH)+; (CI) : 451 (MH)+
The above thioacetate was deacetylated to thiol, condensed with carbapenem phosphate as in Example 6, and the product purified by chromatography (eluting with ethyl acetate) to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl- 2-fluorophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (DMSO-d, + acetic acid-d,): δ 1.90 (m, part obscured, IH); 2.78 (m, IH); 3.22 (dd, IH); 3.26 (m, IH); 3.52 (ra, IH); 3.83-4.03 (m, 2H) ; 4.09 (dd, IH); 4.22 (m, IH); 4.53 (m, IH) ; 4.53-4.65 (m, 4H); 4.80 (dt, 2H); 5.05-5.43 ( , 6H) ; 5.73-5.98 (m, 2H); 5.98-6.09 (m, IH); 7.38 (dd, IH) ; 7.78 (br s, IH); 8.49 (m, IH) ; 8.62 ( , IH).
Ms (+ve FAB): 658 (MH)+, 680 (M + Na)+
Example 8
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-2,4-difluorophenyl carbamoylpyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, was prepared from the appropriate protected carbapenem as in Example 7. Nmr: (DMSO-dg + acetic acid-d4): δ 1.29 (d, 6H) ; 1.94-1.99 (m, part obscured IH); 2.81-3.07 (m, IH) ; 3.05 (dd, IH); 3.37 (dd, IH) ; 3.56 (m, IH); 3.75 (dd, IH); 3.92 (q, IH); 4.10 (dq, IH); 4.29-4.38 (m, 2H); 7.22 (t, IH); 8.07 (m, IH) .
Ms (+ve FAB): 512 (MH)+, 534 (M + Na)+
The starting materials were prepared as follows:
Allyl 3-amino-2,6-difluorobenzoate
2,6-Difluoro-3-nitrobenzoic acid was allylated as in Example 6 to give allyl 2,6-difluoro-3-nitrobenzoate. Nmr (CDCl-.): 4.90 (dt, 2H); 5.33-5.50 (m, 2H); 5.95-6.03 (m, IH); 7.09-7.27 (ddd, IH); 8.22-8.27 (ddd, IH).
Ms (El): 244 (MH) ; (CI): 261 (M + NH,)'
The above ester was reduced as in Example 2, except that methanol was used as the solvent, to give allyl
3-amino-2,6-difluorobenzoate. Nmr (CDCl-.): δ 4.86 (dt, 2H) ; 5.27-5.49 (m, 2H); 5.95-6.09 (m, IH); 6.77-6.86 (m, 2H) .
SUBSTITUTE SHEET MS (El) : 213 M+; (CI) : 214 (MH)+
The above amine was condensed with the proline acid as in Example 1, purifying by chromatography and eluting with ethyl acetate/hexane (40:60), to give (2S,4S)-l-allyloxycarbonyl-2- (3-allyloxycarbonyl-2,4-difluorophenylcarbamoyl)pyrrolidin-4- ylthioacetate. Nmr (CDCL-.): δ 2.32 (s, 3H); 2.60 (br, 2H); 3.40 (dd, IH); 3.95-4.19 (m, 2H); 4.57 (t, IH) ; 4.67 (dt, 2H); 4.86 (dt, 2H); 5.20-5.50 (m, 4H); 5.81-6.13 (m, 2H); 6.95 (ddd, IH); 8.4 (ddd, IH); 9.2 (br, IH).
MS (+ve FAB): 469 (MH)+
The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as in Example 6. The product was purified by chromatography on silica, eluting with ethyl acetate, to give allyl (IR,5S,6S,8R,2S',4S')-2-(l-allyloxycarbonyl-2-(3-carboxy-2,4-difluoro phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl- carbapenem-3-carboxylate. Nmr (CDCl-.): δ 1.26 (d, 3H); 1.36 (d, 3H); 1.80 (d, IH); 2.62 (br, 2H); 3.19-3.36 (m, 2H) ; 3.44 (dd, IH); 3.08 (q, IH); 4.05 (dd, IH); 4.19-4.33 (m, 2H); 4.50-4.80 (m, 5H) ; 4.86 (dt, 2H); 5.17-5.50 (m, 6H); 5.82-6.10 (m, 3H); 6.95 (dt, IH) ; 8.38 (dt, IH); 9.00 (br, IH).
Ms (+ve FAB): 676 (MH)+, 698 (M + Na)+
Example 9
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3,4-Dicarboxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, trisodium salt was prepared using the technique of Example 2 except that a mixture of DMSO and THF was used. Nmr (DMS0-dfi + acetic acid-d4): δ 1.18 (d, 6H); 1.84 (m, part obscured, IH); 2.78 (m, IH); 3.02 (dd, IH) ; 3.23 (dd, IH); 3.40 (quintet, IH) ; 3.58 (dd, IH); 3.83 (quintet, IH); 4.00 (quintet, IH) ; 4.20 (dd overlapping m, 2H); 7.92 (dd, IH) ; 8.17 (d, IH) ; 8.33 (d, IH).
SUBSTITUTE SHEET Ms (+ve FAB) : 542 (MH) + , (Na salt)4"; 564 (Na2 salt)"1"
The starting material was prepared as follows:
2-Carboxy-4-nitrobenzoic acid was allylated according to the procedure of Example 1 to give allyl 2-allyloxycarbonyl-4-nitrobenzoate. Nmr (CDCl,): δ 4.85 (dt, 4H); 5.29-5.47 (m, 4H); 5.91-6.12 (m, 2H); 7.88 (d, IH); 8.38 (dd, IH); 8.63 (d, IH).
Reduction of the above nitro compound by the method of Example 2, and purifying by medium pressure chromatography on silica using a gradient of dichloromethane/diethyl ether (100:0 to 90:10), gave allyl 2-allyloxycarbonyl-4-amino-benzoate. Nmr (CDCl,): δ 3.94 (br, 2H); 4.71-4.80 (m, 4H) ; 5.22-5.42 (m, 4H); 5.88-6.10 (m, 2H) ; 6.69 (dd, IH) ; 6.75 (d, IH); 7.74 (d, IH).
The above amine was condensed with proline acid as Example 1, purifying by medium pressure chromatography on silica using a gradient from dichloromethane to 20% diethyl ether in dichloromethane, to give (2S,4S)-l-allyloxycarbonyl-2-(3,4-diallyloxycarbonylphenylcarbamoyl) pyrrolidin-4-ylthioacetate. Nmr (CDCL,): δ 2.32 (s, 3H); 2.59 (br, 2H) ; 3.37 (dd, IH); 4.03 (quintet, IH) ; 4.12 (dd, IH) ; 4.56 (t, IH) ; 4.67 (d, 2H); 4.77 (t, 4H) ; 5.25-5.42 (m, 6H) ; 5.84-6.11 (m, 3H); 7.79 (m, 3H); 9.52 (br, IH).
The above thioacetate was deacetylated to thiol, which was condensed without further purification with carbapenem phosphate as Example 1, finally purifying by medium pressure chromatography on silica, using dichloromethane/ethyl acetate 3:2 as eluant, to.give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3,4-diallyloxycarbonyl- phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylate. Nmr (CDCLj): δ 1.24 (d, 3H); 1.35 (d, 3H) ; 2.62 (br, 2H); 3.26 (dd overlapping m, 2H) ; 3.47 (br, IH) ; 3.81 (quintet, IH); 3.97 (dd, IH); 4.19-4.29 (overlapping m, 2H); 4.53 (t, IH) ; 4.62-4.82 (m, 8H); 5.19-5.44 (m, 8H); 5.84-6.07 (m, 4H); 7.82 (s, 3H); 9.30 (br, IH).
UBSTITUTE SHEET Example 10
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-4-hydroxyphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid was prepared using the technique of Example 1, except that the crude acid was of sufficient purity, and did not require chromatography. Nmr (DMSO-dg + acetic acid-d4): δ 1.17 (d, 6H); 1.95 (m, obscured, IH); 2.87 (m, obscured, IH) ; 3.17 (dd, IH) ; 3.25 (dd, IH) ; 3.42 (dt, IH); 3.75 (dd, IH); 3.99-4.05 (m, 2H); 4.22 (dd, IH) ; 4.33 (t, IH); 6.76 (d, IH); 7.56 (dd, IH); 7.97 (d, IH).
Ms (+ve FAB): 492 (MH)+, 514 (H + Na)+
The starting materials were prepared as follows:
2-Hydroxy-5-nitrobenzoic acid was allylated essentially as in Example 1, except that the final extraction solvent was diethyl ether, to give allyl 2-allyloxy-5-nitrobenzoate. Nmr (CDCL,): δ 4.82 (m, 4H); 5.26-5.55 (m, 4H); 5.97-6.13 (m, 2H); 7.49 (d, IH); 8.41 (dd, IH); 8.52 (d, IH).
Reduction of the above nitro compound by the method of Example 2, except that the solvent was methanol, and NaHCO, solution was used to basify, gave allyl 2-allyloxy-5-aminobenzoate. Nmr (CDCl,): δ 3.23 (br, 2H); 4.53 (dt, 2H) ; 4.79 (d, 2H) ; 5.21-5.49 (m, 4H) ; 5.93-6.14 (m, 2H);
6.80 (m, 2H); 7.16 (d, IH) .
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of dichloromethane/diethyl ether (100:0 to 85:15) to give (2S,4S)-l-allyloxycarbonyl-2-(4- allyloxy-3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDC13): δ 2.33 (s, 3H); 2.56 (br, 2H); 3.39 (dd, IH); 4.01 (quintet, IH); 4.13 (dd, IH) ; 4.52 (t, IH) ; 4.60 (dt, 2H) 4.66 (m, 2H); 4.81 (dt, 2H); 5.23-5.51 (m, 6H); 5.85-6.13 (m, 3H); 6.91 (d, IH); 7.76 (dd, IH);
7.81 (d, IH); 8.97 (br, IH). The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as Example 1, purifying by chromatography using gradient elution from dichloromethane to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-( -allyloxy-3- allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.24 (d, 3H) ; 1.36 (d, 3H); 2.57 (br, 2H); 3.25, 3.28 (dd overlapping quintet, 2H) ; 3.47 (br, IH); 3.78 (quintet, IH); 4.01 (dd, IH) ; 4.18-4.27 (dd overlapping m, 2H); 4.51 (t, IH); 4.58-4.79 (m, 6H) ; 4.79 (dt, 2H) ; 5.19-5.51 (m, 8H) ; 5.83-6.12 (m, 4H) ; 6.93 (d, IH); 7.79 (dd, IH) ; 7.85 (d, IH) ; 8.88 (br, IH).
Ms (+ve FAB): 696 (MH)+, 718 (M + Na)+
Example 11
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3,5-Dicarboxyphenylcarbamoyl)pyrrolidin- 4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid was prepared using the technique of Example 1, except that the crude acid was of sufficient purity, and did not need chromatography. Nmr (DMSO-d, + acetic acid-d4): δ 1.15 (d, 6H) ; 1.77 (m, part obscured, IH); 2.69 (m, part obscured, IH) ; 2.85 (m, part obscured, IH) ; 3.19 (dd, IH); 3.33-3.51 (m, 2H) ; 3.71 (quintet, IH) ; 3.94 (quintet, IH); 4.03 (t, IH); 4.15 (dd, IH) ; 8.18 (t, IH); 8.45 (d, 2H).
Ms (+ve FAB): 520 (MH)+, 542 (M + Na)+
The starting materials were prepared as follows:
3-Carboxy-5-nitrobenzoic acid was allylated essentially as in Example 1 to give allyl 3-allyloxycarbonyl-5-nitrobenzoate. Nmr (CDC13): δ 4.89-4.93 (m, 4H); 5.33-5.50 (m, 4H) ; 5.97-6.17 (m, 2H); 9.00 (t, IH); 9.04 (d, 2H) . Reduction of the above nitro compound by the method of Example 2 gave allyl 3-allyloxycarbonyl-5-aminobenzoate. Nmr (CDCl,): δ 3.91 (br, 2H); 4.80-4.84 (m, 4H) ; 5.26-5.45 (m, 4H); 5.96-6.11 (m, 2H); 7.53 (d, 2H) ; 8.09 (t, IH).
The above amine was condensed with proline acid as Example 1, to give (2S,4S)-l-allyloxycarbonyl-2-(3,5-diallyloxycarbonylphenyl- carbamoyl)pyrrolidin-4-yl-thioacetate. Nmr (CDCL,): δ 2.33 (s, 3H); 2.60 (br, 2H); 3.40 (dd, IH) ; 4.03 (quintet, IH) ; 4.14 (dd, IH); 4.58 (t, IH); 4.65-4.70 (m, 2H) ; 4.83-4.87 ( , 4H); 5.24-5.47 (m, 6H); 5.84-6.16 (m, 3H) ; 8.39 (d, 2H) ; 8.45 (t, IH) ; 9.36 (br, IH).
The above thioacetate was deacetylated to thiol, and condensed with carbapenem phosphate as Example 1, to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3,5-diallyloxy- carbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (CDCl-.): δ 1.23 (d, 3H); 1.35 (d, 3H); 2.63 (br, 2H); 3.25, 3.29 (dd overlapping m, 2H) ; 3.49 (br, IH); 3.84 (quintet, IH) ; 3.98 (dd, IH) ; 4.19-4.30 (m, 2H); 4.55 (t, IH); 4.63-4.78 (m, 4H); 4.84 (d, 4H); 5.19-5.45 (m, 8H) ; 5.84-6.12 (m, 4H); 8.46 (s, 3H); 9.18 (br, IH) .
Ms (+ve FAB): 724 (MH)+, 746 (M + Na)+
Example 12
(IR,5S,6S,8R,2'S,4 S)-2-(2-(3-Carboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid.
To a solution of 4-nitrobenzyl (lR,5S,6S,8R,2'S,4'S)-2-(2-(3-allyloxy- carbonylphenylcarbamoyl)-l-(4-nitrobenzyloxycarbonyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate (10 g, 12 mM) and Meldrum's acid (5.2 g, 36 mM) in THF (70 ml), under an atmosphere of argon and with the exclusion of light, was added tetrakis(triphenylphosphine)palladium (1.4 g, 1.2 mM). The mixture was stirred at ambient temperature for 30 minutes. The mixture was diluted with ethyl acetate (230 ml) and added to a solution of sodium bicarbonate (1.5 g) in distilled water (200 ml). 10% Pd-charcoal (4 g) was added and the mixture hydrogenated in an atmosphere of hydrogen for 3 hours. The catalyst was filtered, the filtrate extracted with ethyl acetate (2 x 100 ml) and ether (2 x 100 ml), and the aqueous layer concentrated under reduced pressure to about 250 ml. This solution was split into two and each sample purified by passage through a 1 litre HP20SS column using water as eluent. The pure fractions were collected and freeze-dried giving the title compound as a pale yellow solid (3.5 g). Nmr (DMSO-d, + acetic acid-d4, positions sensitive to exact solvent ratio): δ 1.19 (d, 6H) ; 1.94 (dt, IH); 2.97 (dt, IH); 3.13 (dd, IH); 3.25 (dd, IH); 3.42 (dt, IH); 3.68 (dd, IH); 3.94 (quintet, IH); 4.02 (quintet, IH) ; 4.22 (dd, IH) ; 4.32 (t, IH) ; 7.46 (t, IH) ; 7.73 (dt, IH); 7.88 (dm, IH); 8.27 (t, IH) .
Ms (+ve FAB): 498 (Na salt), 520 (di-Na salt).
The starting material was prepared as follows;
3-Nitrobenzoic acid (50 g, 0.3 M) was allylated by a similar method to that described in Example 1. Solid -.C0, (82.7 g, 0.6 M) was added to the acid in dry DMF (700 ml) with stirring. There was a slight exotherm and the mixture became thick. Allyl bromide (38.8 ml, 0.45 M) was added over 30 minutes and the mixture was left stirring overnight. After filtration through diatomaceous earth, the solution was evaporated to dryness under reduced pressure and the residue partitioned between ether and aqueous NaHCO,. The ether layer was washed with dilute HCl, brine and water, dried and evaporated giving a yellow oil (62g). Nmr (DMSO-dg): δ 4.85-4.92 (m, 2H) ; 5.27-5.5 (m, 2H); 5.97-6.2 (m, IH); 7.85 (t, IH); 8.37-8.42 (dt, IH); 8.48-8.54 (dq, IH); 8.64 (t, IH) .
Without further purification this oil was reduced to allyl 3-aminobenzoate (53 g) using stannous chloride and the method described in example 6. Nmr (CDC13): δ 3.6 (broad, 2H) ; 4.77-4.82 (dt, 2H); 5.24-5.44 (m, 2H) ; 5.96-6. 1 (m, IH) ; 6.83-6.88 (m, IH) ; 7.17- 7.25 (m, IH) ; 7.35-7.47 (m, 2H) .
The above allyl 3-aminobenzoate (26.6 g, 0.15 M) was condensed with 4-acetylthio-l-(4-nitrobenzyloxycarbonyl)-2-carboxy- pyrrolidine (55.2 g, 0.15 M) by suspension in toluene (750 ml) and addition of EEDQ (44.5 g, 0.18 M). The mixture was stirred overnight, diluted with EtOAc (21) and washed with dilute HCl, water and brine. The EtOAc phase was dried and evaporated, and the residue recrystallised from ethanol giving (2S,4S)-4-acetylthio-l-(4- nitrobenzyloxycarbonyl)-2-(3-allyloxycarbonylphenylcarbamoyl)- pyrrolidine (67.7 g) . Nmr (DMSO-dg): δ 1.93 (quintet, IH); 2.9 (m, IH); 3.35 (m, IH); 3.91-4.14 (m, 2H); 4.49 (quintet, IH); 4.81 (dd, 2H); 5.22 (dd, 2H); 5.2-5.44 (m, 2H) ; 5.95-6.10 (m, IH); 7.47 (d, 2H); 7.66 (t, 2H) ; 7.8-7.93 (m, 2H); 8.18-8.3 (m, 2H); 10.31 (s, IH).
The above thioacetate (52.7 g, 0.1 M) was converted to the thiol by dissolving it in degassed allyl alcohol (11) and adding aqueous NaOH (2M, 50 ml) at 0°C. After 3 hours aqueous HCl (2 M, 52.5 ml) was added, the solvent evaporated and the residue partitioned between EtOAc and brine. The EtOAc phase was dried over MgS04, filtered and evaporated. The thiol was used without further purification.
A solution of 4-nitrobenzyl (lR,5R,6S,8R)-6-(l-hydroxyethyl)- l-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (59.68 g, 0.1 M) in acetonitrile (500 ml) and methylene chloride (120 ml) was cooled to -15 C and ethyl diisopropylamine (52.5 ml) was added slowly. (2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-allyloxycarbonylphenyl- carbamoyl)pyrrolidin-4-ylthiol (0.1 M) , in acetonitrile (400 ml) was added under argon and the mixture left overnight. The solvent was evaporated and the residue subjected to chromatography on silica, eluting with methylene chloride, EtOAc and acetonitrile, giving 4-nitrobenzyl (IR,5R,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2- (3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy-
SUB TITUTE SHEET ethyl)-l-methylcarbapenem-3-carboxylate as a yellow solid (52.6 g) . Nmr (DMS0-d6+CD30D) : δ 1.26 (d, 3H) ; 1.35 (d, 3H) ; 2.2-2.4 (m, IH) ; 2.7-2.95 (m, IH) ; 3.28-3.40 (m, 2H) ; 3.54-3.63 (m, IH); 3.8 (t, IH); 4.01-4.1 (q, IH); 4.21-4.33 (m, 2H) ; 4.61 (dd, IH) ; 4.73 (d, 2H); 5.17-5.45 (m, 6H) ; 5.93-6.11 (m, IH) ; 7.37-8.22 (complex pattern of doublets and double doublets, 12H).
Example 13
The deprotection and hydrogenation were carried out by a similar method to that described in example 12, except that 4-nitrobenzyl (lR,5S,6S,8R,2'S,4'S)-2-(2-(3-allyloxycarbonyl-5-carbamoylphenyl- carbamoyl)-l-(4-nitrobenzyloxycarbonyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate (0.44 g) was used. After the hydrogenation, the aqueous layer was was freeze-dried, without HP20SS chromatography, to give (lR,5S,6S,8R,2'S,4'S)-2-(2- (3-carboxy-5-carbamoylphenylcarbamoyl)pyrrolidin-4-ylthio)-6- (l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, as a pale yellow solid (125 mg). Nmr (DMSO-dg + acetic acid-d : δ 1.9 (d, 6H) ; 1.98-2.06 (m, IH) ; 2.85-2.98 (m, IH) ; 3.16- 3.21 (m, IH); 3.26 (dd, IH); 3.43 (quintet, IH); 3.74 (dd, IH); 3.91-3.97 (m, IH); 4.0 (t, IH); 4.23 (dd, IH) ; 4.39 (t, IH); 8.24 (t, IH) ; 8.33 (t, IH) ; 8.44 (t, IH).
The starting material was prepared as follows:
5-Nitroisophthalic acid (5g) was converted to the mono allyl ester using one equivalent of allyl bromide (2 ml) using a similar method to that described in example 1. The required acid (2.7 g) was extracted from the organic phase with aqueous NaHCO,. The organic layer contained the di-allyl ester (2.7 g). The mono acid, 3-allyloxycarbonyl-5-nitrobenzoic acid, was obtained as a white solid. Nmr (CDC13): 4.87 (d, 2H); 5.3-5.5 (q, 2H); 5.97-6.15 (m, IH); 9.01 (t, 3H).
Ms (CI): 252 (MH)+
BSTITUTE SHEET DCCI (1.3 g) was added to a solution of the above acid (1.5 g) and N-hydroxysuccinimide (0.76 g) in methylene chloride (50 ml) and the mixture stirred at ambient temperature for 2 hours. A white solid was filtered and the solution evaporated to dryness. The active ester was purified on silica gel eluting with methylene chloride then it was dissolved in methylene chloride and treated with ammonia gas at 5°C. The white solid which precipitated was 3-allyloxycarbonyl-5- nitrobenzamide (1.1 g). Nmr (DHSO-dg): δ 4.9 (dt, 2H); 4.88-4.93 (m, 2H); 6.03-6.11 (m, IH) ; 7.83 (broad s, IH); 8.55 (broad s, IH) ; 8.75 (t, IH); 8.84 (t, IH); 8.94 (t, IH).
Ms (CI): 268 (M + NH4)+
3-Allyloxycarbonyl-5-nitrobenzamide (1 g) was reduced with SnCl2 by a similar method to the reduction in example 12, giving 3-allyloxycarbonyl-5-aminobenzamide (0.5 g) . Nmr (DMS0-dfi) : 4.78 (dt, 2H) ; 5.2-5.8 (broad, 2H) ; 5.26-5.45 (m, 2H) ; 5.91-6.13 ( , IH) ; 7.22 (broad s , IH) ; 7.27 (t, IH) ; 7.33 (t, IH) ; 7.59 (s , IH) .
Ms (CI) : 221 (MH)+
(2S,4S)-4-Acetylthio-l-(4-nitrobenzyloxycarbonyl)-2-carboxy- pyrrolidine (0.75g) was converted to the acid chloride and reacted with 3-allyloxycarbonyl-5-aminobenzamide (0.45 g) by a similar method to that described in example 12. The crude product was subjected to chromatography on silica gel, eluting with EtOAc and giving 4-acetylthio-1-(4-nitrobenzyloxycarbonyl)-2-(3-allyloxycarbony1-5- carbamoylphenylcarbamoyl)pyrrolidine (0.58 g) . Nmr (DMS0-dβ): δ 1.92-2.06 (m, IH); 2.3 (s, 3H) ; 2.79-2.83 (m, IH); 3.38 (dd, IH); 3.97-4.12 (m, 2H); 4.49 (dd, IH) ; 4.83 (dt, 2H) ; 5.19 (dd, 2H); 5.25-5.43 (m, 2H); 5.97-6.11 (m, IH) ; 7.31 (broad s, 2H) ; 7.54 (d, 2H) ; 8.04 (d, 2H); 8.12 (t, IH); 8.26 (t, IH) ; 8.31 (t, IH); 10.0 (s, IH).
The thiol was generated from the above thioacetate by the method described in example 12. A solution of 4-nitrobenzyl (lR,5R,6S,8R)-6-(l-hydroxyethyl)- l-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (0.6 g) and (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2-(3-allyloxycarbonyl-5- aminocarbamoylphenylcarbamoyl)pyrrolidin-4-ylthiol (0.48 g) in acetonitrile (20 ml) was reacted by a similar method to that as described in example 12. Purification was by flash chromatography, eluting with EtOAc then 5% HeOH/EtOAc, giving 4-nitrobenzyl (lR,5R,6S,8R,2'S,4'S)-2-(l-(4-nitrobenzyloxycarbonyl)-2-(3-allyloxy- carbonyl-5-carbamoylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate as a yellow solid (0.44 g). Nmr (DMS0-d6): δ 1.19-1.22 (d, 6H) ; 2.0-2.11 (m, IH) ; 2.8-2.92 (m, IH) ; 3.32 (dd, IH); 3.42-3.62 (m, 2H); 3.92-4.2 (m, 2H) ; 4.31 (broad d, IH) ; 4.53 (q, IH); 4.84 (d, 2H); 4.98-5.46 (m, 6H); 5.98-6.14 (m, IH); 7.42- 8.52 (complex pattern of doublets and double doublets, 11H).
Example 14
The deprotection and hydrogenation was carried out by a similar method to that described in example 12, except that p-nitrobenzyl (lR,5S,6S,8R,2'S,4'S)-2-(2-(3-allyloxycarbonyl-6- carbamoylphenylcarbamoyl)-l-(4-nitrobenzyloxycarbonyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carb'oxylate was used. After the hydrogenation, the aqueous layer was freeze-dried to give (lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-carbamoylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid. Nmr (DMSO-d, + acetic acid-d4): δ 1.3-1.38 (2xd, 6H); 2.0-2.11 (m, IH) ; 2.85-2.96 (m, IH) ; 3.09 (dd, IH); 3.37 (dd, IH); 3.53 (quintet, IH) ; 3.79 (dd, IH) ; 3.94 (t, IH); 4.16 (t, IH); 4.33 (dd, IH); 4.43 (t, IH) ; 7.87 (dd, IH); 7.97 (d, IH); 9.12 (d, IH).
Ms (+ve FAB): 541 (Na salt), 563 (di-Na salt).
The starting material was prepared as follows: Nitroterephthalic acid (6.33 g) in methylene chloride (75 ml) and THF (15 ml) was converted to the mono acid chloride using oxalyl chloride (2.63 ml), DMF (2.55 ml) and N-methylmorpholine (7.95 ml) at -10 C. After 1 hour the solvents were removed and, without further purification, the product was dissolved in allyl alcohol (20 ml) and THF (10 ml) and stirred overnight at ambient temperature. The solvents were removed and the residue partitioned between EtOAc and aqueous NaHCO-.. Acidification of the NaHCO, solution and extraction with EtOAc gave the product, 4-allyloxycarbonyl-2-nitrobenzoic acid (6.8 g). Nmr (CDC13): δ 4.89 (d, 2H) ; 5.31-5.49 (m, 2H); 5.95-6.15 (m. IH); 7.94 (d, IH); 8.36 (dd, IH) ; 8.54 (d, IH) . Without purification, this acid was converted by the method above to the acid chloride which was dissolved in THF (100ml) at 0 C. Ammonia gas was bubbled into the solution until the reaction was completed. The solution was partitioned between EtOAc and water, and the product from the organic fraction purified on silica, eluting with methylene chloride followed by EtOAc. The product (4 g) , containing a small impurity, was reduced with SnCl- by a similar method to that in example 12 giving 4-allyloxycarbonyl-2-aminobenzamide. Nmr (DMS0-dfi): δ 4.79 (d, 2H); 5.22-5.46 (m, 2H); 5.91-6.13 (m, IH); 7.02 (dd. IH); 7.37 (d, IH); 7.61 (d, IH).
(2S, S)-4-Acetylthio-l-(4-nitrobenzyloxycarbonyl)-2-carboxy- pyrrolidine (1.58g) was converted to the acid chloride by suspension in methylene chloride (25 ml) and addition of oxalyl chloride (1.52 ml). A few drops of DMF were added. After 2 hours the solvents were evaporated and the acid chloride, dissolved in methylene chloride (10 ml), was added under argon to a solution of 4-allyloxycarbonyl-2-amino- benzamide (0.52 g) in THF (10 ml) and methylene chloride (5 ml) containing N-methylmorpholine (0.38 ml) at 0 C. The reaction was left overnight and partitioned between methylene chloride and dilute aqueous HCl. The methylene chloride fraction was washed with water, brine and dried. Purification was by silica chromatography, eluting with increasing concentrations of EtOAc in methylene chloride, giving (2S,4S)-4-acetylthio-l-(4-nitrobenzyloxycarbonyl)-2-(3-allyloxy- carbonyl-6-carbamoylphenylcarbamoyl)pyrrolidine (0.84 g) . Nmr (CDC13 ) : δ 2.25 (quintet, IH) ; 2.29 ( s , 3H) ; 2.83 (m, IH) ; 3.53 (dd, IH) ; 4.02 (quintet, IH) ; 4.2 (dd, IH) ; 4.49 (dd, IH) ; 4.85 (d, 2H) ; 5.23-5.46 (m, 2H) ; 5.97-6.13 (m, IH) ; 7.31-7.5 (broad, 2H) ; 7.57 (d, IH) ; 7. 75 (dd, IH) ; 7.81-7.95 (broad, 2H) ; 9.27 (d, IH) .
The thiol was generated from the above thioacetate by a similar method to that described in example 12.
A solution of 4-nitrobenzyl (lR,5R,6S,8R)-6-(l-hydroxyethyl)- l-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate and (2S,4S)- l-(4-nitrobenzyloxycarbonyl)-2-(2-carbamoyl-5-allyloxycarbonylphenyl- carbamoyl)pyrrolidin-4-ylthiol in acetonitrile (20 ml) were reacted as described in example 12, giving 4-nitrobenzyl (lR,5R,6S,8R,2'S,4'S)-2- (l-(4-nitrobenzyloxycarbonyl)-2-(3-allyloxy- 3-carbonyl-6-carbamoylphenylcarbamoyl)pyrrolidin-4-ylthio)-6- (l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate as a yellow foam (1.24 g). Nmr 1.23-1.35 (m, 6H); 2.2-2.38 (m, IH) ; 2.77-2.93 (m, IH); 3.27 (dd, IH); 3.28-3.42 (m IH); 3.65-3.92 (m, 2H); 4.17- 4.35 (m, 3H); 4.53 (t, IH); 4.83 (d, 2H) ; 4.92-5.44 (m, 6H) ; 5.93-6.11 (m, IH) ; 6.22-6.58 (broad, 2H); 7.35- 8.23 (complex pattern of doublets and double doublets, 10H); 9.20 (d, IH).
Example 15
The deprotection and purification were carried out by a similar method to that described in example 2 (chromatography of the final product was on an HP20SS column) except that allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(2-dimethylaminocarbonyl- 3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate was used. The appropriate aqueous fractions from the column were freeze-dried to give (lR,5S,6S,8R,2'S,4'S)-2-(2-(2-dimethylaminocarbonyl-3-carboxyphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid. Nmr (DMS0-dβ + acetic acid-d4, mixture of rotamers): δ 1.17 (d, 6H); 1.75 (m, 2H) ; 2.65,2.72 (2 x s, overlapping m, 4H);
E SHEET 3.00,3.01 (2 x s, overlapping m, 4H); 3.17 (dd, IH) ; 3.41 (quintet, IH); 3.55 (m, 2H) ; 3.96 (m, 2H); 4.15 (dd, IH); 7.43 (t, IH); 7.68 (m, IH); 8.20-8.40 (2 x d, IH).
The starting material was prepared as follows:
2-Dimethylaminocarbonyl-3-nitrobenzoic acid (1 g) was to the allyl ester by a similar method to that described in example 1 for the formation of allyl 3-allyloxy-5-aminobenzoate giving allyl 2-dimethylaminocarbonyl-3-nitrobenzoate (0.88 g). Nmr (DMS0-d6): δ 2.45 (s, 3H); 2.97 (s, 3H) ; 4.79 (dd, 2H) ; 5.28-5.47 (m, 2H); 5.9-6.1 (m, IH) ; 7.81 (t, IH); 8.28-8.4 (dq, 2H).
Hs (CI): 279 (MH)+
The allyl ester (0.44 g) was reduced with SnCl., by a similar method to the reduction described in example 1, giving allyl 2-dimethylaminocarbonyl-3-aminobenzoate (0.41 g) as a clear red oil. Nmr (CDC13): δ 2.24 (s, 3H); 3.06 (s, 3H) ; 3.64 (broad, 2H); 4.68 (dd, 2H); 5.17-5.37 (m, 2H) : 5.82-6.02 (m, IH); 6.83 (dd, IH); 7.09-6.85 ( , IH); 7.37 (dd, IH).
Ms (CI): 249 (MH)+
Allyl 2-dimethylaminocarbonyl-3-aminobenzoate (0.39 g, 1.4 mM) was condensed with (2S,4S)-4-acetylthio-l-alloxycarbonyl-2- carboxypyrrolidine (0.42 g, 1.54 mM) using a similar method to the EEDQ method described in example 12, giving (2S,4S)-l-allyloxycarbonyl-2-(2- dimethylaminocarbonyl-3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-yl thioacetate (0.84 g). Nmr (CDCl,, mixture of rotamers): δ 2.32 (s, 3H); 2.38 (br m, part obscured, IH); 2.38 (br m, part obscured, IH); 2.74,2.76 (2 x s overlapping br m, 4H) ; 3.11,3.14 (2 x s, 3H); 3.36-3.45 (m, IH) ; 3.98-4.14 (m, 2H) ; 4.50 (dd, IH); 4.56-4.79 (m, 4H); 5.16-5.44 ( , 4H); 5.93-6.06 (m, 2H) ; 7.45 (t, IH); 7.81-7.86 (m, IH); 8.33-8.41 (2 x d, IH); 8.60 (br, IH) .
SUBSTITUTE SHEET Ms (CI) : 504 (MH)'
The thiol was generated from the above thioacetate by a similar method to that described in example 12.
A solution of allyl (lR,5R,6S,8R)-6-(l-hydroxyethyl)-l- methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (0.73 g, 1.47 mM) and (2S,4S)-l-allyloxycarbonyl)-2-(2-dimethylaminocarbonyl- 3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthiol in acetonitrile (12 ml) were reacted by a similar method to that described in the preparation of protected carbapenem' step in example 1, giving allyl (IR,5R,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(2-dimethylaminocarbon l- 3-allylo ycarbonylphenylcarbamoyl)p rrolidin-4-ylthio)-6-(l-hydro-cy- ethyl)-l-methylcarbapenem-3-carboxylate as a white solid (0.63 g). Nmr (CDCL,, mixture of rotamers): δ 1.24 (d, 3H) ; 1.35 (2 x d, 3H); 1.98 (br, IH); 2.34 (br, IH); 2.73 (s, 3H) ; 3.11,3.13 (2 x s, 3H) ; 3.22-3.46 (m, 3H) ; 3.66-3.85 (m, IH) ; 4.00-4.26 (m, 3H) ; 4.50 (t, IH); 4.62-4.80 (m, 6H); 5.08-5.46 (m, 6H); 5.83-6.06 (m, 3H); 7.46 (td, IH); 7.86 (d, IH); 8.29 (m, IH); 8.55 (br, IH).
Ms (CI): 711 (MH)+
Example 16
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-acetamidophenylcarbamoyl)- pyrrolidin-4-ylthio1-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, dipotassium salt.
To a solution of 4-allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-(4- nitrobenzyloxycarbonyl)-2-(3-carboxy-5-acetamidophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylate (0.4 g, 0.53 mmol) in DMF (20 ml) were added Meldrum's acid (0.2 g, 1.39 mmol) and tetrakis triphenylphosphine palladium (40 mg, 0.035 mmol). The reaction mixture was stirred for one hour, at ambient temperature. A solution of 1M potassium phosphate buffer (20 ml) and zinc powder (0.5 g) were added to the solution and after one hour, at ambient temperature, the reaction mixture was filtered over diatomaceous earth and the pH of the filtrate adjusted to 7.5 with solid potassium carbonate. The solution was filtered, concentrated under reduced pressure and the resulting residue purified by reverse phase chromatography (Nucleosil C18), with water as eluant, to give, after freeze drying, the title compound (78 mg, 28%). Nmr (DMS0-dg + acetic acid-d4) : δ 1.15 (d, 3H) ; 1.17 (d, 3H); 1.74 (m, IH); 2.06 (s, 3H); 2.66 (m, IH); 2.84 (m, IH) ; 3.20 (dd, IH); 3.40 (m, 2H); 3.70 (m, IH); 3.97 (m, 2H) ; 4.16 (dd, IH) ; 7.92 (s, IH); 7.94 (s, IH) ; 8.19 (s, IH).
The starting material was prepared as follows:
A solution of (2S,4S)-4-acetylthio-2-carboxy-l-(4-nitro- benzyloxycarbonyl)pyrrolidine (1 g, 1.8 mmol) and EEDQ (0.53 g, 3 mmol) in chloroform (70 ml) was stirred at ambient temperature for 1 hour. 3-Acetamido-5-aminobenzoic acid (0.53 g, 2.7 mmol) and diisopropylethylamine (0.7 ml, 4 mmol) were then added to the reaction mixture, which was stirred for 2 hours, at ambient temperature. After evaporation of the solvent, the crude compound was purified by chromatography on HP20SS using methanol/water (80:20) as the eluant. Partial evaporation of the solvents and lyophilisation gave (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-acetamidophenyl- carbamoyl)pyrrolidin-4-ylthioacetate (lg, 67%).
(2S,4S)-l-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5- acetamidophenylcarbamoyl)pyrrolidin-4-ylthioacetate was dissolved in a mixture of methanol (60 ml) and water (20 ml) and the pH of the solution was adjusted to 11 with a 1M aqueous solution of NaOH. After 30 minutes at ambient temperature, the reaction mixture was neutralised with methanol, evaporated and purified by chromatography on HP20SS, using methanol/water (80:20) as the eluant. Evaporation and lyophilisation gave (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2-(3- carboxy-5-acetamidophenylcarbamoyl)pyrrolidin-4-ylthiol (0.68 g. 74%). Nmr (DMSOdg + acetic acid-d4): δ 2.05 (s, 3H) ; 2.05 (m, IH) ; 2.75 (m, IH) ; 3.20-3.80 (m, 2H) ; 4.00 (m, IH) ; 4.42 (m, IH) ; 5.40 (br s , 2H) ; 7.45-8.30 (m, 7H) .
To a solution of 4-nitrobenzyl (lR,5S,6S,8R)-6-(l-hydroxy- ethyl)-l-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (0.6 g, 1.2 mmol) in DMF (12 ml) were added sequentially diisopropylethylamine (0.6 ml, 3.4 mmol), (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy- 5-acetamidoρhenylcarbamoyl)pyrrolidin-4-ylthiol (0.6 g, 1.2 mmol), tri-n-butylphosphine (0.6 ml, 2.4 mmol) and water (0.1 ml, 5.5 mmol). The reaction mixture was stirred overnight, at 4°C, evaporated to dryness and the residue was purified by chromatography on HP20SS resin, using acetonitrile/water (40:60) as the eluant. Evaporation and lyophilisation gave allyl (lR,5R,6S,8R,2S',4'S)-2-(l-(4-nitrobenzyl- oxycarbonyl)-2-(3-carboxy-5-acetamidophenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate (0.8 g, 88%). Nmr (DMSO-dg + acetic acid-d4): δ 1.15 (d, 3H) ; 1.17 (d, 3H), 2.05 (s, 3H); 2.17 (m, IH); 2.81 (m, IH); 3.26 (dd, IH); 3.36 (td, IH); 4.56-4.74 (m, 2H); 5.02-5.73 (m, 4H) ; 5.91 (m, IH) ; 7.47 (d, IH); 7.68 (d, IH) ; 7.85-7.99 (m, 3H) ; 8.20-8.29 (m, 2H).
Example 17
(lR,5S,6S,8R,2'S,4'S)-2-(2-(4-Acetamido-3-carboxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, dipotassium salt.
The title compound was prepared from 4-allyl (1R,5S,6S,8R, 2'S,4'S)-2-(l-(4-nitrobenzyloxycarbonyl)-2-(4-acetamido-3-carboxy- phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarba- penem-3-carboxylate (diisopropylethylamine salt) using a similar method to that of example 16. Nmr (DMS0-d6 + acetic acid-d4): δ 1.14 (d, 3H) ; 1.16 (d, 3H); 1.75 (m, IH) ; 2.07 (s, 3H) ; 2.73 (m, IH); 2.96 (dd, IH) ; 3.21 (dd, IH); 3.39 (m, IH); 3.54 (dd, IH); 3.78 (m, IH); 3.96 (m, IH); 4.08 (t, IH); 4.18 (dd, IH); 7.69 (dd, IH); 8.18 (d, IH); 8.42 (d, IH) .
SUBSTITUTE SHEET MS (+ve FAB) : 571 (MH)+, ( salt)
The starting material was prepared as follows:
(2S,4S)-l-(4-Nitrobenzyloxycarbonyl) -2-( -acetamido-3- carboxyphenylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from 2-acetamido-5-aminobenzoic acid using a similar method to that of example 16. Nmr (DMSO-d, + acetic acid-d4): δ 1.95 (m, IH); 2.12 (s, 3H); 2.34 (s, 3H); 2.77 (m, IH); 3.32 (m, IH); 3.93-4.50 (m, 3H); 5.04-5.32 (m, 2H); 7.47-8.42 (m, 7H).
(2S,4S)-1-(4-Nitrobenzyloxycarbonyl) -2-(4-acetamido-3- carboxyphenylcarbamoyl)pyrrolidin-4-ylthiol was prepared from (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(4-acetamido-3-carboxy- phenylcarbamoyl)pyrrolidin-4-ylthioacetate using a similar method to that of example 16.
Allyl (LR,5R,6S,8R,2'S,4'S)-2-(l-(4-nitrobenzyloxy- carbonyl)-2-(4-acetamido-3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)- 6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylate (diisopropylethyl¬ amine salt) was prepared from (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2- (4-acetamido-3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthiol and allyl (IR,5R,6S,8R)-6-(1-hydroxyethyl)-l-methyl-2-diphenylphosphoryloxy- carbapenem-3-carboxylate using a similar method to that of example 16. Nmr (CDC13) δ: 1.14-1.80 (m, 23H) ; 2.17 (s, 3H); 2.67 (m, IH); 3.00-3.30 (m, 3H) ; 3.35-3.90 (m, 4H) ; 3.90-4.40 (m, 3H); 4.40-4.75 (m, 3H); 5.00-5.75 (m, 4H) ; 5.70-6.10 (m, IH); 7.38-8.65 (m, 7H) .
Example 18
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-methylsulphonamidophenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarba enem-3- carboxylic acid dipotassiu salt.
The title compound was prepared from allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5- methylsulphonamidophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem 3-carboxylate using a similar method to that of example 16. Nmr (DMSOd, + acetic acid-d4): δ 1.16 (d, 3H); 1.17 (d, 3H); 1.74 (m, IH) ; 2.64 (m, IH); 2.81 (dd, IH); 3.01 (s, 3H); 3.20 (m, IH); 3.40 (m, 2H); 3.68 (m, IH) ; 3.96 (m, 2H) ; 4.17 (dd, IH); 7.54 (s, IH); 7.82 (s, IH) ; 8.00 (s, IH) .
MS (+ve FAB): 607 (M+H)+ for monopotassium salt; 645 (M+H)+ for dipotassium salt.
The starting material was prepared as follows:
(2S,4S)-l-(4-(Nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methyl- sulphonamidophenylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from 3-amino-5-methylsulphonamidobenzoic acid using a similar method to that of example 16. Nmr (DMSO-d, + acetic acid-d4): δ 2.00 (m, IH) ; 2.30 (s, 3H); 2.84 (m, IH); 2.95 (s, 3H) ; 3.20-3.51 (m, IH); 3.83-4.20 (m, 2H); 4.30-4.58 (m, IH); 5.20 (m, 2H) ; 7.48-8.22 (m, 7H) .
(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methyl- sulphonamidophenylcarbamoyl)pyrrolidin-4-ylthiol was prepared from (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methylsulphonamido- phenylcarbamoyl)pyrrolidin-4-ylthioacetate using a similar method to that of example 16. Nmr (DMSO-d, + acetic acid-d4): δ 2.10 (m, IH) ; 2.78 (m, IH); 2.99 (s, 3H); 3.43 (m, IH) ; 3.68 (m, IH) ; 4.05 (m, IH) ; 4.42 (m, IH); 5.13-5.32 (m, 3H); 7.50-8.82 (m, 7H).
SUBSTITUTE SHEET Allyl (lR,5R,6S,8R,2'S,4'S)-2-(l-(4-nitrobenzyloxycarbonyl)- 2-(3-carboxy-5-methylsulphonamidophenylcarbamoyl)pyrrolidin-4-ylthio)- 6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate was prepared from (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-methylsulphonamido- phenylcarbamoyl)pyrrolidin-4-ylthio and allyl (lR,5R,6S,8R)-6-(l- hydroxethyl)-l-methyl-2-diphenylphosphoryloxycarbapenem-3- carboxylate using a similar method to that of example 16. Nmr (DMS0-dfi + acetic acid-d4): δ 1.20 (d, 3H); 1.22 (d, 3H); 1.96 (m, IH); 2.83 (m, IH); 3.00 (s, 3H); 2.26-3.57 (m, 3H) ; 3.87-4.28 (m, 4H); 4.42-4.76 (m, 3H); 5.08-5.42 (m, 4H) ; 5.92 (m, IH) ; 7.22-8.22 (m, 7H) .
Example 19
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-sulphophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, disodium salt.
To a stirred solution of 4-nitrobenzyl (1R,5S,6S,8R,2'S,4'S)- 2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-sulphophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylat e (0.5 g, 0.56 mmol) in DMF (5 ml) and water (5 ml) was added a solution of 1M sodium phosphate buffer (5 ml) followed by zinc powder (1 g). The reaction mixture was stirred for 1 hour and the pH of the solution was adjusted to 8 by adding a saturated aqueous solution of sodium hydrogen carbonate. After filtration over diatomaceous earth, the filtrate was concentrated and purified by subjecting to preparative chromatography (Nucleosil C-18), using water as the eluant. Concentration and lyophilisation of the required fractions gave the title compound (44 mg, 12%). Nmr (DMS0-dg + acetic acid-d4): δ 1.15 (d, 3H); 1.16 (d, 3H) ; 1.78 (m, IH) ; 2.73 (m, IH); 2.92 (m, IH); 3.21 (dd, IH); 3.40 (m, IH); 3.48 (m, IH) ; 3.75 (m, IH) ; 3.97 (m, IH); 4.03 (m, IH); 4.18 (m, IH); 7.93 (s, IH); 8.11 (s, IH) ; 8.29 (s, IH) .
MS (-ve FAB): 576 (M-H)" for monosodium salt; 598 (M-H)" for disodium salt. The starting material was prepared as follows:
(2S,4S)-l-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5-sulpho- phenylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from 3-amino-5- sulphobenzoic acid using a similar method to that of example 16. Nmr (DMS0-d6 + acetic acid-d4): δ 1.97 (m, IH); 2.30 (s, 3H); 2.80 (m, IH); 3.37 (m, IH); 3.86-4.15 (m, 2H); 4.46 (m, IH); 5.05-5.28 (m, 2H); 7.46-9.25 (m, 7H).
(2S,4S)-l-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-5- sulphophenylcarbamoyl)pyrrolidin-4-ylthiol was prepared from (2S,4S)-1- (4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-sulphophenylcarbamoyl)- pyrrolidin-4-ylthioacetate using a similar method to that of example 16. Nmr (DMSO-dg + acetic acid-d4): δ 1.25 (d, 3H) ; 1.27 (d, 3H) ; 2.07 (m, IH); 2.70 (m, IH) ; 3.4 (m, IH) ; 3.67 (m, IH) ; 3.99 (m, IH) ; 4.49 (m, IH); 5.07-5.30 (m, 2H) ; 7.47-8.40 (m, 7H).
4-Nitrobenzyl (lR,5S,6S,8R,2'S,4'S)-2-(l-(4-nitrobenzyloxy carbonyl)-2-(3-carboxy-5-sulphophenylcarbamoyl)pyrrolidin-4-ylthio)-6- (l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate was prepared from (2S,4S)-l-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-5-sulphophenyl- carbamoyl)pyrrolidin-4-ylthiol and 4-nitrobenzyl (lR,5R,6S,8R)-6-(l- hydroxyethyl)-l-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate using a similar method to that of example 1. Nmr (DMS0-dfi + acetic acid-d4): δ 1.20 (d, 3H) ; 1.21 (d, 3H) ; 1.96 (m, IH): 2.77 (m, IH) ; 3.18-3.47 (m, 2H); 3.66-4.90 (m, 6H); 5.04-5.50 (m, 4H) ; 7.30-8.35 (m, 11H).
Example 20
(5R,6S,8R,2'S,4'S)-2-(2-(3-Carboxyphenylcarbamoyl) yrrolidin-4- ylthio)-6-(l-hydroxyethyl)carbapenem-3-carboxylic acid, disodium salt.
To a stirred solution of allyl (5R,6S,8R,4'S)-2-(l- allyloxycarbonyl)-2-(3-allyloxycarbonylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)carbapenem-3-carboxylate (0.185 g, 0.296 mmol) in CH2C12 (4 ml), at ambient temperature, were added sequentially N-methylaniline (0.190 g, 1.776 mmol), water (4 ml), sodium bicarbonate (100 mg) and tetrakis(triphenylphosphine)palladium (34 mg, 0.029 mmol). After 10 minutes the aqueous phase was separated and injected onto a C18 preparative HLPC column giving the title compound (43 mg, 27%). Nmr (DHSO-d, + acetic acid-d4): 1.16 (d, 3H); 1.81 (m, IH); 2.64 (m, IH); 2.84 (m, IH); 3.26 (m, 3H); 3.4 (m, IH); 3.67 (m, IH); 3.94 (m, 2H); 4.12 (m, IH) ; 7.42 (t, IH); 7.65 (d, IH); 7.83 (d, IH); 8.27 (s, IH) .
The starting allyl (5R,6S,8R,2'S,4'S)-2-(l-allyloxy- carbonyl-2-(3-allyloxycarbonylphenylcarbamoyl)pyrrolidin-4-yl-thio)-6- (l-hydroxyethyl)carbapenem-3-carboxylate was prepared in 67% yield using a similar procedure to that described in example 1, by reacting (2S,4S) l-allyloxycarbonyl-2-(3-allyloxycarbonylphenyl- carbamoyl)pyrrolidine-4-thiol, described in example 4, with allyl (5R,6S,8R)-6-(l-hydroxyethyl)-2-diphenylphosphoryloxycarbapenem-3- carboxylate (EP-A-126780 and EP-A-208889).
Example 21
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-cyanophenylcarbamoyl- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, disodium salt
To a solution of allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxy- carbonyl-2-(3-allyloxycarbonyl-5-cyanophenylcarbamoyl)pyrrolidin-4-yl- thio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylate (358 mg, 0.54 mM) and 2,2-dimethyl-l,3-dioxane-4,6-dione (388 mg, 2.7 mM) in a mix¬ ture of DMF (8 ml) and THF (4 ml), under an argon atmosphere, was added tetrakis(triphenylphosphine)palladium (62 mg, 0.054 mM) . The solution was stirred, under argon with protection from light, for 1.75 hours, and solvent removed by evaporation. The residue was dissolved in a mixture of THF (6 ml) and DMF (2 ml), and a solution of sodium 2-ethyl- hexanoate (295 mg, 1.77 mM) in THF (4 ml) was added, followed by
SUB diethyl ether (20 ml). The resultant precipitate was centrifuged, and supernatant removed. The product was washed twice by resuspension in a mixture of THF (4 ml) and diethyl ether (10 ml), then diethyl ether (20 ml) followed by centrifugation. Crude product was dissolved in water (20 ml) and the pH adjusted to 7.4 with NaHCO.,. After filtration, the solution was chromatographed on HP20SS resin, and fractions combined as appropriate to give the title product (206 mg, 70%). Nmr (DMSO-d, + acetic acid-d4): δ 1.17 (d, 6H); 1.95 (m, part obscured, IH); 2.83 (m, IH); 3.09 (dd, IH) ; 3.25 (dd, IH) ; 3.41 (quintet, IH); 3.64 (dd, IH); 3.88 (quintet, IH); 4.02 (quintet, IH); 4.22 (dd, IH); 4.31 (t, IH); 8.00 (s, IH); 8.28 (t, IH); 8.46 (t, IH) .
Ms (+ve FAB): 523 (MH)+, (Na salt)
The starting materials were prepared as follows:
3-Cyano-5-nitrobenzoic acid
3-Amino-5-nitrobenzoic acid (3.64 g, 20 mM) was dissolved in concentrated hydrochloric acid (20 ml), diluted with water (75 ml), cooled to 0°, and added over 30 minutes to a solution of NaN02 (1.38 g, 20 mM) in water (10 ml). The pH was adjusted to 6.2 with saturated Na2C03 solution. A mixture of CuS04-5H20 (10 g, 42 mM) in water (40 ml) and KCN (10 g, 154 mM) in water (20 ml) was heated to 65°, the solution of diazonium salt added over 15 minutes, and the mixture refluxed for 40 minutes. After cooling, and acidifying with 2M hydrochloric acid, the organics were extracted into ethyl acetate (2 x 200 ml). The combined extracts were washed with aqueous NaH2P04, water, brine, and dried over Na2S04- Evaporation gave 3-cyano-5- nitrobenzoic acid (3.6 g, 94%).
Nmr (DMS0-d6): δ 8.69 (t, IH); 8.80 (t, IH); 8.97 (t, IH)
Ms (-ve FAB): 191 (M - H)
Ir (nujol): v 2220 cm-1
SUBSTITUTE 3-Cyano-5-nitrobenzoic acid was allylated essentially as in Example 1, except that the chromatographic purification used a mixture of petrol/ethyl acetate (5:1), to give allyl 3-cyano-5-nitrobenzoate. Nmr (DMS0-d6): δ 4.91 (dt, 2H); 5.39-5.53 (m, 2H) ; 5.99-6.19 (m, IH); 8.78 (t, IH); 8.81 (t, IH) ; 9.04 (t, IH).
Ms (+ve FAB): 202 M+; 232 (H + NH4)+; (both for amino compound by ammonia reduction)
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-5-cyanobenzoate, mp 112-113°. Nmr (DMS0- dg): δ 4.79 (dt, 2H); 5.25-5.45 (m, 2H) ; 5.94-6.13 (m overlapping br, IH); 7.10 (t, IH); 7.37 (t, IH) ; 7.48 (t, IH) .
Ms (+ve FAB): 202 M+; 232 (M + NH4)+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of dichloromethane/ethyl acetate (19:1 to 9:1) to give (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-cyanophenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDC13): δ 2.33 (s, 3H) ; 2.59 (br, 2H) ; 3.38 (dd, IH); 3.97-4.17 (m, 2H); 4.56 (t, IH); 4.69 (d, 2H) ; 4.84 (d, 2H) ; 5.26-5.48 (m, 4H); 5.85- 6.14 (m, 2H); 8.03 (br s, IH) ; 8.18 (t, IH); 8.29 (br s, IH) ; 9.69 (br, IH).
Ms (+ve FAB): 458 (MH)+; 480 (M + Na)+
The above thioacetate was deacetylated as Example 1, to give (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5-cyanophenyl- carbamoyl)pyrrolidin-4-ylthiol. Nmr (CDCL,): δ 1.90 (d, IH) ; 2.52 (br, IH); 2.65 (br, IH) ; 3.34-3.52 (m, 2H) ; 4.07 (dd, IH); 4.54 (t, IH); 4.69 (d, 2H); 4.84 (d, 2H); 5.27-5.47 (m, 4H) ; 5.87-6.11 (m, 2H) ; 8.01 (s, IH); 8.21 (t, IH); 8.28 (s, IH) ; 9.56 (br, IH). The above thiol was condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloro- methane/ethyl acetate (3:2 to 2:3) to give allyl (1R,5S,6S,8R,2'S,4'S)- 2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5-cyanophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylate. Nmr (CDCl3): δ 1.27 (d, 3H); 1.35 (d, 3H); 2.67 (v br, 2H); 3.21-3.33 (overlapping m, 2H) ; 3.53 (br, IH); 3.83 (quintet, IH) ;
3.93 (dd, IH); 4.20-4.31 (overlapping m, 2H); 4.54 (t, IH) ; 4.63-4.86 (m, 6H); 5.21-5.47 (m, 6H); 5.82-6.11 (m overlapping br, 3H) ; 8.05 (t, IH); 8.33 (br s, IH); 8.37 (br s, IH) ; 9.35 (br, IH) .
Ms (+ve FAB): 665 (MH)+; 687 (M + Na)+
Example 22
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-methoxyphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 21. Nmr (DMSO-dg + acetic acid-d : δ 1.17 (d, 3H); 1.18 (d, 3H); 1.83 (m, part obscured, IH); 2.76 (quintet, IH); 2.98 (dd, IH); 3.22 (dd, IH); 3.39 (quintet, IH) ; 3.56 (dd, IH) ; 3.81 (s overlapping m, 4H); 4.00 (quintet, IH); 4.15,4.18 (t overlapping dd, 2H); 7.22 (t, IH); 7.58 (t, IH); 7.84 (t, IH) .
Ms (-ve FAB): 505 (M - H)", (Na salt)
The starting materials were prepared as follows:
3-Hydroxy-5-nitrobenzoic acid was methylated essentially as the allylation step of Example 1, except that the allyl bromide was replaced by dimethyl sulfate, and purification by chromatography was unnecessary, to give methyl 3-methoxy-5-nitrobenzoate. Nmr (CDCl,): δ
3.94 (s, 3H); 3.97 (s, 3H) ; 7.87 (t, IH); 7.90 (t, IH) ; 8.44 (t, IH) .
SUBSTITUTE SHEET The above ester (3.45 g, 16 mM) was dissolved in THF (100 ml) , treated with 1M NaOH (25 ml) , and stirred at ambient temperature for 5 hours. After removal of the solvent, the residue was treated with water (50 ml), acidified with 2M sulfuric acid, and extracted with ethyl acetate (3 x 60 ml) . The combined organic extracts were washed with aqueous NaH-.P04, brine, and dried over MgS04- Evaporation gave 3- methoxy-5-nitrobenzoic acid, which was allylated essentially as in Example 1, except that the chromatographic purification used a mixture of petrol/ethyl acetate (6:1), to give allyl 3-methoxy-5-nitrobenzoate. Nmr (CDC13): δ 3.95 (s, 3H) ; 4.87 (dt, 2H); 5.31-5.48 (m, 2H); 5.95- 6.15 (m, IH); 7.89 (t, IH) ; 7.92 (t, IH); 8.46 (t, IH).
Ms (CI): 237 M+; 255 (M + NH4)+
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-5-methoxybenzoate. Nmr (DMSO-d,): δ 3.72 (s, 3H); 4.50 (v br, 2H) ; 4.75 (dt, 2H); 5.25-5.43 (m, 2H); 5.95-6.11 (m, IH); 6.47 (t, IH); 6.75 (t, IH); 6.93 (t, IH).
Ms (CI): 208 (MH)+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of petrol/ethyl acetate (5:2 to 2:1) to give (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl- 5-methoxyphenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCl,): δ 2.32 (s, 3H); 2.59 (br, 2H) ; 3.38 (dd, IH); 3.85 (s, 3H) ; 4.02 (quintet, IH) ; 4.15 (dd, IH) ; 4.55 (t, IH); 4.68 (d, 2H) ; 4.81 (d, 2H); 5.22-5.46 (m, 4H) ; 5.83-6.13 (m, 2H); 7.35 (t, IH) ; 7.58 (br s, IH); 7.64 (t, IH); 9.12 (br, IH) .
Ms (+ve FAB): 463 (MH)+; 485 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloro ethane/ethyl acetate (60:40 to 45:55) to give allyl (IR,5S,6S,8R,2'S, 'S)-2-(l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.25 (d, 3H); 1.37 (d, 3H); 2.64 (v br, 2H) ; 3.21-3.33 (overlapping m, 2H); 3.48 (br, IH); 3.80 (quintet, IH) ; 3.85 (s, 3H); 4.01 (dd, IH) ; 4.19-4.29 (over¬ lapping m, 2H); 4.53 (t, IH) ; 4.62-4.83 (m, 6H); 5.20-5.45 (m, 6H); 5.84-6.11 (m overlapping br, 3H); 7.25 (t, IH); 7.63 (m, 2H); 8.90 (br, IH).
Ms (+ve FAB): 670 (MH)+; 692 (M + Na)+
Example 23
(lR,5S,6S,8R,2'S,4'S)-2-(2-(5-Carboxy-2-methanesulphinyl- phenylcarbamoyl)pyrrolidin-4-yl-thio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylic acid, disodium salt was prepared as a mixture of diastereoisomers at the sulfoxide centre, using the technique of Example 21. Nmr (DMSO-dg + acetic acid-d4): δ 1.18 (d, 6H); 1.87 (m, part obscured, IH); 2.64-2.91, 2.82, 2.84 (m overlpping 2 x s, 5H); 3.21 (dd, IH); 3.40 (quintet, IH) ; 3.52 (dd, IH) ; 3.71 (quintet, IH) ; 4.01 (quintet, IH); 4.01 (m, IH) , 4.18 (dd, IH); 7.83 (t, IH); 7.94 (td, IH); 8.45 (d, IH).
Ms (+ve FAB): 560 (MH)+, (Na salt); 582 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
4-Methanesulphinyl-3-nitrobenzoic acid
4-Methylthio-3-nitrobenzoic acid (4.36 g, 20 mM) was dissolved in acetic acid (200 ml), and treated at ambient temperature with H202 (2.5 ml, 30%, 22 mM). After stirring at ambient temperature for 4 days, excess peroxide was decomposed with sodium metabisulfite, and solvent evaporated. The residue was purified by chromatography on silica, eluting with methanol, to give 4-methanesulphinyl-3- nitrobenzoic acid (4.1 g, 89%), mp 238-239°. Nmr (DMSO-dg): δ 2.90 (s,
UB TITUTE SHEET 3H) ; 8.29 (d, IH) ; 8.56 (dd, IH) ; 8.68 (d, IH) .
Hs (-ve FAB) : 229 (H - H) ~
The above acid was allylated essentially as in Example 1, except that the chromatographic purification was unnecessary, to give allyl 4-methanesulphinyl-3-nitrobenzoate, p 119-121°. Nmr (DHSO-d,): δ 2.91 (s, 3H); 4.91 (dt, 2H); 5.29-5.50 (m, 2H); 5.99-6.18 (m, IH); 8.34 (d, IH); 8.61 (dd, IH); 8.69 (d, IH).
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-4-methanesulphinylbenzoate. Nmr (CDCl,): δ 2.92 (s, 3H); 4.82 (dt, 2H) ; 5.17 (br, 2H); 5.28-5.46 (m, 2H); 5.96- 6.11 (m, IH); 7.30 (dd, IH); 7.41 (m, 2H).
Ms (El): 223 (M - 0)+; 239 M+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of hexane/ethyl acetate (3:2 to 1:1) to give (2S,4S)-l-allyloxycarbonyl-2-(5-allyloxycarbonyl- 2-methanesulphinylphenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (DMSO-dg at 100°): δ 1.98 (m, IH); 2.32 (s, 3H); 2.73 (s, 3H); 2.86 (m, part obscured, IH); 3.36 (m, IH); 3.91-4.10 (overlapping m, 2H); 4.48 (dd, IH); 4.53 (m, 2H) ; 4.86 (d, 2H); 5.11-5.49 (m, 4H) ; 5.80-5.97 (m, IH); 6.01-6.15 (m, IH); 8.09 (s, 2H); 8.35 (s, IH).
Hs (+ve FAB): 495 (MH)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from ethyl acetate to ethyl acetate/isopropanol (98:2) to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5- allyloxycarbonyl-2-methanesulphinylphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (DMSO-dg, mixture of rotamers): δ 1.18 (d, 6H); 1.99 (br, IH); 2.80 (s overlapping m, 5H) ; 3.25 (solvent overlapping m, 2H); 3.54 (m, IH); 3.90-4.18 (m, 3H) ; 4.15 (dd, IH); 4.55 (m, 4H); 4.85 (d, 2H) ; 5.06 (d, IH); 5.14-5.46 (m, 6H); 5.79-6.13 (m, 3H); 7.80-8.05(m, 2H) ; 8.12 (m, IH); 10.10 (m, IH).
Ms (+ve FAB): 702 (MH)+
Example 24
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-methanesulphonyl- phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylic acid, disodium salt was prepared using the technique of Example 21. Nmr (DMSO-dg + acetic acid-d4): δ 1.16 (d, 3H); 1.18 (d, 3H); 1.75 (quintet, IH) ; 2.63 (m, IH) ; 2.79 (dd, IH); 3.20 (s overlapping m, 4H) ; 3.38 (m, 2H) ; 3.64 (quintet, IH) ; 3.95 (m, 2H); 4.14 (dd, IH) ; 8.09 (t, IH); 8.44 (m, 2H) .
Ms (-ve FAB): 574 (M - H)", (Na salt)
The starting materials were prepared as follows:
3-Methylthio-5-nitrobenzoic acid
3-Amino-5-nitrobenzoic acid (1.82 g, 10 mM) was dissolved in concentrated sulphuric acid (1.9 ml), diluted with water (10 ml), and cooled to 5°. A solution of NaN02 (0.7 g, 10 mM) in water (3 ml) was added and the mixture stirred for 30 minutes. The cold solution of diazonium salt was added to a slurry of thiomethylcopper(I) at 3°, and the mixture stirred for 45 minutes. Organics were extracted into ethyl acetate (5 x 60 ml), and the combined organic layers washed with aqueous NaH2P04, water, brine, and dried over Na2S04. Evaporation gave 3-metbylthio-5-nitrobenzoic acid (1.77 g, 83%). Nmr (DMSO-dg): δ 2.63 (s, 3H); 8.10 (t, IH) ; 8.21 (t, IH) ; 8.32 (t, IH) ; 13.68 (br, IH) .
Ms (-ve FAB): 213 (M - H)~
SUBSTITUTE SHEET The above acid was allylated essentially as in Example 1, except that the chromatography eluant was a mixture of petrol/ethyl acetate (6:1), to give allyl 3-methylthio-5-nitrobenzoate. Nmr (CDC13): δ 2.60 (s, 3H) ; 4.87 (dt, 2H) ; 5.32-5.49 (m, 2H); 5.93-6.07 (m, IH); 8.20 (m, 2H); 8.57 (t, IH).
Ms (El): 253 M+
Allyl 3-methylsulphonyl-5-nitrobenzoate
Allyl 3-methylthio-5-nitrobenzoate (1.12 g, 4.4 mM) was dissolved in methanol (30 ml), and cooled to 2°. A solution of "potassium peroxymonopersulfate,r (2 HS0-..KHS04.K2S04, 8.13 g, 13.2 mM) in water (25 ml) was added slowly, and stirring continued for 4 hours. The mixture was diluted with water (60 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed with water, brine, and dried over Na2S04. Crude product was purified by chromatography on silica using a gradient of petrol/ethyl acetate (3:1 to 2:1) to give allyl 3-methylsulphonyl-5-nitrobenzoate (0.74 g, 59%). Nmr (DHSO-dg): δ 3.44 (s, 3H); 4.94 (dt, 2H); 5.32-5.53 (m, 2H); 6.01- 6.25 (m, IH); 8.78 (t, IH) ; 8.89 (t, IH) ; 8.91 (t, IH) .
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-5-methanesulphonylbenzoate. Nmr (DMSO- dg): δ 3.15 (s, 3H); 4.80 (dt, 2H) ; 5.26-5.47 (m, 2H) ; 5.95-6.15 (m overlapping br, 3H) ; 7.29 (t, IH) ; 7.47 (t, IH) ; 7.51 (t, IH) .
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient of hexane/ethyl acetate (2:1 to 1:1) to give (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl- 5-methanesulphonylphenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDC13): δ 2.34 (s, 3H) ; 2.48 (m, IH) ; 2.62 (m, IH) ; 3.17 (s, 3H) ; 3.41 (dd, IH); 4.03 (quintet, IH) ; 4.15 (dd, IH) ; 4.58 (dd, IH); 4.71 (d, 2H); 4.84 (dt, 2H) ; 5.27-5.47 ( , 4H) ; 5.88-6.14 (m, 2H); 8.23 (br s, 2H); 8.37 (t, IH) ; 9.69 (br, IH) . Ms (+ve FAB) : 511 (MH)+; 533 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloromethane/ethyl acetate (55:45 to 20:80) to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-met-hanesulphonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.24 (d, 3H); 1.36 (d, 3H); 2.54 (br, IH); 2.66 (br, IH) ; 3.12 (s, 3H); 3.19-3.22 (overlapping m, 2H); 3.54 (br, IH); 3.87 (quintet, IH); 3.94 (dd, IH); 4.25,4.29 (quintet overlapping dd, 2H) ; 4.55 (t, IH) ; 4.65- 4.80 (m, 4H); 4.85 (d, 2H) ; 5.20-5.46 (m, 6H) ; 5.86-6.12 (m overlapping br, 3H); 8.31 (br, IH) ; 8.43 (br, IH) ; 8.52 (br, IH) ; 9.40 (br, IH).
Ms (+ve FAB): 718 (MH)+; 740 (M + Na)+
Example 25
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-trifluoromethyl- phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylic acid, disodium salt was prepared using the technique of Example 2. Nmr (DMSO-d, + acetic acid-d4): δ 1.16 (d, 6H); 1.92 (m, part obscured, IH); 2.77 (m, part obscured, IH); 3.00 (dd, IH); 3.21 (dd, IH) ; 3.37 (quintet, IH); 3.59 (quintet, IH) ; 3.80 (quintet, IH) ; 3.97 (quintet, IH); 4.20 (m, 2H) ; 7.91 (br s, IH); 8.27 (br s, IH); 8.44 (br s, IH).
Hs (-ve FAB): 542 (M - H)", (acid); 564 (M - H)", (Na salt)
The starting materials were prepared as follows:
3-Nitro-5-trifluoromethylbenzoic acid was allylated essentially as in Example 1, except that the product was sufficiently pure for use without chromatography, to give allyl 3-nitro-5-trifluoro- methylbenzoate. Nmr (DMSO-dg): δ 4.91 (dt, 2H); 5.30-5.51 (m, 2H) ;
SUBSTITUTE SHEET 5.99-6.20 (m, IH); 8.58 (br s, IH); 8.77 (br s, IH); 8.84 (t, IH).
Ms (CI): 275 H+; 293 (M + NH4)+
Reduction of the above nitro compound by the method of Example 2 gave allyl 3-amino-5-trifluoromethylbenzoate, sufficiently pure for use without chromatography. Nmr (DMS0-dfi): δ 4.78 (dt, 2H); 5.24-5.43 (m, 2H); 5.93-6.13 (m, IH); 7.08 (t, IH); 7.27 (br s, IH); 7.44 (t, IH).
Ms (CI): 245 H+; 263 (M + NH,)"
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (9:1) to give (2S,4S)-l-allyloxycarbonyl- 2-(3-allyloxycarbonyl-5-trifluoromethylphenylcarbamoyl)pyrrolidin-4- ylthioacetate. Nmr (CDCl.-): δ 2.33 (s, 3H); 2.59 (m, 2H); 3.39 (dd, IH); 4.04 (quintet, IH) ; 4.14 (dd, IH); 4.58 (t, IH); 4.62 (dt, 2H); 4.85 (dt, 2H); 5.23-5.48 (m, 4H) ; 5.84-6.15 (m, 2H) ; 8.03 (br s, IH); 8.23 (br s, 2H) ; 9.60 (br, IH) .
Ms (+ve FAB): 501 (MH)+; 523 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate/dichloromethane (9:1) to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-trifluoromethylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (DMSO-dg + acetic acid-d4): δ 1.21 (d, 6H) ; 2.05 (br, IH); 2.85 (br, IH) ; 3.29 (dd, IH); 3.44 (dd, IH); 3.51 (quintet, IH) ; 3.93 (br, IH); 4.05-4.18 (m, 2H); 4.27 (dd, IH); 4.43-4.71 (overlapping m, 5H); 4.85 (d, 2H); 5.16-5.46 (m, 6H); 5.70-6.16 (m, 3H) ; 7.94 (br s, IH); 8.37 (br s, IH); 8.53 (br s, IH). Ms (+ve FAB): 708 (MH)+; 730 (M + Na)+
Example 26
(lR,5S,6S,8R,2'S,4'S)-2-(2-(5-Carboxy-2-methoxyphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 1. Nmr (DMSO-dg + acetic acid-d4): δ 1.20 (d, 6H); 1.93 (m, part obscured, IH) ; 2.86 (quintet, IH) ; 3.02 (dd, IH); 3.26 (dd, IH) ; 3.44 (quintet, IH) ; 3.68 (dd, IH); 3.84 (quintet, IH) ; 3.95 (s, 3H); 4.03 (quintet, IH) ; 4.22 (dd, IH) ; 4.34 (t, IH); 7.13 (d, IH) ; 7.78 (dd, IH); 8.25 (d, IH) .
Ms (+ve FAB): 528 (MH)+, (Na salt); 550 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
4-Methoxy-3-nitrobenzoic acid was allylated essentially as in Example 1, except that the product was sufficiently pure for use without chromatography, to give allyl 3-nitro-4-methoxybenzoate. Nmr (CDC13): δ 4.03 (s, 3H) ; 4.83 (dt, 2H) ; 5.29-5.46 (m, 2H) ; 5.93-6.14 (m, IH); 7.14 (d, IH) ; 8.24 (dd, IH); 8.52 (d, IH).
Ms (CI): 237 M+; 255 (M + NH4)+
Reduction of the above nitro compound by the method of Example 2 gave allyl 3-amino-4-methoxybenzoate sufficiently pure for use without chromatography. Nmr (CDCL,): δ 3.72 (br, 2H); 3.90 (s, 3H); 4.77 (dt, 2H) ; 5.24-5.43 (m, 2H) ; 5.95-6.10 (m, IH) ; 6.79 (d, IH) ; 7.41 (d, IH); 7.50 (dd, IH) .
Ms (CI): 208 (MH)+
The above amine was condensed with proline acid as Example 4, except that the material was purified by chromatography on silica,
SUBSTITUTE SHEET using a gradient from dichloromethane to dichloromethane/diethyl ether (4:1), giving (2S,4S)-l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2- methoxyphenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCl,): δ 2.33 (s, 3H); 2.51 (br, IH) ; 2.66 (br, IH); 3.41 (dd, IH) ; 3.93 (s, 3H); 4.01 (quintet, IH); 4.17 (dd, IH); 4.55 (t, IH) ; 4.64 (d, 2H); 4.80 (dt, 2H); 5.18-5.44 (m, 4H) ; 5.81-6.14 (m overlapping br, 2H); 6.91 (d, IH); 7.84 (dd, IH) ; 8.90 (br, IH); 9.01 (d, IH).
Ms (+ve FAB): 463 (MH)+; 485 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2- methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.23 (d, 3H) ; 1.36 (d, 3H); 2.52 (br, IH); 2.66 (br, IH); 3.22 (dd, IH) ; 3.28 (quintet, IH); 3.44 (dd, IH); 3.83 (quintet, IH); 3.93 (s, 3H); 4.09 (m, IH); 4.19- 4.31 (overlapping m, 2H) ; 4.53 (t, IH) ; 4.65 (m, 4H); 4.81 (d, 2H) ; 5.19-5.45 (m, 6H) ; 5.83-6.11 (m, 3H); 6.91 (d, IH); 7.83 (dd, IH); 8.79 (br, IH); 9.04 (d, IH) .
Hs (+ve FAB): 670 (MH)+; 692 (M + Na)+
Example 27
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-4-methoxyphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg + acetic acid-d4): δ 1.17 (d, 6H) ; 1.83 (m, part obscured, IH) ; 2.75 (quintet, IH) ; 2.97 (dd, IH) ; 3.23 (dd, IH) ; 3.40 (quintet, IH); 3.56 (dd, IH); 3.82 (s + m, 4H) ; 3.99 (quintet, IH); 4.12 (t, IH); 4.19 (dd, IH); 7.09 (d, IH) ; 7.75 (dd, IH); 7.95 (d, IH).
Ms (+ve FAB): 528 (MH)+, (Na salt); 550 (MH)+, (Na2 salt)
TE SHEET The starting materials were prepared as follows:
2-Methoxy-5-nitrobenzoic acid was allylated essentially as in Example 1, except that the product was sufficiently pure for use without chromatography, to give allyl 2-methoxy-5-nitrobenzoate. Nmr (CDC13): δ 4.03 (s, 3H); 4.85 (dt, 2H); 5.30-5.49 (m, 2H); 5.95-6.14 (m, IH); 7.08 (d, IH) ; 8.48 (dd, IH); 8.72 (d, IH) .
Ms (CI): 238 (MH)+; 255 (M + NH4)+
Reduction of the above nitro compound by the method of Example 2 gave allyl 5-amino-2-methoxybenzoate sufficiently pure for use without chromatography. Nmr (CDCl-.): δ 3.39 (br, 2H); 3.83 (s, 3H); 4.80 (dt, 2H); 5.23-5.47 (m, 2H) ; 5.94-6.13 (m, IH) ; 6.83 (d, 2H) ; 7.18 (t, IH).
Ms (CI): 208 (MH)+
The above amine was condensed with proline acid as Example 4, except that the material was purified by chromatography on silica, using a gradient from dichloromethane to dichloromethane/diethyl ether (4:1), giving (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl-4- methoxyphenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCl,): δ 2.32 (s, 3H); 2.58 (br, 2H) ; 3.39 (dd, IH) ; 3.89 (s, 3H) ; 4.02 (quintet, IH); 4.13 (dd, IH) ; 4.53 (t, IH); 4.66 (dt, 2H) ; 4.80 (dt, 2H) ; 5.23- 5.48 (m, 4H); 5.84-6.13 (m, 2H); 6.94 (d, IH); 7.80 (m, 2H); 8.94 (br, IH).
Ms (CI): 463 (MH)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-4- methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-
TE SHEET methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.25 (d, 3H); 1.36 (d, 3H); 2.65 (br, 2H) ; 3.25 (dd, IH) ; 3.28 (quintet, IH); 3.47 (br, IH); 3.79 (quintet, IH) ; 3.89 (s, 3H); 4.01 (dd, IH); 4.18-4.29 (overlapping m, 2H); 4.51 (t, IH) ; 4.66 (m, 4H); 4.79 (dt, 2H); 5.19-5.46 (m, 6H); 5.84-6.11 (m, 3H); 6.95 (d, IH) ; 7.79-7.87 (m, 2H); 8.70 (br, IH).
Ms (+ve FAB): 670 (MH)+; 692 (M + Na)+
Example 28
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-2-methoxyphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg + acetic acid-d4) : δ 1.18 (d, 6H); 1.85 (m, part obscured, IH); 2.66-2.86 (overlapping m, 2H) ; 3.21 (dd, IH); 3.41 (quintet, IH); 3.52-3.72 (overlapping m, 2H); 3.82 (s, 3H); 3.99 (quintet, IH); 4.08 (dd, IH); 4.17 (dd, IH); 7.17 (t, IH); 7.45 (dd, IH); 8.41 (dd, IH).
Ms (+ve FAB): 528 (MH)+, (Na salt); 550 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
2-Hydroxy-3-nitrobenzoic acid was methylated essentially as the allylation step of Example 1, except that the allyl bromide was replaced by methyl iodide, and purification by chromatography was unnecessary, to give methyl 2-methoxy-3-nitrobenzoate. Nmr (DMSO-d,): δ 3.88 (s, 3H); 3.90 (s, 3H) ; 7.44 (t, IH); 8.04 (dd, IH) ; 8.12 (dd, IH).
Ms (CI): 212 (MH)+; 229 (M + NH4)+
The above ester (3.45 g, 16 mM) was hydrolysed by essentially the method of Example 22, except that the solvent was DMSO in place of THF, to give 2-methoxy-3-nitrobenzoic acid. Nmr (DMSO-dg): δ 3.89 (s, 3H); 7.40 (t, IH) ; 8.01 (dd, IH); 8.06 (dd, IH) .
ITUTE SHEET Ms (CI) : 215 (M + NH4)+
The above nitro acid was allylated essentially as in Example 1, except that the product was sufficiently pure for use without chromatography, to give allyl 2-methoxy-3-nitrobenzoate. Nmr (CDCl,): δ 4.00 (s, 3H); 4.86 (dt, 2H); 5.31-5.50 (m, 2H); 5.96-6.16 (m, IH); 7.27 (d, IH); 7.92 (dd, IH) ; 8.06 (dd, IH).
Ms (CI): 238 (MH)+; 255 (M + NH4)+
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-2-methoxybenzoate sufficiently pure for use without chromatography. Nmr (CDCL,): δ 3.86 (s, 3H) ; 3.92 (br, 2H); 4.82 (dt, 2H) ; 5.26-5.49 (m, 2H) ; 5.96-6.16 (m, IH); 6.91 (dd, IH); 7.00 (t, IH); 7.23 (dd, IH).
Ms (CI): 208 (MH)+; 225 (M + NH4)+
The above amine was condensed with proline acid as Example 4, to give (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl-2-methoxy- phenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCl,): δ 2.30 (s, 3H); 2.53 (br, IH); 2.65 (br, IH) ; 3.41 (dd, IH) ; 3.86 (s, 3H) ; 4.04 (quintet, IH) ; 4.16 (dd, IH) ; 4.58 (t, IH); 4.66 (d, 2H) ; 4.83 (dt, 2H); 5.20-5.47 (m, 4H) ; 5.83-6.13 (m overlapping br, 2H) ; 7.16 (t, IH) ; 7.60 (dd, IH); 8.57 (dd, IH) ; 9.15 (br, IH).
Ms (+ve FAB): 463 (MH)+; 485 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-2- methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l- methylcarbapenem-3-carboxylate. Nmr (CDCl-.): δ 1.24 (d, 3H) ; 1.35 (d, 3H); 2.53 (br, IH); 2.68 (br, IH); 3.24 (dd, IH); 3.28 (quintet, IH) ;
SUBSTITUTE SHEET 3.43 (br, IH); 3.80 (quintet, IH); 3.83 (s, 3H) ; 4.12 (m, IH); 4.19- 4.29 (overlapping m, 2H) ; 4.57 (t, IH); 4.64 (m, 4H) ; 4.83 (d, 2H); 5.18-5.48 (m, 6H); 5.81-6.14 (m, 3H) ; 7.17 (t, IH); 7.61 (dd, IH); 8.56 (dd, IH); 9.02 (br, IH).
Ms (+ve FAB): 670 (MH)+; 692 (M + Na)+
Example 29
(IR,5S,6S,8R,2'S,4'S)-2-(2-(5-Carboxy-2-methylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg + acetic acid-d4) : δ 1.19 (d, 6H); 1.88 (m, part obscured, IH); 2.31 (s, 3H); 2.77 (dt, IH); 2.93 (dd, IH) ; 3.22 (dd, IH) ; 3.42 (quintet, IH); 3.57 (dd, IH); 3.77 (quintet, IH); 4.01 (quintet, IH); 4.16 (t, IH); 4.19 (dd, IH); 7.35 (d, IH); 7.69 (dd, IH); 8.39 (d, IH).
Ms (+ve FAB): 512 (MH)+, (Na salt); 534 (HH)+, (Na2 salt); 556 (M + Na)+, (Na2 salt);
The starting materials were prepared as follows:
4-Methyl-3-nitrobenzoic acid was allylated as in Example 1, except that purification by chromatography was unnecessary, to give allyl 4-methyl-3-nitrobenzoate. Nmr (DMSO-dg): δ 2.59 (s, 3H) ; 4.84 (dt, 2H); 5.27-5.47 (m, 2H); 5.96-6.16 (m, IH) ; 7.67 (d, IH); 8.16 (dd, IH); 8.44 (d, IH) .
Ms (El): 222 (MH)+
Reduction of the above nitro compound by the method of Example 2, except that the solvent was methanol, gave allyl 3-amino-4- methylbenzoate sufficiently pure for use without chromatography. Nmr (DMSO-dg): δ 2.10 (s, 3H) ; 4.74 (dt, 2H) ; 5.15 (br, 2H); 5.22-5.43 ( , 2H); 5.93-6.12 (m, IH); 7.04 (d, IH); 7.11 (dd, IH); 7.28 (d, IH) . 4
Ms (CI) : 192 (MH) - 209 (M + NH +
The above amine was condensed with proline acid as Example 4, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (9:1), to give (2S,4S)-l-allyloxy- carbonyl-2-(5-allyloxycarbonyl-2-methylphenylcarbamoyl)pyrrolidin-4- ylthioacetate. Nmr (DMS0-dfi, mix of rotamers): δ 1.97 (quintet, IH);
2.26 (s, 3H); 2.34 (s, 3H) ; 2.80 (br, IH); 3.30 (br, IH); 3.93-4.08 (br m, 2H); 4.53 (br, 3H); 4.80 (dt, 2H) ; 5.10-5.44 (m overlapping br, 4H); 5.78-6.13 (m overlapping br, 2H); 7.38 (d, IH); 7.72 (dd, IH); 7.94 (br, 0.5H); 8.01 (br, 0.5H); 9.61 (br, 0.5H); 9.67 (br, 0.5H).
Ms (CI): 447 (MH)+; 464 (M + NH4)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyl- oxycarbonyl-2-methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate. Nmr (DMSO-d, + acetic acid- d4, mix of rotamers): δ 1.16 (d, 3H) ; 1.18 (d, 3H) ; 1.98 (quintet, IH) ;
2.27 (s, 3H); 2.86 (br, IH); 3.27 (dd, IH); 3.33 (t, IH); 3.56 (quin¬ tet, IH); 3.95 (quintet, IH) ; 4.02 (dd, IH); 4.15 (quintet, IH) ; 4.27 (dd, IH); 4.48-4.70 (overlapping m, 5H); 4.80 (d, 2H) ; 5.10-5.45 (m overlapping br, 6H) ; 5.81-6.14 (m overlapping br, 3H); 7.38 (d, IH); 7.75 (dd, IH); 8.01 (br, 0.5H); 8.07 (br, 0.5H); 9.60 (br, IH).
Ms (+ve FAB): 654 (MH)+; 676 (M + Na)+
Example 30
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-4-methylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg +
UTE SHEET acetic acid-d4) : δ 1. 15 (d, 3H) ; 1. 16 (d, 3H) ; 1.78 (dt, IH) ; 2.48 (s, 3H) ; 2.60 (dt, IH) ; 2.90 (dd, IH) ; 3.21 (dd, IH) ; 3.39 (quintet, IH) ; 3.49 (dd, IH) ; 3.73 (quintet, IH) ; 3.99 (quintet, IH) ; 4.03 (t, IH) ; 4. 17 (dd, IH) ; 7.23 (d, IH) ; 7.70 (dd, IH) ; 8. 12 (d, IH) .
Ms (+ve FAB): 512 (MH)+, (Na salt); 534 (MH)+, (Na2 salt); 556 (M + Na)+, (Na2 salt)
The starting materials were prepared as follows:
2-Methyl-5-nitrobenzoic acid was allylated as in Example 1, except that purification by chromatography was unnecessary, to give allyl 2-methyl-5-nitrobenzoate. Nmr (DMSO-dg): δ 2.65 (s, 3H) ; 4.84 (dt, 2H); 5.28-5.47 (m, 2H); 5.99-6.18 (m, IH); 7.65 (d, IH); 8.31 (dd, IH); 8.57 (d, IH).
Ms (CI): 222 (MH)+; 099 (M + NH4)+
Reduction of the above nitro compound by the method of Example 2, except that the solvent was methanol, gave allyl 5-amino-2- methylbenzoate sufficiently pure for use without chromatography. Nmr (DMSO-dg): δ 2.33 (s, 3H) ; 4.73 (dt, 2H); 5.18 (br, 2H); 5.23-5.44 (m, 2H); 5.93-6.12 (m, IH) ; 6.68 (dd, IH); 6.95 (d, IH) ; 7.12 (d, IH).
Ms (CI): 192 (MH)+; 209 (M + NH4)+
The above amine was condensed with proline acid as Example 4, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (9:1), to give (2S,4S)-l-allyloxy- carbonyl-2-(3-allyloxycarbonyl-4-methylphenylcarbamoyl)pyrrolidiπ-4- ylthioacetate. Nmr (DMSO-d,, mix of rotamers): δ 1.91 (br m, IH); 2.33 (s, 3H); 2.76 (br m, IH) ; 3.28 (s overlapping m, 4H); 4.00 (br m, 2H); 4.38 (t, IH); 4.51 (br, 2H) ; 4.78 (dt, 2H) ; 5.01-5.46 (m overlapping br, 4H); 5.68-6.16 (m overlapping br, 2H); 7.27 (d, IH) ; 7.72 (dd, IH); 8.11 (br, 0.5H); 8.05 (br, 0.5H); 10.17 (br, IH). Ms (+ FAB) : 447 (MH)+; 469 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyl- oxycarbonyl-4-methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate. Nmr (DMSO-d, + acetic acid- d4): δ 1.19 (d, 6H) ; 1.92 (br, part obscured, IH); 2.48 (s, 3H); 2.79 (br, IH); 3.25 (dd, IH); 3.32 (t, IH); 3.54 (quintet, IH); 3.91 (br m, IH); 4.01 (quintet, IH) ; 4.12 (dd, IH); 4.25 (dd, IH) ; 4.45 (m, IH); 4.50-4.68 (m, 4H); 4.78 (dt, 2H); 5.18-5.45 (m, 6H) ; 5.70-6.13 (m over¬ lapping br, 3H); 7.25 (d, IH); 7.76 (dd, IH) ; 8.12 (br m, IH).
Ms (+ve FAB): 654 (MH)+; 676 (M + Na)+
Example 31
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, disodium salt
Allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyl- oxycarbonyl-5-methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylate (3 g, 4.59 mM) and 2,2- dimethyl-l,3-dioxane-4,6-dione (3.97 g, 27.6 mM) were dissolved in a mixture of DMSO (15 ml) and THF (5 ml), under an argon atmosphere, and tetrakis(triphenylphosphine)palladium (531 mg, 0.46 mM) was added. The solution was stirred, under argon with protection from light, for 1 hour. A solution of sodium 2-ethylhexanoate (1.53 g, 9.22 mM) in THF (5 ml) was added, followed by THF (250 ml). The resultant precipitate was filtered, under an argon blanket to exclude moisture, and washed successively with small portions of THF (twice), and diethyl ether. Crude product and NaHCO-. (1.5 g) were dissolved in water (100 ml), and the solution chromatographed on HP20SS resin using a gradient elution from water to water/acetonitrile (9:1). Appropriate fractions were combined and freeze-dried to give (lR,5S,6S,8R,2'S,4'S)-2-(2-(3- carboxy-5-methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxy- ethyl)-l-methylcarbapenem-3-carboxylic acid, disodium salt. Nmr (DMSO- dg + acetic acid-d4): δ 1.13 (d, 3H); 1.15 (d, 3H); 1.76 (dt, IH) ; 2.32 (s, 3H); 2.68 (dt, IH) ; 2.87 (dd, IH); 3.18 (dd, IH); 3.36 (quintet, IH); 3.45 (dd, IH) ; 3.71 (quintet, IH) ; 3.95 (quintet, IH) ; 4.02 (t, IH); 4.14 (dd, IH); 7.49 (s, IH) ; 7.65 (s, IH); 8.05 (s, IH).
Ms (+ve FAB): 512 (MH)+, (Na salt); 534 (HH)+, ( a2 salt); 556 (M + Na)+, (Na2 salt)
The starting materials were prepared as follows:
3-Methyl-5-nitrobenzoic acid
3,5-Dimethylnitrobenzene (30 g, 0.198 M) was heated with stirring to 80° in a mixture of pyridine (400 ml) and water (250 ml). Mn04 (62.7 g, 0.396 M) was added in portions over 0.75 hours, and heating continued at 85-90° for 1.75 hours. The hot solution was filtered through celite, washing with hot water (150 ml). The pink filtrates were decolourised with a few drops of sodium metabisulfite, and evaporated to dryness. The residue was dissolved in water (250 ml), and extracted with diethyl ether (2 x 90 ml). The aqueous layer was acidified (concentrated hydrochloric acid), and extracted with ethyl acetate (3 x 120 ml) . Combined organic extracts were washed with NaH-,P04 solution, brine, and dried over MgS04. Crude product was eluted through a pad of silica, using a mixture of ethyl acetate/dichloromethane/acetic acid (25:25:1), to give 3-methyl-5- nitrobenzoic acid (14.5 g, 40%), mp 171-172°. Nmr (DMSO-dg): δ 2.51 (s, 3H); 8.17 (s, IH) ; 8.30 (t, IH) ; 8.42 (t, IH) ; 13.58 (br, IH) .
Ms (CI): 181 (MH)+
3-Methyl-5-nitrobenzoic acid was allylated as in Example 1, except that purification by chromatography was unnecessary, to give
UBSTITUTE SHEET allyl 3-methyl-5-nitrobenzoate. Nmr (CDCl3): δ 2.53 (s, 3H); 4.87 (dt, 2H); 5.31-5.48 (m, 2H); 5.99-6.13 (m, IH); 8.20 (s, IH); 8.23 (s, IH); 8.68 (s, IH).
Ms (CI): 222 (MH)+
Reduction of the above nitro compound by the method of Example 1, gave allyl 5-amino-3-methylbenzoate sufficiently pure for use without chromatography. Nmr (CDCl,): δ 2.30 (s, 3H); 3.46 (br, 2H); 4.78 (dt, 2H); 5.23-5.45 (m, 2H) ; 5.93-6.12 (m, IH); 6.68 (t, IH); 7.17 (t, IH); 7.27 (t, IH).
Ms (CI): 192 (HH)- 220 (M + C2H5)+
The above amine was condensed with proline acid as Example 4, purifying by chromatography using hexane/ethyl acetate (3:1) as eluant, to give (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5-methyl- phenylcarbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCl,): δ 2.33 (s, 3H); 2.39 (s, 3H); 2.58 (br, 2H); 3.29 (dd, IH); 4.02 (quintet, IH) ; 4.13 (dd, IH); 4.56 (t, IH); 4.68 (dm, 2H) ; 4.82 (dt, 2H); 5.23-5.44 (m, 4H); 5.86-6.12 (m, 2H); 7.63 (s, IH); 7.85 (s, IH) ; 7.85 (s, IH); 9.09 (br, IH).
Ms (+ FAB): 447 (MH)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient of dichloromethane/ethyl acetate (3:2 to 2:3), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5- methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylate. Nmr (CDC13): δ 1.23 (d, 3H) ; 1.35 (d, 3H) ; 2.38 (s, 3H); 2.63 (br, 2H); 3.23 (dd, IH); 3.27 (quintet, IH) ; 3.46 (br, IH); 3.78 (quintet, IH) ; 4.00 (dd, IH); 4.24 (overlapping m, 2H) ; 4.51 (t, IH); 4.59-4.63 (m, 4H); 4.79 (d, 2H) ; 5.17-5.42 (m, 6H) ; 5.82- 6.09 (m, 3H); 7.61 (s, IH); 7.73 (s, IH); 7.99 (s, IH); 8.87 (br, IH).
SUBSTITUTE SHEET Ms (+ve FAB): 654 (MH)'
Example 32
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-5-methoxycarbonyl- phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl- carbapenem-3-carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg + acetic acid-d4): δ 1.18 (d, 6H); 1.92 (br, part obscured, IH); 2.81 (m, IH) ; 3.03 (dd, IH); 3.23 (dd, IH); 3.41 (quintet, IH); 3.61 (m, IH); 3.90 (s overlapping m, 4H); 4.00 (quintet, IH); 4.21 (overlapping m, 2H) ; 8.25 (t, IH) ; 8.50 (m, 2H).
Hs (+ve FAB): 556 (MH)+, (Na salt); 578 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
3-Methoxycarbonyl-5-nitrobenzoic acid was allylated as in Example 1, except that purification by chromatography was unnecessary, to give allyl 3-methoxycarbonyl-5-nitrobenzoate. Nmr (DMSO-d,): δ 3.97 (s, 3H); 4.91 (dt, 2H); 5.31-5.51 (m, 2H); 6.00-6.19 (m, IH); 8.75 (t, IH); 8.81 (d, 2H) .
Ms (El): 265 H+
Reduction of the above nitro compound by the method of Example 2, except that the solvent was methanol, gave allyl 3-amino-5- methoxycarbonylbenzoate sufficiently pure for use without chromato¬ graphy. Nmr (DMSO-dg): δ 3.79 (br, 2H) ; 3.92 (s, 3H); 4.82 (dt, 2H); 5.26-5.46 (m, 2H) ; 5.94-6.14 (m, IH) ; 7.53 (m, 2H); 8.07 (t, IH).
Ms (CI): 236 (MH)+; 253 (M + NH )+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient from dichloromethane to
HEET dichloromethane/diethyl ether (9:1), to give (2S,4S)-l-allyloxy- carbonyl-2-(3-allyloxycarbonyl-5-methoxycarbonylphenylcarbamoyl)- pyrrolidin-4-ylthioacetate. Nmr (CDCl-.): δ 2.33 (s, 3H); 2.60 (br, 2H); 3.40 (dd, IH) ; 3.94 (s, 3H) ; 4.04 (quintet, IH); 4.14 (dd, IH) ; 4.58 (t, IH); 4.68 (dm, 2H); 4.85 (dt, 2H); 5.25-5.47 (m, 4H); 5.85- 6.16 (m, 2H); 8.36 (t, IH); 8.43 (m, 2H); 9.40 (br, IH).
Ms (+ FAB): 491 (MH) ; 513 (M + Na)'
(2S,4S)-l-Allyloxycarbonyl-2-(3-allyloxycarbonyl-5-methoxy- carbonylphenylcarbamoyl)pyrrolidin-4-ylthioacetate (1.2 g, 2.4 mM) was dissolved in THF (50 ml) under an argon atmosphere, and aqueous methyl- amine (33% w/v, 0.51 g, 5.4 mM) was added. Stirring was continued for 3 hours, and solvent removed. The residue was treated with 2M hydro¬ chloric acid and extracted with ethyl acetate. The organic solution was washed with water, brine, aqueous NaHCO, and dried over MgS04. Removal of solvents gave (2S,4S)-l-allyloxycarbonyl-2-(3-allyloxy- carbonyl-5-methoxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthiol (1.02 g, 93%). The thiol was condensed without further purification with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyl- oxycarbonyl-5-methoxycarbonylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l- hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.24 (d, 3H); 1.37 (d, 3H); 2.64 (br, 2H); 3.26 (dd overlapping quintet, 2H); 3.48 (br, IH); 3.86 (quintet, IH) ; 3.94 (s overlapping m, 4H); 4.25 (quintet, IH) ; 4.29 (dd, IH); 4.56 (t, IH) ; 4.69 (m, 4H) ; 4.86 (dm, 2H); 5.19-5.46 (m, 6H) ; 5.85-6.13 (m, 3H) ; 8.46 (m, 3H) ; 9.18 (br, IH).
Ms (+ve FAB): 698 (MH)+; 720 (M + Na)+
Example 33
—-tlffT5576S,8R,2'S,4'S)-2-(2-(5-Carboxy-2,4-difluorophenyl¬ carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-
SU carboxylic acid, disodium salt was prepared using the technique of Example 2. Nmr (DMSO-dg + acetic acid-d : δ 1.20 (d, 6H); 1.96 (m, part obscured, IH); 2.81 (m, IH) ; 3.14 (dd, IH); 3.27 (dd, IH); 3.43 (quintet, IH) ; 3.73 (m, IH) ; 3.91 (quintet, IH); 4.04 (quintet, IH); 4.23 (dd, IH); 4.43 (t, 2H) ; 7.29 (t, IH) ; 8.54 (t, IH).
Ms (+ve FAB): 534 (MH)+, (Na salt); 556 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
2,4-Difluoro-5-nitrobenzoic acid
2,4-Difluorobenzoic acid (5 g, 0.031 M) was dissolved in concentrated sulfuric acid (30 ml), and cooled to 0°. The mixture was stirred, and fuming nitric acid (d 1.567 g/ml, 1.91 ml, 0.047 M) added dropwise, keeping the temperature below 5°. After stirring for 3 hours, the mix was poured onto ice, and organics extracted into dichloromethane (2 x 75 ml). The combined organic layers were washed with water, dried (MgS04), and evaporated to give 2,4-difluoro-5-nitro- benzoic acid (3.9 g, 61%). Nmr (DMSO-dg): δ 7.18 (t, IH); 8.88 (t, IH); 9.93 (br, IH).
Ms (-FAB): 202 (M - H)~
2,4-Difluoro-5-nitrobenzoic acid was allylated as in Example 1, except that the reaction time was only 1.5 hours, the DMF was stirred over IR-120-H ion exchange resin before use, and purification by chromatography was unnecessary, to give allyl 2,4-difluoro-5-nitro- benzoate. Nmr (CDCl-.): δ 4.88 (dt, 2H) ; 5.31-5.50 (m, 2H); 5.93-6.13 (m, IH); 7.13 (t, IH) ; 8.80 (dd, IH) .
Ms (El): 265 M+
ReductiorT^t-^lι-a---]-LQ---_£^ιitro compouff-αH5y~the method of Example 2, except that the solvent was methanoT^-ga*e allyl 5-amino- 2,4-difluorobenzoate, sufficiently pure for use without ciro x^ raph ^^ Nmr (CDC13): δ 3.61 (br, 2H) ; 4.81 (dt, 2H); 5.26-5.48 (m, 2H) ; 5.92- 6.12 (m, IH); 6.83 (t, IH) ; 7.38 (dd, IH) .
Ms (CI): 214 (MH)+; 231 (M + NH )+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (9:1), to give (2S,4S)-l-allyloxy- carbonyl-2-(5-allyloxycarbonyl-2,4-difluorophenylcarbamoyl)pyrrolidin- 4-ylthioacetate. Nmr (CDC13): δ 2.33 (s, 3H); 2.63 (br, 2H); 3.39 (dd, IH); 4.04 (quintet, IH); 4.14 (dd, IH) ; 4.59 (t, IH) ; 4.66 (dt, 2H) ; 4.83 (dt, 2H); 5.22-5.49 (m, 4H); 5.84-6.13 (m, 2H) ; 6.94 (t, IH) ; 8.82 (t, IH); 9.22 (br, IH) .
Ms (+ FAB): 469 (MH)+; 491 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyl- oxycarbonyl-2,4-difluorophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1- hydroxyethyl)-l-methylcarbapenem-3-carboxylate. Nmr (CDCl,): δ 1.25 (d, 3H); 1.38 (d, 3H) ; 2.62 (br, 2H); 3.24 (dd overlapping quintet, 2H) ; 3.45 (dd, IH) ; 3.88 (quintet, IH); 4.03 (dd, IH); 4.25 (quintet, IH); 4.29 (dd, IH); 4.57 (t, IH) ; 4.68 (m, 4H); 4.82 (dm, 2H); 5.21-5.48 (m, 6H) ; 5.85-6.10 (m, 3H) ; 6.94 (t, IH); 8.85 (t, IH); 9.12 (br, IH).
Ms (+ve FAB): 676 (MH)+; 698 (M + Na)+
Example 34
(lR,5S,6S,8R,2'S,4'S)-2-(2-(5-Carboxy-2,4-dimethoxyphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2. Nmr (DMSO-dg + acetic acid-d4): δ 1.20 (d, 6H); 1.95 (m,
UTE SHEET part obscured, IH) ; 2.87 (dt, IH) ; 3.08 (dd, IH) ; 3.26 (dd, IH); 3.41 (quintet, IH) ; 3.71 (dd, IH) ; 3.87 (quintet, part obscured, IH); 3.91 (s, 3H); 3.96 (s, 3H) ; 4.03 (quintet, IH); 4.21 (dd, IH) ; 4.39 (t, 2H); 6.76 (s, IH); 8.44 (s, IH) .
Ms (+ve FAB): 558 (MH)+, (Na salt); 580 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
2,4-Dimethoxy-5-nitrobenzoic acid
A solution of sodium methoxide was prepared by dissolving sodium metal (1.42 g, 0.062 M) in methanol (40 ml) with cooling. Allyl 2,4-difluoro-5-nitrobenzoate (5 g, 0.021 M) was added and the mixture was stirred for 2 hours. A solution of NaOH (2 g, 0.05 M) in water (10 ml) was added, and the mixture stirred at ambient temperature for 16 hours. Solvent was evaporated, the residue dissolved in water (50 ml), and extracted with diethyl ether (40 ml). The aqueous layer was acidified with sulfuric acid, and the precipitate filtered and dried to give 2,4-dimethoxy-5-nitrobenzoic acid (4.23 g, 91%). Nmr (CDCl,): δ 4.07 (s, 3H); 4.16 (s, 3H) ; 6.62 (s, IH) ; 8.81 (s, IH).
Ms (CI): 228 (MH)+; 245 (M + NH4)+
2,4-Dimethoxy-5-nitrobenzoic acid was allylated as in Example 1, except that purification by chromatography was unnecessary, to give allyl 2,4-dimethoxy-5-nitrobenzoate. Nmr (CDCl..): δ 4.02 (s, 3H) ; 4.04 (s, 3H); 4.79 (dt, 2H) ; 5.26-5.46 (m, 2H) ; 5.93-6.13 (m, IH) ; 6.54 (s, IH); 8.63 (s, IH).
Ms (+ FAB): 268 (MH)+; 290 (M + Na)+
Reduction of the above nitro compound by the method of Example 1, gave allyl 5-amino-2,4-dimethoxybenzoate. Nmr (CDCl,): δ 3.25 (br, 2H); 3.87 (s, 3H); 3.90 (s, 3H); 4.76 (dt, 2H); 5.22-5.46 (m, 2H); 5.93-6.12 (m, IH); 6.47 (s, IH); 7.29 (s, IH) . Ms (CI) : 238 (MH)+
The above amine was condensed with proline acid as Example 4, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (4:1), to give (2S,4S)-l-allyloxy- carbonyl-2-(5-allyloxycarbonyl-2,4-dimethoxyphenylcarbamoyl)pyrrolidin- 4-ylthioacetate. Nmr (CDCl..): δ 2.32 (s, 3H); 2.49 (br, IH); 2.64 (br, IH); 3.40 (dd, IH); 3.91 (s, 3H); 3.93 (s, 3H); 4.00 (quintet, IH); 4.17 (dd, IH); 4.53 (t, IH) ; 4.64 (d, 2H) ; 4.77 (dt, 2H); 5.19-5.46 (m, 4H); 5.80-6.14 (m overlapping br, 2H) ; 6.49 (s, IH); 8.69 (br, IH); 8.81 (s, IH).
Ms (+ FAB): 493 (MH)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate, to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2,4- dimethoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (CDCL-,): δ 1.22 (d, 3H) ; 1.36 (d, 3H); 2.48 (br, IH) ; 2.65 (br, IH) ; 3.23 (dd, IH); 3.28 (quintet, IH) ; 3.43 (dd, IH); 3.80 (quintet, IH); 3.91 (s, 3H) ; 3.92 (s, 3H) ; 4.09 (dd, IH); 4.24 (quintet, IH); 4.27 (dd, IH) ; 4.51 (t, IH); 4.66 (m, 4H); 4.77 (dt, 2H) ; 5.20-5.45 (m, 6H) ; 5.83-6.11 (m overlapping br, 3H); 6.49 (s, IH) ; 8.45 (br, IH) ; 8.82 (s, IH) .
Ms (+ve FAB): 700 (MH)+
Example 35
(lR,5S,6S,8R,2'S,4'S)-2-(2-(5-carboxy-2-cyanophenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg + acetic acid-d4): δ 1.17 (d, 6H); 1.83 (m, part obscured, IH) ; 2.62-2.79
SUB TI E EET (overlapping m, 2H); 3.18 (dd, IH); 3.41 (quintet, IH) ; 3.66 (quintet, IH); 3.98 (quintet, IH); 4.07 (dd, IH); 4.17 (dd, IH); 7.79 (m, 2H); 8.67 (s, IH).
Ms (+ve FAB): 523 (MH)+, (Na salt); 545 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
4-Cyano-3-nitrobenzoic acid
4-Chloro-3-nitrobenzoic acid (5.84 g, 29 mM) , cuprous cyanide (5.2 g, 58 mM), cuprous chloride (0.96 g, 9.7 mM) , and quinoline (6.9 ml, 58 mM) were heated under an argon atmosphere at 180° for 3.5 hours. After cooling, the mixture was dissolved in concentrated hydrochloric acid (60 ml), diluted with water (80 ml), and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with aqueous NaH2P04, brine, and dried over MgS04. Crude product was purified by chromatography on silica, eluting with a mixture of di- chloromethane/acetic acid (98:2), to give 4-cyano-3-nitrobenzoic acid (2.65 g, 48%). Nmr (DMSO-dg): δ 8.31 (d, IH); 8.41 (dd, IH); 8.68 (d, IH).
Ms (El) : 192 M+
The above nitro acid was allylated essentially as in Example 1, purifying the crude product by chromatography on silica, using an eluant of hexane:ethyl acetate (6:1), to give allyl 4-cyano-3-nitro- benzoate. Nmr (CDC13): δ 4.93 (dt, 2H) ; 5.37-5.50 (m, 2H); 5.97-6.13 (m, IH); 8.03 (d, IH); 8.46 (dd, IH) ; 8.94 (d, IH).
Hs (CI): 221 (MH)+; 250 (M + NH4)+
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-4-carbamoylbenzoate, recrystallised from ethyl acetate/petrol, mp 149-150°. Nmr (DMSO-dg): δ 4.77 (dt, 2H); 5.25-5.43 (m, 2H); 5.96-6.11 (m, IH); 6.72 (br, 2H) ; 7.04 (dd, IH);
SUBSTITUTE SHEET 7.25 (br, IH) ; 7.35 (d, IH) ; 7.63 (d, IH) ; 7.87 (br, IH) .
Ms (El) : 220 M+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using hexane/ethyl acetate (1:1) to give (2S,4S)-l-allyloxycarbonyl-2-(5-allyloxycarbonyl-2-carbamoylphenyl- carbamoyl)pyrrolidin-4-ylthioacetate. Nmr (CDCl,, mix of rotamers): δ 2.25 (quintet, IH); 2.28 (s, 3H); 2.82 (br, IH); 3.52 (dd, IH); 4.13 (t, IH); 4.20 (br m, IH) ; 4.52 (dd, IH) ; 4.61 (br, 2H); 4.85 (d, 2H) ; 5.01-5.48 (m overlapping br, 4H); 5.66-6.12 (m overlapping br, 2H); 6.55 (br, IH); 6.89 (br, IH); 7.64 (br m, IH); 7.79 (br m, IH); 9.30 (br m, IH); 11.68 (br, 0.5H); 12.06 (br, 0.5H).
Ms (+ve FAB): 476 (MH)+
(2S,4S)-l-Allyloxycarbonyl-2-(5-allyloxycarbonyl-2-cyanophenyl- carbamoyl)pyrrolidin-4-ylthioacetate
DMF (0.2 ml, 2.5 mM) was dissolved in acetonitrile (10 ml), cooled to -5°, and treated with oxalyl chloride (0.2 ml, 2.3 mM). After stirring for 30 minutes, a solution of (2S,4S)-l-allyloxy- carbonyl-2-(5-allyloxycarbonyl-2-carbamoylphenylcarbamoy1)pyrrolidin-4- ylthioacetate (1 g, 2.1 mM) in acetonitrile (15 ml) was added, followed by pyridine (0.38 ml, 4.6 mM) . After 15 minutes, the mixture was diluted with ethyl acetate (200 ml), washed with hydrochloric acid (2M, 20 ml), water, aqueous NaHCO,, and brine, and dried over Na2S04. Crude product was purified by chromatography using a gradient from dichloro¬ methane to ethyl acetate to give (2S,4S)-l-allyloxycarbonyl-2-(5- allyloxycarbonyl-2-cyanophenylcarbamoyl)pyrrolidin-4-ylthioacetate (0.9 g, 93%). Nmr (CDCl-.): δ 2.32 (s, 3H); 2.63 (br, 2H) ; 3.46 (dd, IH); 4.06 (quintet, IH) ; 4.16 (dd, IH); 4.64 (t, IH) ; 4.71 (dt, 2H) ; 4.85 (dt, 2H); 5.22-5.47 (m, 4H); 5.87-6.14 (m, 2H); 7.67 (d, IH); 7.87 (dd,
** IH); 8.96 (d, IH) ; 9.42 (br, IH).
Ms (+ve FAB): 458 (MH)+; 480 (M + Na)+ The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (IR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-2- methoxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1- methylcarbapenem-3-carboxylate. Nmr (CDCl-,): δ 1.24 (d, 3H); 1.35 (d, 3H); 2.60 (br, 2H); 3.25 (dd overlapping quintet, 2H) ; 3.52 (br, IH) ; 3.88 (quintet, IH); 4.02 (dd, IH) ; 4.25 (quintet, IH) ; 4.28 (dd, IH); 4.55-4.74 (m, 5H) ; 4.85 (dt, 2H); 5.18-5.468 (m, 6H) ; 5.83-6.11 (m, 3H); 7.65 (dt, IH); 7.87 (dd, IH) ; 9.00 (br s, IH) ; 9.25 (br, IH) .
Ms (+ve FAB): 665 (MH)+; 687 (M + Na)+
Example 36
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-fluorophenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO. Nmr (DMSO-dg + acetic acid-d4): δ 1.20 (d, 6H) ; 1.99 (dt, IH) ; 2.91 (dt, IH) ; 3.26 (dd overlapping m, 3H) ; 3.42 (quintet, IH); 3.74 (dd, IH); 3.96 (quintet, IH); 4.04 (quintet, IH); 4.22 (dd, IH) ; 4.41 (t, IH) ; 7.43 (dm, IH) ; 7.81 (dd, IH); 8.00 (t, IH).
Ms (+ve FAB): 516 (MH)+, (Na salt); 538 (MH)+, ( a2 salt)
The starting materials were prepared as follows:
3-Fluoro-5-nitrobenzoic acid
A vigorously stirred slurry of nitrosonium tetrafluoroborate (3.53 g, 30.2 mM) in acetonitrile (50 ml) under an atmosphere of argon was cooled in an ice bath, and 3-amino-5-nitrobenzoic acid (5.0 g, 27.5 mM) was added in three portions. The temperature was then allowed to rise to ambient, and the mixture was stirred for 48 hours. 1,2-Di-
SUBSTITUTE SHEET chlorobenzene (50 ml) was added, and acetonitrile distilled from the mixture at reduced pressure. The mixture was then heated to 170° for 30 minutes, when gas evolution had ended. After cooling, the mix was poured into dichloromethane (200 ml), and extracted with NaHCO, solution. After back washing the aqueous phase with dichloromethane, it was acidified (2M hydrochloric acid), and organics extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with brine, and dried over MgS04- Crude product was purified by chromatography on silica, eluting with a gradient from dichloro- methane/acetic acid (99:1) to dichloromethane/isopropanol/acetic acid (80:20:1), to give 3-fluoro-5-nitrobenzoic acid (3.26 g, 64%). Nmr (DMSO-dg): δ 8.14 (dm, IH); 8.37 (dt, IH) ; 8.46 (m, IH) .
Ms (El): 185 M+
Allyl 3-fluoro-5-nitrobenzoate
3-Fluoro-5-nitrobenzoic acid (3 g, 16.2 mM) , £-toluene- sulfonic acid (1.54 g, 8.1 mM), and allyl alcohol (50 ml) were heated to reflux, passing the distillate through 3a molecular sieves, for 16 hours. After cooling, the mixture was neutralised with triethylamine, and solvent removed. The residue was dissolved in ethyl acetate, washed with 2M hydrochloric acid, aqueous NaHCO,, and brine, and dried over MgS04- Crude product was purified by chromatography on silica, using a gradient elution from dichloromethane to ethyl acetate/di¬ chloromethane (3:1), to give allyl 3-fluoro-5-nitrobenzoate. Nmr (CDC13): δ 4.89 (dt, 2H); 5.33-5.49 (m, 2H); 5.95-6.15 (m, IH); 8.11 (m, 2H); 8.70 (t, IH) .
Ms (CI): 226 (MH) ; 253 (M + C2H5)
Reduction of the above nitro compound by the method of Example 1 gave allyl 3-amino-5-fluorobenzoate. Nmr (CDCl,): δ 3.89 (br, 2H); 4.79 (dt, 2H) ; 5.25-5.45 (m, 2H) ; 5.92-6.12 (m, IH) ; 6.54 (dt, IH); 7.07-7.15 (m, 2H).
SUBSTITUTE SHEET Ms (CI) : 196 (MH)'
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (85:13) to give (2S,4S)-l-allyloxy- carbonyl-2-(3-allyloxycarbonyl-5-fluorophenylcarbamoyl)pyrrolidin-4- yLthioacetate. Nmr (CDC13): δ 2.33 (s, 3H); 2.59 (br, 2H); 3.48 (dd, IH); 4.03 (quintet, IH); 4.13 (dd, IH); 4.56 (t, IH); 4.68 (dt, 2H); 4.82 (dt, 2H); 5.25-5.46 (m, 4H); 5.86-6.11 (m, 2H); 6.47 (dm, IH); 7.72 (t, IH); 7.87 (dt m, IH); 9.38 (br, IH).
Ms (+ve FAB): 451 (MH)+; 473 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2'S,4'S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-5- fluorophenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl- carbapenem-3-carboxylate. Nmr (CDCU): δ 1.24 (d, 3H); 1.36 (d, 3H); 2.63 (br, 2H); 3.26 (dd, IH) ; 3.29 (quintet, IH); 3.48 (br, IH); 3.81 (quintet, IH); 3.97 (dd, IH); 4.27 (dd overlapping m, 2H); 4.54 (t, IH); 4.62-4.76 (m, 4H); 4.81 (dt, 2H) ; 5.20-5.46 (m, 6H) ; 5.85-6.10 (m overlapping br, 3H); 7.48 (dt, IH); 7.83 (br s, IH); 7.88 (dt, IH); 9.18 (br, IH).
Ms (+ve FAB): 658 (MH)+; 680 (M + Na)+
Example 37
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-N'-methylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid, disodium salt was prepared using the technique of Example 2, except that the DMF was replaced by DMSO, and product was purified by chromatography on a CHP20P column, eluting with water. Nmr (DHS0-dg + acetic acid-d4, run at 50°): δ 1.12 (d, 3H); 1.18 (d, 3H);
SUBSTITUTE 1.67 (br, IH); 2.13 (br, IH) ; 3.02 (dd, IH) ; 3.17 (dd, IH) ; 3.28 (s overlapping m, 5H) ; 3.65 (br, IH); 3.98 (quintet overlapping m, 2H); 4.12 (dd, IH); 7.58 (d, IH); 7.91 (d, IH); 7.98 (m, IH).
Ms (+ve FAB): 512 (MH)+, (Na salt); 534 (MH)+, (Na2 salt)
The starting materials were prepared as follows:
Allyl 3-methylaminobenzoate
Allyl 3-aminobenzoate (5 g, 28.2 mM) was dissolved in tri- ethyl orthoformate (50 ml) and trifluoroacetic acid (5 drops) was added. The soluiton was stirred and refluxed up through 3a molecular sieves for 5 hours. Solvent was removed, and the residue dissolved in ethanol (50 ml), followed by the addition of acetic acid (8.08 ml) and sodium cyanoborohydride (6.85 g, 0.108 M) in several portions. The mixture was stirred at ambient temperature for 16 hours, and solvent removed. The residue was dissolved in diethyl ether, washed with water, brine, and dried over MgS04- Crude product was purified by chromatography on silica, eluting with a gradient from dichloromethane to dichloromethane/ethyl acetate (95:5), to give allyl 3-methylamino- benzoate (0.93 g, 17%). Nmr (CDC13): δ 2.88 (s, 3H) ; 4.81 (dt, 2H); 5.23-5.45 (m, 2H) ; 5.94-6.13 (m, IH) ; 6.83 (dd, IH) ; 7.25 (dd, IH) ; 7.33 (t, IH); 7.43 (dm, IH) .
Ms (CI): 192 (MH)+
The above amine was condensed with proline acid as Example 1, purifying by chromatography using a gradient from dichloromethane to dichloromethane/diethyl ether (4:1) to give (2S,4S)-l-allyloxycarbonyl- 2-(3-allyloxycarbonyl-N'-methylphenylcarbamoyl)pyrrolidin-4-ylthio- acetate. Nmr (CDCl,, mixture of rotamers): δ 1.93 (m, IH) ; 2.32 (s, 3H); 2.48 (m, part obscured, IH) ; 3.28, 3.31 (2 x s, 3H) ; 3.40 (quintet, IH); 3.76 (m, IH); 4.01 (m, IH) ; 4.24 (m, IH) ; 4.50-4.74 (m, 2H); 4.86 (d, 2H) ; 5.18-5.48 (m, 4H) ; 5.84-6.13 (m, 2H); 7.38-7.68 (m, 2H); 7.90-8.11 (m, 2H) . Ms (+ve FAB) : 447 (MH)+; 469 (M + Na)+
The above thioacetate was deacetylated and condensed with carbapenem phosphate as Example 1, purifying by chromatography using a gradient from dichloromethane to ethyl acetate to give allyl (lR,5S,6S,8R,2/S,4 S)-2-(l-allyloxycarbonyl-2-(3-allyloxycarbonyl-N'- methylphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methyl- carbapenem-3-carboxylate. Nmr (CDCl,, mixture of rotamers): δ 1.20 (2 x d, 3H); 1.34 (2 x d, 3H); 1.87 (br, IH); 2.30 (br, IH); 3.29, 3.31 (2 x s, overlapping m, 6H); 4.05-4.30 (m, 4H); 4.50-4.81 (m, 5H); 4.96 (d, 2H); 5.20-5.48 (m, 6H); 5.85-6.13 (m, 3H) ; 7.39-7.68 ( , 2H); 7.91-8.11 (m, 2H).
Ms (+ve FAB): 654 (MH)+; 676 (M + Na)+

Claims

1. A compound of the formula (I) :
Figure imgf000099_0001
or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein:
R is 1-hydroxyethyl, l-fluoroethyl or hydroxymethyl;
2 R is hydrogen or C. ,alkyl; R 3 is hydrogen or C- alkyl;
4 5 R and R are the same or different and are selected from hydrogen, halo, cyano, C. alkyl, nitro, hydroxy, carboxy, C- alkoxy,
C. 4alkoxycarbonyl, aminosulphonyl, C. alkylaminosulphonyl, di-C. , - alkylaminosulphonyl, carbamoyl, C. 4alkylcarbamoyl, di-C. . alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C. 4alkylamino, di-C. 4alkylamino, C. 4alkanoylamino, C. 4alkanoyl(N-C- 4alkyl)amino,
C. 4alkanesulphonamido and -S(0) C. 4alkyl wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a
3 position ortho to the link to -NR -.
2. A compound according to claim 1 wherein R is 1-hydroxyethyl.
2
3. A compound according to either claim 1 or claim 2 wherein R is hydrogen or methyl.
2
4. A compound according to either claim 1 or claim 2 wherein R is methyl.
3
5. A compound according to any one of claims 1 to 4 wherein R is hydrogen.
SUBSTITUT
6. A compound according to any one of claims 1 to 5 of the formula (IV):
Figure imgf000100_0001
wherein R , R and R are as hereinbefore defined.
7. A compound according to claim 6 wherein R 4 and R5 are the same or different and selected from hydrogen, fluoro, chloro, hydroxy, carboxy, cyano, nitro, methyl, ethyl, methoxy, ethoxy, methoxycarbonyl, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, trifluoromethyl, sulphonic acid, methylsulphinyl, methylsulphonyl, methanesulphonamido or acetamido.
8. A compound according to either claim 6 or claim 7 wherein at
4 5 least one of R and R is hydrogen.
4
9. A compound according to claim 6 wherein R is hydrogen, carboxy, fluoro, chloro, methyl, methoxy, cyano, sulphonic acid or methoxycarbonyl and R is hydrogen.
10. A compound according to claim 1 which is
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-hydroxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, ( lR,5S, 6S, 8R, 2 'S, 4 'S) -2- (2- (3-carboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-methanesulphonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(1R,5S,6S,8R,2'S, 'S)-2-(2-(3-carboxy-2,4-difluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3,4-dicarboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-hydroxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3,5-dicarboxyphenylcarbamoyl)pyrrolidin-
4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S, 'S)-2-(2-(2-carbamoyl-3-carboxyphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-carbamoylphenylcarbamoyl) pyrrolidin-4-ylthio) -6- ( 1 -hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S, 'S)-2-(2-(3-carboxy-5-carbamoylphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-acetamidophenylcarbamoyl) pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-acetamidophenylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
SUBSTITUTE SHEET (lR, 5S , 6S, 8R, 2 'S, 4 'S) -2-(2-(3-carboxy-5-methylsulphonamidophenyl- carbamoyl) pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3- carboxylic acid,
( lR,5S, 6S, 8R, 2'S, 4AS) -2- (2-(3-carboxy-5-sulphophenylcarbamoyl) pyrrolidin-4-ylthio) -6-(l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-carbamoylphenylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-2-dimethylaminocarbonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(5R,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)carbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-2-methoxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 'S , 4 ' S ) -2- (2- (3-carboxy-4-methoxyphenylcarbamoyl) - pyrrolidin-4-ylthio) -6- (l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
( lR,5S , 6S , 8R, 2'S , 4 ' S) -2-(2- (3-carboxy-5-methoxyphenylcarbamoyl) - pyrrolidin-4-ylthio) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3 -carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , 4 ' S ) -2- (2- (3-carboxy-6-methoxyphenylcarbamoyl) - pyrrolidin-4-ylthio) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , 4 ' S) -2- (2- (3-carboxy-4 , 6-dimethoxyphenylcarbamoyl) - pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methoxycarbonylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-cyanophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-trifluoromethylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy- ,6-difluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-methylsulphinylphenyl- carbamoyl)pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3- carboxylic acid,
(IR,5S,6S,8R,2'S, 'S)-2-(2-(3-carboxy-5-methylsulphonylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
( IR, 5S , 6S , 8R, 2 ' S , ' S) -2- (2- (3-carboxy-6-cyanophenylcarbamoyl) - pyrrolidin-4-ylthio) -6- ( 1 -hydroxyethyl ) -l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy N'-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 1 which is
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-methylphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
SUBSTITUTE SHEET (lR,5S, 6S,8R,2 'S, 4'S)-2-(2-(3-carboxy-5-methoxyphenylcarbamoyl)- pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3 -carboxylic acid,
(lR,5S, 6S,8R, 2 'S, 4'S)-2-(2-(3-carboxy-6-met±oxyphenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(lR,5S, 6S,8R,2 ,S, 4'S)-2-(2-(3-carboxy-5-methoxycarbonylphenyl- carbamoyl) pyrrolidin-4-ylthio ) -6- ( 1 -hydroxyethyl) -l-methylcarbapenem-3- carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-cyanophenylcarbamoyl)- pyrrolidin-4-ylthio ) -6- ( 1-hydroxyethyl) -l-methylcarbapenem-3-carboxylic acid,
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-chlorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4- ylthio) -6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid.
(lR,5S, 6S, 8R,2 'S, 4'S) -2-(2-(3-carboxy-4-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio) -6- (l-hydroxyethyl) -l-methylcarbapenem-3 -carboxylic acid,
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-fluorophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid,
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3,4-dicarboxyphenylcarbamoyl)pyrrolidin-4- ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid.
(IR,5S,6S,8R,2'S,4'S)-2-(2-(3,5-dicarboxyphenylcarbamoyl) yrrolidin-4- ylthio)-6-(l-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid.
(lR,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-5-sulphophenylcarbamoyl)- pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-l-methylcarbapenem-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.
13. A method of treatment of an infection by administering an antibacterially effective amount of a compound of the formula (I) to a patient in need thereof.
14. A process for preparing a compound according to claim 1 which comprises deprotecting a compound of the formula (V):
Figure imgf000105_0001
2 4 5 4 5 wherein R , R and R are as defined in claim 1 (R and R being optionally protected if appropriate); -C00R and -C00R are carboxy or
8 3 protected carboxy; R is a group R (as defined in claim 1) or an amino protecting group; R 9 is hydrogen or an amino protecting group; and R10 is a group R (as defined in claim 1), protected 1-hydroxyethyl or protected hydroxymethyl; and wherein at least one protecting group is present; and thereinafter if necessary;
(i) forming a pharmaceutically acceptable salt,
(ii) esterifying to form an in vivo hydrolysable ester.
15. A compound of the formula (V) as defined in claim 14.
16. A process for preparing a compound according to claim 1 or a compound of the formula (V) as defined in claim 14 which comprises:
a) reacting compounds of the formulae (VI) and (VII):
Figure imgf000105_0002
SUBSTITUTE SHEET wherein R , R -R are as defined in claim 14 and L is a leaving group,
Figure imgf000106_0003
(VIII)
Figure imgf000106_0001
wherein R , R -R are as hereinbefore defined and R -R are independently selected from C,_,alkoxy, aryloxy, di-C. ,alkylamino and
11 13 diarylamino or any two of R -R represent £-phenylenedioxy;
11 13 or one of R -R is C. ^alkyl, allyl, benzyl or phenyl and the other two values are independently selected from C. 4alkyl, trifluoromethyl or phenyl, wherein any phenyl group is optionally substituted with
C-_,alkyl or C._,alkoxy; and wherein any functional group is optionally protected and thereinafter if necessary:
(i) removing any protecting groups;
(ii) forming a pharmaceutically acceptable salt;
(iii) esterifying to form an in vivo hydrolysable ester.
17. A compound of the formula (I), as defined in claim 1, in the form of a non-pharmaceutically acceptable salt.
18. A compound of the formula (VII) or (VIII) as defined in claim 16.
19. A compound of the formula (IX), (XII) or (XIV):
Figure imgf000106_0002
SUBSTITUTE SHEET
Figure imgf000107_0001
Figure imgf000107_0002
wherein R and R -R are as defined in claim 14 and R is a protecting group.
SUBSTITUTE SHEET
PCT/GB1993/000217 1992-02-04 1993-02-02 Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics WO1993015078A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DK93914514T DK0579826T3 (en) 1992-02-04 1993-02-02 Carbapenems containing a carboxy-substituted phenyl group, processes for their preparation, intermediates and
PL93317448A PL174936B1 (en) 1992-02-04 1993-02-02 Pharmaceutic agent containing novel carbapenemes
AU34574/93A AU668133B2 (en) 1992-02-04 1993-02-02 Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics
US08/129,056 US5478820A (en) 1992-02-04 1993-02-02 Antibiotic compounds
KR1019930702942A KR100200986B1 (en) 1992-02-04 1993-02-02 Carbapenems containing carboxy substituted phenyl group, process for their preparation, intermediates and pharmaceutical composition containing the same
JP5513073A JP2730600B2 (en) 1992-02-04 1993-02-02 Antibiotic composition
CA002106370A CA2106370C (en) 1992-02-04 1993-02-02 Antibiotic compounds
PL93317447A PL174601B1 (en) 1992-02-04 1993-02-02 Carbapenemes containing phenyl group i and method of obtaining them
DE2002199041 DE10299041I2 (en) 1992-02-04 1993-02-02 Carbapenems containing carboxy substituted phenyl group; Process for their preparation, intermediates and use as antibiotics.
CZ19932067A CZ286878B6 (en) 1992-02-04 1993-02-02 Carbapenems, process of their preparation, intermediates for their preparation, those carbapenems used for treating infections and pharmaceutical preparations
EP93914514A EP0579826B1 (en) 1992-02-04 1993-02-02 Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics
DE69322007T DE69322007T2 (en) 1992-02-04 1993-02-02 CARBOXY SUBSTITUTED PHENYL GROUP CONTAINING CARBAPENEME; METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS AND USE AS ANTIBIOTICS
PL93300768A PL174649B1 (en) 1992-02-04 1993-02-02 Carbaphenemes containing carboxylic group substituted phenyl group, methods of obtaining sames, semiproducts therefor and their application as antibiotics
SK1063-93A SK280890B6 (en) 1992-02-04 1993-02-02 Carbapenem compounds with 2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio group in the position 2, processes for their preparation, intermediates and pharmaceutical compositions containing them
NO933530A NO304315B1 (en) 1992-02-04 1993-10-01 Carbapenems containing a carboxy-substituted phenyl group, intermediates for their preparation, and pharmaceutical preparations containing them
US08/833,056 US5856321A (en) 1992-02-04 1997-04-03 Antibiotic compounds
HK98115416A HK1013998A1 (en) 1992-02-04 1998-12-24 Carbapenems containing a carboxy substituted phenyl group processes for their preparation intermediates and use as antibiotics
NO2002010C NO2002010I2 (en) 1992-02-04 2002-10-09 ertapenem
LU90970C LU90970I2 (en) 1992-02-04 2002-10-09 Carbapenemes constituting a carboxy-substituted phenyl group processes and intermediates intended for their preparation and their use as antibiotics
NL300104C NL300104I2 (en) 1992-02-04 2002-10-18 Carbapenemes containing a carboxy-substituted phenyl group, methods for their preparation, intermediates and use as antibiotics.
US10/293,561 US7041836B2 (en) 1992-02-04 2002-11-14 Antibiotic compounds
US11/126,331 US7342005B2 (en) 1992-02-04 2005-05-11 Antibiotic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9202298.7 1992-02-04
GB929202298A GB9202298D0 (en) 1992-02-04 1992-02-04 Antibiotic compounds

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08/129,056 A-371-Of-International US5478820A (en) 1992-02-04 1993-02-02 Antibiotic compounds
US08/426,037 Continuation US5596544A (en) 1990-06-14 1995-04-21 Very large scale integrated planar read only memory
US08/462,037 Continuation US5652233A (en) 1992-02-04 1995-06-05 Antibiotic compounds

Publications (1)

Publication Number Publication Date
WO1993015078A1 true WO1993015078A1 (en) 1993-08-05

Family

ID=10709764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000217 WO1993015078A1 (en) 1992-02-04 1993-02-02 Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics

Country Status (35)

Country Link
US (7) US5478820A (en)
EP (1) EP0579826B1 (en)
JP (1) JP2730600B2 (en)
KR (1) KR100200986B1 (en)
CN (1) CN1036006C (en)
AP (1) AP398A (en)
AT (1) ATE173262T1 (en)
AU (1) AU668133B2 (en)
CA (1) CA2106370C (en)
CZ (1) CZ286878B6 (en)
DE (2) DE69322007T2 (en)
DK (1) DK0579826T3 (en)
ES (1) ES2123654T3 (en)
FI (1) FI104074B (en)
GB (2) GB9202298D0 (en)
GE (1) GEP20022694B (en)
HK (1) HK1013998A1 (en)
HR (1) HRP930103B1 (en)
HU (3) HUT66514A (en)
IL (1) IL104588A (en)
LU (1) LU90970I2 (en)
MY (1) MY111685A (en)
NL (1) NL300104I2 (en)
NO (2) NO304315B1 (en)
NZ (2) NZ246917A (en)
PL (3) PL174649B1 (en)
RU (1) RU2117659C1 (en)
SG (1) SG48817A1 (en)
SI (1) SI9300056B (en)
SK (1) SK280890B6 (en)
TW (1) TW408124B (en)
UA (1) UA44885C2 (en)
WO (1) WO1993015078A1 (en)
YU (1) YU48998B (en)
ZA (1) ZA93453B (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592167A1 (en) * 1992-10-07 1994-04-13 Zeneca Limited Antibiotic pyrrolidinylthiopenem derivatives
WO1997045430A1 (en) * 1996-05-28 1997-12-04 Merck & Co., Inc. Carbapenem antibiotic, composition and method of preparation
WO1998002439A1 (en) * 1996-07-12 1998-01-22 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
US5872250A (en) * 1997-07-30 1999-02-16 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
EP0937079A1 (en) * 1996-10-28 1999-08-25 Merck & Co., Inc. (a New Jersey corp.) Stabilized carbapenem antibiotic compositions and method of making
US5952323A (en) * 1996-05-28 1999-09-14 Merck & Co., Inc. Carbapenem antibiotic
US6232338B1 (en) 1995-08-04 2001-05-15 Zeneca Limited 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
US6486150B2 (en) 1999-10-29 2002-11-26 Merck & Co., Inc. Process for formulation of antibiotic compounds
US6548492B1 (en) 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
US6777438B2 (en) 1999-12-22 2004-08-17 Astrazeneca Ab Inhibitors of farnesyl protein transferase
US6946468B1 (en) 1996-08-17 2005-09-20 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
US7101897B2 (en) 1999-12-22 2006-09-05 Astrazeneca Ab Farnesyl transferase inhibitors
WO2007065288A3 (en) * 2005-12-07 2008-06-05 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CZ301440B6 (en) * 2001-01-16 2010-03-03 Merck Sharp & Dohme Corp. Process for preparing carbapenem derivatives
EP2266590A2 (en) 2002-02-22 2010-12-29 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
WO2014057079A1 (en) * 2012-10-12 2014-04-17 Sandoz Ag Preparation of ertapenem intermediates
AU2012233003B2 (en) * 2005-12-07 2014-12-18 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
EP2968274A4 (en) * 2013-03-15 2016-08-24 Kala Pharmaceuticals Inc Meropenem derivatives and uses thereof
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
RU2811476C2 (en) * 2019-01-23 2024-01-12 Гликолисис Биомед Ко., Лтд Beta-lactam compounds or their salts for use in long-term prevention or treatment of disorders of glucose metabolism

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
US5602118A (en) * 1993-03-16 1997-02-11 American Cyanamid Company 2-thiosubstituted carbapenems
US5877328A (en) * 1996-10-10 1999-03-02 Merck & Co., Inc. Process for synthesizing carbapenem side chain intermediates
AU714155B2 (en) * 1996-10-10 1999-12-23 Merck & Co., Inc. Process for synthesizing carbapenem side chain intermediates
DE69819727T2 (en) * 1997-06-16 2004-09-23 Merck & Co., Inc. STABILIZED CARBAPENEM INTERMEDIATE PRODUCTS AND THEIR USE IN SYNTHESIS
US6180783B1 (en) 1997-06-16 2001-01-30 Merck & Co., Inc. Stabilized carbapenem intermediates and improved process for carbapenem synthesis
US5965747A (en) * 1997-07-10 1999-10-12 Merck & Co., Inc. Crystalline forms of antibiotic side chain intermediates
EP0998457A4 (en) * 1997-07-10 2010-03-10 Crystalline forms of antibiotic side chain intermediates
US6504027B1 (en) 1998-03-02 2003-01-07 Merck & Co., Inc. Decarboxylation process for synthesizing carbapenem antibiotics
EP1060180B1 (en) * 1998-03-02 2006-03-29 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
DE69916287T2 (en) 1998-06-17 2005-03-24 Merck & Co., Inc. PROCESS FOR SYNTHESIS OF CARBAPENEM INTERMEDIATE PRODUCTS
ATE518864T1 (en) * 2001-09-26 2011-08-15 Merck Sharp & Dohme METHOD FOR PRODUCING CARBAPENEM COMPOUNDS
US7145002B2 (en) 2001-09-26 2006-12-05 Merck & Co. Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
US20040186089A1 (en) * 2001-11-08 2004-09-23 Scolnick Edward M. Compounds useful in the treatment of anthrax
IL165259A0 (en) * 2002-05-29 2005-12-18 Merck & Co Inc Compounds useful in the treatment of anthraxa and inhibiting lethal factor
US7845870B2 (en) * 2004-05-07 2010-12-07 Infinum Labs, Inc. Multi-position multi-level user interface system
US7579487B2 (en) * 2004-05-11 2009-08-25 Merck & Co., Inc. Process for making N-sulfonated-amino acid derivatives
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
CN100344613C (en) * 2005-10-20 2007-10-24 上海交通大学 Preparatino method of (2S,4S)-1-(4-nitro carbobenzoyl)-2-[(3-allyloxycarbonyl)-phenyl aminoformyl]-pyrrolidine -4-thioalcohol
WO2008062279A2 (en) * 2006-11-20 2008-05-29 Orchid Chemicals & Pharmaceuticals Limited An improved process for the preparation of carbapenem antibiotic
CN101357916B (en) * 2007-06-22 2010-12-15 山东轩竹医药科技有限公司 Penem compound containing dihydroimidazole formamido
CN101367815B (en) * 2007-06-28 2012-07-04 山东轩竹医药科技有限公司 Six-membered ring methanamide substituted sulfhydryl pyrrolidine carbpenem compound
CN101367807B (en) * 2007-06-28 2011-01-12 山东轩竹医药科技有限公司 Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant
CN101362760B (en) * 2007-08-07 2010-12-15 山东轩竹医药科技有限公司 1beta-methyl carbapenem compound
CN101362761B (en) * 2007-08-12 2011-05-18 山东轩竹医药科技有限公司 Carbapenem antibiotic containing sulfhydryl piperidine
CN101412720B (en) * 2007-08-27 2011-05-18 山东轩竹医药科技有限公司 Carbapenem compound containing mercapto nitrogen heterocyclic vinyl
CN101376641B (en) * 2007-08-28 2010-12-08 上海医药工业研究院 Carbapenem penicillin ertapenem intermediate, and preparation and use thereof
US20110172201A1 (en) * 2008-06-11 2011-07-14 Ranbaxy Laboratories Limited Process for preparing a carbapenem antibiotic composition
CA2732619A1 (en) * 2008-07-30 2010-02-04 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
CA2737879C (en) * 2008-09-18 2014-07-08 Manu Chaudhary Single unit carbapenem aminoglycoside formulations
KR101694506B1 (en) 2009-04-30 2017-01-10 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Intermediates of ertapenem, compositions containing them and preparation methods thereof
WO2011048583A1 (en) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
US8729260B2 (en) 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
CN102558182B (en) 2010-12-31 2015-02-11 石药集团中奇制药技术（石家庄）有限公司 Ertapenem sodium crystal form E and preparation method thereof
US8691803B2 (en) 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
WO2013121279A2 (en) * 2012-02-14 2013-08-22 Aurobindo Pharma Limited Process to prepare ertapenem
WO2015087245A1 (en) 2013-12-11 2015-06-18 Unimark Remedies Ltd. Process for preparation of ertapenem and salts thereof
US11180504B2 (en) * 2016-03-16 2021-11-23 Orchid Pharma Ltd. Substituted carbapenems for the treatment of bacterial infections
CN106565579A (en) * 2016-06-26 2017-04-19 宁夏海诚电化信息科技有限公司 Ertapenem side chain production technology
CN110698480B (en) * 2018-07-09 2023-09-08 武汉启瑞药业有限公司 Synthesis and purification method of ertapenem intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126587A1 (en) * 1983-05-09 1984-11-28 Sumitomo Pharmaceuticals Company, Limited Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof
WO1992017481A1 (en) * 1991-04-08 1992-10-15 Zeneca Ltd. Antibiotic carbapenem derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206219A (en) * 1978-10-24 1980-06-03 Merck & Co., Inc. 6- and 1-Substituted-1-carbadethiapen-2-em-3-carboxylic acid
US4208422A (en) * 1978-10-24 1980-06-17 Merck & Co., Inc. 1-Substituted-pen-2-em-3-carboxylic acids
US4232036A (en) * 1978-10-24 1980-11-04 Merck & Co., Inc. 6-, 1- and 2-Substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4218462A (en) * 1978-10-24 1980-08-19 Merck & Co., Inc. 6-(1-Hydroxyethyl)-2-(2-aminoethylthio)-1-substituted-1-carbade-thiapen-2-em-3-carboxylic acids
DK165280A (en) * 1979-04-19 1980-10-20 Merck & Co Inc PROCEDURE FOR PREPARING 2- AND 6-SUBSTITUTED 1-CARBADETHIAPEN-2-EM-3-CARBOXYLIC ACIDS AND INTERMEDIATES FOR USE IN THE PRESENTATION OF THE PROCEDURE
US4746736A (en) * 1982-09-28 1988-05-24 Bristol-Myers Company Carbapenem antibiotics
JPS60202886A (en) * 1984-03-27 1985-10-14 Sankyo Co Ltd 1-substituted carbapenem-3-carboxylic acid derivative and its preparation
JPS60233076A (en) * 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd Novel beta-lactam and its preparation
EP0182213B1 (en) * 1984-11-08 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Carbapenem compounds and production thereof
FI81576C (en) * 1984-12-25 1990-11-12 Sankyo Co FOERFARANDE FOER FRAMSTAELLNING AV DERIVAT AV 6- (1-HYDROXYTHYL) -2- (1,2-DISUBSTITUERADE-4-PYRROLIDINYLTHIO) -2-CARBAPENEM-3-CARBOXYL SYRA, VILKA AER ANVAENDBARA SOM LAEKEMEDEL.
EP0243686B1 (en) * 1986-03-27 1992-07-15 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production
US4974544A (en) * 1986-10-07 1990-12-04 Ricoh Company, Co. Vapor deposition apparatus
US5194624A (en) * 1988-05-23 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Intermediates for the preparation of compounds of antimicrobial activity
US4963544A (en) * 1988-05-23 1990-10-16 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
GB8923844D0 (en) * 1989-10-23 1989-12-13 Fujisawa Pharmaceutical Co Carbapenem compounds
NO178498C (en) * 1990-02-23 1996-04-10 Sankyo Co Analogous method of preparing therapeutically active carbapenem derivatives
US5554606A (en) * 1990-03-12 1996-09-10 Zeneca Limited Antibiotic compounds
AU644008B2 (en) * 1990-08-10 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production and use
GB9107342D0 (en) * 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
CZ167792A3 (en) * 1991-06-04 1995-12-13 Sankyo Co 1-methylcarbapenem derivatives process of their preparation and use
ZA929008B (en) * 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
CA2091309A1 (en) * 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds
GB9304156D0 (en) * 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
CA2099818A1 (en) * 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
CA2099817A1 (en) * 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
CA2099811A1 (en) * 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
CA2106141A1 (en) * 1992-09-28 1994-03-29 Michael J. Betts Antibiotic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126587A1 (en) * 1983-05-09 1984-11-28 Sumitomo Pharmaceuticals Company, Limited Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof
WO1992017481A1 (en) * 1991-04-08 1992-10-15 Zeneca Ltd. Antibiotic carbapenem derivatives

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592167A1 (en) * 1992-10-07 1994-04-13 Zeneca Limited Antibiotic pyrrolidinylthiopenem derivatives
US6232338B1 (en) 1995-08-04 2001-05-15 Zeneca Limited 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
KR100403497B1 (en) * 1996-05-28 2003-10-30 머크 앤드 캄파니 인코포레이티드 Carbapenem antibiotic
WO1997045430A1 (en) * 1996-05-28 1997-12-04 Merck & Co., Inc. Carbapenem antibiotic, composition and method of preparation
US5952323A (en) * 1996-05-28 1999-09-14 Merck & Co., Inc. Carbapenem antibiotic
KR100344479B1 (en) * 1996-05-28 2002-10-31 머크 앤드 캄파니 인코포레이티드 How to stabilize carbapenem antibiotics
WO1998002439A1 (en) * 1996-07-12 1998-01-22 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
US6946468B1 (en) 1996-08-17 2005-09-20 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
EP0937079A1 (en) * 1996-10-28 1999-08-25 Merck & Co., Inc. (a New Jersey corp.) Stabilized carbapenem antibiotic compositions and method of making
EP0937079A4 (en) * 1996-10-28 2001-01-24 Merck & Co Inc Stabilized carbapenem antibiotic compositions and method of making
US5872250A (en) * 1997-07-30 1999-02-16 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
US6548492B1 (en) 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
US6486150B2 (en) 1999-10-29 2002-11-26 Merck & Co., Inc. Process for formulation of antibiotic compounds
US6777438B2 (en) 1999-12-22 2004-08-17 Astrazeneca Ab Inhibitors of farnesyl protein transferase
US7101897B2 (en) 1999-12-22 2006-09-05 Astrazeneca Ab Farnesyl transferase inhibitors
CZ301440B6 (en) * 2001-01-16 2010-03-03 Merck Sharp & Dohme Corp. Process for preparing carbapenem derivatives
EP2266590A2 (en) 2002-02-22 2010-12-29 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP2484680A1 (en) * 2005-12-07 2012-08-08 Basilea Pharmaceutica AG Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors
US8901293B2 (en) 2005-12-07 2014-12-02 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
AU2012233003B2 (en) * 2005-12-07 2014-12-18 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
WO2007065288A3 (en) * 2005-12-07 2008-06-05 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
US9546171B2 (en) 2012-10-12 2017-01-17 Sandoz Ag Preparation of ertapenem intermediates
WO2014057079A1 (en) * 2012-10-12 2014-04-17 Sandoz Ag Preparation of ertapenem intermediates
EP2968274A4 (en) * 2013-03-15 2016-08-24 Kala Pharmaceuticals Inc Meropenem derivatives and uses thereof
US9725451B2 (en) 2013-03-15 2017-08-08 Kala Pharmaceuticals, Inc. Meropenem derivatives and uses thereof
AU2014227737B2 (en) * 2013-03-15 2018-05-17 KALA BIO, Inc. Meropenem derivatives and uses thereof
US10392388B2 (en) 2013-03-15 2019-08-27 Kala Pharmaceuticals, Inc. Meropenem derivatives and uses thereof
US11091487B2 (en) 2013-03-15 2021-08-17 Kala Pharmaceuticals, Inc. Meropenem derivatives and uses thereof
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
CN113423405A (en) * 2019-01-23 2021-09-21 醣解生医股份有限公司 Use of beta-lactam compounds or salts thereof for the long-lasting prevention or treatment of disorders of glucose metabolism
TWI820289B (en) * 2019-01-23 2023-11-01 醣解生醫股份有限公司 Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
RU2811476C2 (en) * 2019-01-23 2024-01-12 Гликолисис Биомед Ко., Лтд Beta-lactam compounds or their salts for use in long-term prevention or treatment of disorders of glucose metabolism

Also Published As

Publication number Publication date
NZ246917A (en) 1995-09-26
DE69322007T2 (en) 1999-04-01
CA2106370A1 (en) 1993-08-05
HRP930103A2 (en) 1994-12-31
LU90970I2 (en) 2002-12-09
FI930474A0 (en) 1993-02-03
CZ206793A3 (en) 1994-04-13
SK280890B6 (en) 2000-09-12
NO933530D0 (en) 1993-10-01
YU48998B (en) 2003-04-30
HK1013998A1 (en) 1999-09-17
HUT64764A (en) 1994-02-28
ZA93453B (en) 1993-08-05
NO933530L (en) 1993-10-04
NO2002010I1 (en) 2002-10-09
AU3457493A (en) 1993-09-01
PL174649B1 (en) 1998-08-31
US6521612B2 (en) 2003-02-18
HUT66514A (en) 1994-12-28
HU9302777D0 (en) 1993-12-28
GB9300456D0 (en) 1993-03-03
MY111685A (en) 2000-11-30
DE69322007D1 (en) 1998-12-17
JPH06506704A (en) 1994-07-28
PL174936B1 (en) 1998-10-30
NL300104I2 (en) 2003-02-03
GB9202298D0 (en) 1992-03-18
PL174601B1 (en) 1998-08-31
AP398A (en) 1995-08-29
AU668133B2 (en) 1996-04-26
HU213675B (en) 1997-09-29
SG48817A1 (en) 1998-05-18
US6187804B1 (en) 2001-02-13
NO304315B1 (en) 1998-11-30
US20020042408A1 (en) 2002-04-11
SI9300056A (en) 1993-09-30
HU211840A9 (en) 1995-12-28
TW408124B (en) 2000-10-11
ATE173262T1 (en) 1998-11-15
CZ286878B6 (en) 2000-07-12
EP0579826B1 (en) 1998-11-11
IL104588A (en) 1999-03-12
JP2730600B2 (en) 1998-03-25
CN1036006C (en) 1997-10-01
US20030144264A1 (en) 2003-07-31
AP9300480A0 (en) 1993-01-31
RU2117659C1 (en) 1998-08-20
YU5493A (en) 1996-05-20
NL300104I1 (en) 2002-12-02
CA2106370C (en) 2003-11-25
KR100200986B1 (en) 1999-06-15
FI104074B1 (en) 1999-11-15
US7342005B2 (en) 2008-03-11
US7041836B2 (en) 2006-05-09
FI104074B (en) 1999-11-15
IL104588A0 (en) 1993-06-10
NZ272038A (en) 1997-07-27
HRP930103B1 (en) 1999-12-31
CN1079224A (en) 1993-12-08
DE10299041I1 (en) 2003-02-20
DK0579826T3 (en) 1999-07-26
SI9300056B (en) 2000-02-29
NO2002010I2 (en) 2005-03-11
SK106393A3 (en) 1994-04-06
US5856321A (en) 1999-01-05
ES2123654T3 (en) 1999-01-16
GEP20022694B (en) 2002-05-10
FI930474A (en) 1993-08-05
DE10299041I2 (en) 2003-06-12
US5478820A (en) 1995-12-26
UA44885C2 (en) 2002-03-15
EP0579826A1 (en) 1994-01-26
US5652233A (en) 1997-07-29
US20050209212A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
EP0579826B1 (en) Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics
EP0508682B1 (en) Antibiotic carbapenem derivatives
US5519015A (en) Carbapenem antibiotic compounds
US5571805A (en) Antibiotic compounds
US5444057A (en) Carbapenem-antibiotic compounds
EP0590885A1 (en) Antibiotic carbapenem compounds
US5527791A (en) Carbapenem antibiotic compounds
US5527793A (en) Antibiotic carbapenem compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL RO RU SD SE SK US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2106370

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 246917

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1993914514

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019930702942

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 106393

Country of ref document: SK

Ref document number: 08129056

Country of ref document: US

Ref document number: PV1993-2067

Country of ref document: CZ

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: KZ

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: BY

WWP Wipo information: published in national office

Ref document number: 1993914514

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1993-2067

Country of ref document: CZ

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: UZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: GE

ENP Entry into the national phase

Ref document number: 1997 833056

Country of ref document: US

Date of ref document: 19970403

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 1993914514

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1993-2067

Country of ref document: CZ